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Ct   Cycle threshold 
CTEPH   Chronic thromboembolic pulmonary hypertension  
DCL1   Dicer-like protein 1 
DEPC   Diethylpyrocarbonate 
DGCR8   DiGeorge syndrome critical region 8 
DIG   Digoxigenin 
DMEM   Dulbeccos modified Eagle medium 
DMSO   Dimethyl sulphoxide 
DNA   Deoxyribonucleic acid 
dNTPs   Deoxynucleoside triphosphates 
dsRBD   Double-stranded RNA binding domain 
dsRNA   Double-stranded RNA 
DTT   Dithiotheitol 
ECL   Chemiluminescence 
EDTA   Ethylenediaminetetracetic acid 
ET-1   Endothelin-1 
ETA   Endothelin A receptor 
ETB   Endothelin B receptor 
Exp5   Exportin-5  
FCS   Fetal calf serum 
FDA   Food and Drug Administration  
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
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HIV   Human immunodeficiency virus 
HP1A   Heterochromatin protein 1A  
HPAECs  Human Pulmonary Artery Endothelial Cells  
HPAFs   Human Pulmonary Artery Fibroblasts  
HPAH   Heritable pulmonary arterial hypertension 
HPASMCs  Human pulmonary artery smooth muscle cells 
HR   Heart rate 
HRP   Horseradish peroxidase 
hsa   Homo sapiens 
HYL1   HYPONASTIC LEAVES1  
ID1   Inhibitor of DNA binding-1 
IPAH   Idiopathic pulmonary arterial hypertension 
I-Smads  Inhibitory Smads  
KCNJ6   Potassium inwardly-rectifying channel, subfamily J, member 6   
kDa   KiloDalton 
KLF4   Kruppel-like factor 4  
KLF5   Kruppel-like factor 5 
KO   Knock-out  
LNAs   Locked nucleotides  
LV   Left ventricle 
LV+S   Left ventricle plus septum 
M   Molar 
MCTP   monocrotaline pyrrole  
MEF2   Myocyte enhancer factor-2 
miRISC   miRNA-Induced silencing complex 
miRNA   Micro ribonucleic acid (microRNA) 
miRNPs  micro-ribonucleoproteins 
mM   Milli molar 
mmu   Mus musculus 
mPAP   Mean pulmonary arterial pressure 
mRNA   Messenger ribonucleic acid 
mSAP   Mean systemic arterial pressure 
Myocd   Myocardin 
MyoD   Myogenic differentiation factor  
NBF   neutral-buffered formalin 
NCASP   Nuclear factor of activated T-cells 5  
nM   Nanomolar (nanomoles per litre) 
NO   Nitric oxide  
nt   Nucleotide 
NYHA   New York Heart Association 
PA   Pulmonary artery 
PABP   Poly A binding protein 
PACT   Protein activator of PKR  
PAECs   Pulmonary artery endothelial cells  
PAFs   Pulmonary artery fibroblasts  
PAH   Pulmonary arterial hypertension 
PAI1   Plasminogen activator inhibitor type 1 
PAP   Pulmonary artery pressure 
Pasha   Partner of Drosha 
PASMCs  Pulmonary artery smooth muscle cells  
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PAZ   Piwi-Argonaute-Zwille 
P-bodies  Processing-bodies 
PBS   Phosphate buffered saline 
PCH   Pulmonary capillary hemangiomatosis  
PCR   Polymerase Chain Reaction 
PDCD4   Programmed cell death protein 4 
PDE-5   Phosphodiesterase type 5 
PDGF   Platelet derived growth factor 
PFA   Paraformaldehyde 
PGI2   Prostacyclin 
piRISC   piRNA-induced silencing complex  
piRNAs   PIWI-interacting RNAs  
piwiRNA  P-element-induced wimpy testis RNA 
PMSF   Phenylmethylsulfonylfluoride 
pol-II   polymerase-II 
pol-III   polymerase-III 
PPAR-gamma  peroxisome proliferator-activated receptor gamma 
PPHN   Persistent pulmonary hypertension of the newborn 
PPP2R5E Protein phosphatase 2, regulatory subunit B (B56), epsilon 
isoform  
pre-miRNA/pre-miR Preliminary miRNA 
pri-miRNA/pri-miR Primary miRNA 
PTEN   Phosphatase and tensin homologue 
PVOD   Pulmonary veno-occlusive disease 
PVR   Pulmonary vascular resistance 
Ran-GTP  RAs-related Nuclear protein-Guanosine-5'-triphosphate 
RBPSUH   Recombining binding protein suppressor of hairless (Drosophila)  
RdRP   RNA-dependent RNA polymerase  
RHC   Right heart catheterization  
RIIID   RNAse III domain  
RISC   RNA induced silencing complex 
RITS   RNA-induced transcriptional gene silencing 
RNA   Ribonucleic acid 
RNAi   RNA interference 
rno   Rattus norvegicus 
RNP   Ribonucleoprotein 
ROC   Receptor operated calcium channel 
ROCK   Rho-kinase 
RPAFs   Rat pulmonary artery fibroblasts  
RPASMCs  Rat pulmonary artery smooth muscle cells  
rRNAs   Ribosomal RNAs  
R-smads  Receptor-activated smads 
RT   Room Temperature 
RV   Right ventricle 
RV/LV+S  Ratio of right ventricle to left ventricle plus septum 
RVH   Right ventricular hypertrophy 
RVP   Right ventricular pressure 
SAP   Systemic arterial pressure 
SDS   Sodium dodecyl sulphate 
SDS-PAGE  Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
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SEM   Standard error of the mean 
SERT   Serotonin transporter 
SERT+   Mice over-expressing SERT  
SILAC   Stable isotope labelling with amino acids in cell culture 
siRNA   Short Interfering ribonucleic acid 
SLC6A4  Serotonin transporter gene 
SMC   Smooth muscle cell 
snoRNAs  Small nucleolar RNAs 
snRNAs  Small nuclear RNAs 
Spry1   sprouty homologue 1 
SRF   Serum response factor  
sRVP   Systolic right ventricular pressure 
stRNAs   Short temporal RNAs  
TACC1    Transforming, acidic coiled-coil containing protein 1   
TBE   Tris/Borate/EDTA  
TEs   Transposable elements  
TGF-beta  Transforming growth factor beta  
TGFBR1   Transforming growth factor, beta receptor 1   
TGFBRAP1    Transforming growth factor, beta receptor associated protein 1   
Tm   Melting temperature 
TNRC6A   Trinucleotide repeat containing 6a   
TPH1   Tryptophan hydroxylase 1 
TRBP   TAR RNA-binding protein  
tRNAs   Transfer RNAs  
U   Unit 
UTR   Untranslated Region 
V   Volt 
v/v   Volume/volume 
VEGF   Vascular endothelial growth factor  
VGCCs   Voltage-gated calcium channels 
VSMC   Vascular smooth muscle cell 
WT   Wild-type 
YWHAZ  Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, zeta polypeptide  
μM   Micromolar (micromoles per litre 
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Abstract 
 
Pulmonary arterial hypertension (PAH) is a disease of the small pulmonary arteries 
(PAs), characterized by an increase in pulmonary arterial pressure and vascular 
remodelling leading to a progressive increase in pulmonary vascular resistance. The 
consequence of vascular obliteration is right heart failure and high mortality. Germline 
mutations in the gene coding for the bone morphogenetic protein (BMP) type-2 
receptor (BMPR2), a receptor for the transforming growth factor (TGF)-beta super-
family, have been identified in approximately 70% of patients with the heritable form 
of PAH (HPAH). Moreover, BMPR2 expression is markedly reduced in PAH cases in the 
absence of mutations in this gene (idiopathic PAH, IPAH). In pulmonary artery smooth 
muscle cells (PASMCs) mutations in BMPR2 are associated with an abnormal growth 
response to BMPs and TGF-beta. In endothelial cells (PAECs), these mutations increase 
the susceptibility of cells to apoptosis. The absence of BMPR2 mutations in some 
families and in the majority of IPAH cases suggests that further pathological 
mechanisms still need to be identified. The serotonin system has also been implicated 
in both experimental and human PAH. In fact, an additional genetic risk factor for the 
development of this pathology has been identified in the serotonin transporter (SERT), 
dysregulated in IPAH patients. Mice over-expressing SERT (SERT+ mice) exhibit PAH 
and exaggerated hypoxia-induced PAH. 
 
Although different advanced PAH therapies are currently available, they can only 
provide a symptomatic relief, and mortality rates remain high. Therefore, the 
identification of novel therapeutic approaches for the treatment of this pathology is 
urgently required. 
 
MicroRNAs (miRNAs) are a class of small, endogenous and non-coding RNAs able to 
negatively regulate gene expression by targeting specific messenger RNAs (mRNAs) 
and inducing their degradation or translational repression. These non-coding 
sequences are transcribed from endogenous loci as long precursors, converted in 
single-stranded molecules of approximately 20 nucleotides after a series of enzymatic 
maturation steps. miRNAs carry out their activity in association with the RNA-induced 
silencing complex (RISC), interacting with the 3’ untranslated region (3’UTR) of specific 
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target mRNAs which they bind with imperfect complementarity. Several recent studies 
have assessed the direct role of miRNAs in vascular inflammation and in the 
development of cardiovascular pathologies. The aim of this project was to investigate 
the role of miRNAs in the development of PAH.  
 
In Chapter 3, two distinct and well established rat models (hypoxic and monocrotaline) 
of PAH were used to determine the regulation of miRNAs during disease initiation and 
progression. We demonstrate time and insult-dependent changes in a specific group if 
miRNAs and this dysregulation was also confirmed in vitro in rat and human PA cells 
exposed to chronic hypoxia. Moreover, the stimulation of rat cells with TGF-beta and 
BMP4 mimicked the alteration of miRNA expression observed in vivo. An analysis of 
the expression level of the main enzymes involved in miRNA maturation (i.e. Dicer, 
Drosha, DGCR8 and Exp5) revealed the significant down-regulation of Dicer in 
response to chronic hypoxia both in vivo and in vitro, suggesting that the manipulation 
of this enzyme could re-establish a normal miRNA expression level in pathological 
samples. We also identified selective targets altered in response to miRNA 
dysregulation, suggesting the possibility of future interventional studies.  
 
In Chapter 4 the specific role of miR-143 and miR-145 in the development of PAH was 
evaluated. We report the significant up-regulation of these miRNAs in WT mice 
exposed to chronic hypoxia and that genetic ablation of miR-145 is protective against 
the development of PAH (with no effects on miR-143 expression), assessed via 
measurement of systolic right ventricular pressure (sRVP), pulmonary vascular 
remodelling and right ventricular hypertrophy (RVH). miR-145 KO has also an effect on 
the expression of specific targets, including kruppel-like factor 4 and 5 (KLF4 and 5), 
which are regulators of smooth muscle proliferation and differentiation. Further, both 
miR-143 and miR-145 are up-regulated in mice heterozygous for a BMPR2 mutation. In 
human tissues we confirm the elevated expression of the miR-143/145 cluster 
observed in hypoxic mice in pathological samples compared with unaffected controls, 
suggesting a conserved regulation of these miRNAs in the two species. The study 
described in this chapter is the first to report a critical role for miR-145 in the 
development of PAH in vivo. 
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Finally, in Chapter 5 a preliminary study focused on miR-21 regulation and function on 
PAH development is shown.  An analysis of the expression of this miRNA in WT mice 
revealed its up-regulation in response to chronic hypoxia, whereas the genetic ablation 
of miR-21 induced an exaggerated hypoxia-induced PAH phenotype. However, the 
analysis of human pathological samples showed a reduced expression of this miRNA in 
comparison with unaffected controls, suggesting its differential regulation in hypoxic 
mice and patients, although the differences observed between the animal and the 
human pathology could be the cause of this different phenothipe. The identification of 
dysregulated targets in both the species will give more informations about the effect 
of miR-21 alteration in the development of PAH.  
 
In summary, the results presented in this thesis support a role for defined miRNAs in 
the development of PAH, both in animal models and patients. Whether this specific 
alteration of selective miRNAs can be used as a novel therapeutical approach still need 
to be evaluated, but represent an attractive possibility to assess in the longer term.  
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1. Introduction 
1.1 The Pulmonary Circulation 
1.1.1 General Structure and Organization of the Circulatory 
System 
The pulmonary circulation comprises the passage of blood from the heart to the lung, 
and back to the heart again. In particular, the right atrium of the heart receives 
through the superior (upper) and inferior (lower) vena cava all the blood de-
oxygenated during its transit in the systemic circulation. This blood reaches then the 
right ventricle and is pumped into the pulmonary artery, travelling through the lungs. 
The pulmonary artery is the only artery of the body that carries deoxygenated blood, 
and it begins at the anterior base of the right ventricle. It then bifurcates into two 
branches, the right and the left pulmonary arteries, which deliver the de-oxygenated 
blood to the lungs, located in two cavities on either side of the heart. The right and the 
left lung are both divided into lobes by interlobular fissures. In particular, the left lung 
is characterized by a superior and inferior lobe, both supplied with a branch of the left 
pulmonary artery, whereas the right lung is divided into three lobes, superior, middle 
and inferior, all supplied with a branch of the right pulmonary artery. The main 
function of the pulmonary circulation is to deliver the whole cardiac output to the 
anatomic sites of gas exchange, located at the level of the terminal alveoli, named 
terminal respiratory units or acini (Murray 2010). The large surface area within the 
alveolar region guarantees an efficient oxygenation of the blood, which leaves the 
lungs and returns to the left atrium of the heart through pulmonary veins, to be then 
distributed to the body through the systemic circulation. Most branches of the 
pulmonary artery lie side by side with branches of the bronchial tree, whereas 
pulmonary veins are isolated structures which normally lie distant from pulmonary 
arteries and bronchi (Murray 2010).  
All the branches originated from the main pulmonary artery can be numerically 
categorized using the diameter-defined Strahler ordering system (Jiang, Kassab et al. 
1994; Huang, Yen et al. 1996). This system defines as “order 1” vessels the most 
peripheral pulmonary arteries and the order number of the confluent vessel is 
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increased by 1 when two vessels of the same order meet, until the main pulmonary 
artery is reached. 15 different orders have been identified in this way, and specific 
characteristics can be assigned to different groups of orders. For example, large 
proximal pulmonary arteries (orders 15-13), which lie next to cartilage-containing 
bronchi, are characterized by an elastic wall, whereas the more distal peripheral 
pulmonary arteries (orders 13-4) have muscular walls, as a consequence of increased 
smooth muscle and decreased elastic laminae in the tunica media. It is important to 
note that these orders of arteries can be defined muscular in comparison with the 
main branches of the pulmonary artery, and therefore within the pulmonary 
circulation, but appear substantially less muscularized than their counterparts in the 
systemic circulation. This layer of smooth muscle cells is decreased even further in the 
precapillary arteries (orders 4-1), mainly composed of a thin endothelial cell layer to 
facilitate gas exchange (Hislop and Reid 1978; Murray 2010).  
Pulmonary arterial walls are composed of three different layers or “tunics”, named 
intima, media and adventitia. Distinct cell types can be identified in each tunic. The 
tunica intima represents the innermost layer of a pulmonary artery, and it is composed 
by a single layer of pulmonary artery endothelial cells (PAECs). Being directly in contact 
with the blood flow, PAECs undoubtedly exert a relevant modulating influence on the 
response of the pulmonary circulation to different stimuli via the release of several 
mediators, including nitric oxide (NO), endothelin-1 (ET-1) and prostacyclin (Aaronson, 
Robertson et al. 2002). The tunica media is the middle coat of an artery and is made up 
of smooth muscle cells and elastic tissue. Multiple phenotypically distinct smooth 
muscle cell populations have been identified in this layer (Frid, Moiseeva et al. 1994). 
Pulmonary artery smooth muscle cells (PASMCs) are able to produce a contractile 
response when stimulated, and they can therefore regulate arterial tone and blood 
pressure. The tunica adventitia represents the last and outermost layer of a pulmonary 
blood vessel, and it is mainly composed of pulmonary artery fibroblasts (PAFs). An 
increasing volume of studies indicates that this layer is a critical regulator of vessel wall 
function in health and disease. In fact, in response to environmental stresses such as 
hypoxia, PAFs are characterized by a variety of functional changes, including cell 
proliferation and secretion of factors able to influence vascular tone and wall structure 
(Stenmark, Fagan et al. 2006). 
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1.1.2 Main Functions of the Pulmonary Circulation 
As already mentioned, the main and most essential function of the pulmonary 
circulation is to determine the re-oxygenation of the poorly oxygenated blood deriving 
from the systemic circulation. The pulmonary artery begins as a single trunk at the 
anterior base of the right heart, but then it divides into a right and a left branch which 
in turn originate thousands of arterioles, and finally hundreds of millions of alveolar 
capillaries. The volume of blood which can go across these capillaries at one time is 
only about 75 ml, but the total surface area of the capillaries is 70 m2. Also the alveolar 
area has a similar surface available for gas exchange (Comroe 1966). However, several 
additional functions can be assigned to the pulmonary circulation. First of all, it 
accomplishes the important function of retaining fine particles present in mixed 
venous blood, preventing these from entering the systemic circulation (Comroe 1966). 
It also acts as a physical barrier against those thrombi which are formed in the 
systemic venous circulation, again preventing their passage to the systemic circulation. 
In fact, there are many more pulmonary capillaries than are needed for effective gas 
exchange in resting man and some of these can be sacrificed to protect the rest of the 
circulation from occlusions which may induce an infarction (Comroe 1966). Moreover, 
pulmonary vessels, normally containing about 600 ml of blood, represents an 
important reservoir that can supply blood to fill the heart and maintain a normal 
output after a trauma (Comroe 1966). 
 
1.1.3 Pulmonary Vascular Resistance and Blood Flow 
Vascular resistance is defined as the resistance to flow that must be overcome to push 
blood across the circulatory system. In particular, a systemic and a pulmonary vascular 
resistance (SVR and PVR respectively) can be identified. During fetal life, oxygenation 
of the blood occurs mainly via the placenta, and only 8-10% of the total cardiac output 
flows through the pulmonary circulation, characterized by an high PVR to divert away 
blood from the lungs (Hislop and Pierce 2000). This is due to the relatively small lumen 
and thick muscle walls of the pulmonary arteries observed at this stage. However, 
immediately after birth, when exposure to atmospheric oxygen fully dilates the 
pulmonary circulation, a decrease in wall thickness occurs, with a consequent drop in 
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PVR, and 100% of the cardiac output can flow across the lungs. In the adult, the 
pulmonary circulation can be therefore considered a high-flow, but low-resistance and 
low-pressure system in comparison with the systemic circulation. In fact, the mean 
pulmonary arterial pressure (mPAP) is substantially lower than the corresponding 
mean systemic arterial pressure (mSAP), being the first around 15 mmHg and the 
second 93 mmHg (Morgan, Lauri et al. 2004). Considering that small changes in the 
diameter of a blood vessel can significantly affect blood flow and PVR, it is not 
surprising that uncontrolled cell growth and vascular remodelling are the main cause 
of the sustained increased in PAP observed in several cardiovascular pathologies.  
 
1.1.4 Passive and Active Regulation and Distribution of the 
Blood Flow 
The lung of a normal healthy person can be divided into three zones characterized by a 
different blood flow, determined by different relative values of pulmonary arterial (Pa), 
pulmonary venous (Pv) and alveolar (PA) pressure. A passive uneven blood flow 
distribution can therefore be identified in the pulmonary circulation, gravity-
dependent and influenced by the site-entry of the pulmonary arteries in the lung, 
localized in the mid-portion of the organ. In particular, zone 1 identifies the upper 
portion of the lung, where the blood flow is extremely low since PA is greater than both 
Pv and Pa (PA > Pa > Pv), with a consequent collapse of the vasculature (Figure 1-1). In 
zone 2, localized in the medium part of the lung, Pa is the greatest among the three 
pressures, but PA still exceeds Pv (Pa > PA > Pv) (Figure 1-1). The blood flow is therefore 
higher, but still not at its maximum level, although modest increases in arterial 
pressure can determine the recruitment of more vessels into the pulmonary 
circulation. The lowest part of the lung is identified as zone 3, where both Pa and Pv are 
higher than PA (Pa > Pv > PA), determining a constant distention of the vessels and a 
high blood flow (Hughes 1975) (Figure 1-1).  
Pulmonary arterial pressure is also deeply influenced by an active regulation of the 
blood flow. In fact, several factors, including sympathetic nerves, humoral mechanisms 
and respiratory gases can act on the PASMC contraction, determining in this way 
changes on the PVR (Barnes and Liu 1995). 
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Figure 1-1  Passive, gravity-dependent blood flow distribution through the lung. The lung 
of an healthy adult can be divided in three different zones, characterized by different relative 
values of pulmonary arterial pressure (Pa), pulmonary venous pressure (Pv) and alveolar 
pressure (PA), resulting in a different blood flow. Reported from University of Michigan Medical 
School, 
http://creativecommons.org/licenses/by/3.0/deed.en 
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1.1.5 Hypoxic Pulmonary Vasoconstriction  
Hypoxic pulmonary vasoconstriction (HPV) is an adaptive response to alveolar hypoxia 
that consent the redistribution of blood from poorly oxygenated areas to better 
ventilated lung segments by an active process of vasoconstriction. This process 
determines a more efficient blood re-oxygenation, and involves mainly the small 
resistance arteries (McCulloch, Kempsill et al. 2000). HPV is an intrinsic mechanism of 
the pulmonary vasculature, since the vasodilator effect of hypoxia on the systemic 
vasculature has been previously reported (Gregor and Janig 1977). PASMCs have been 
identified as the cell type responsible for monitoring the O2 concentration in the 
vasculature, since HPV occurs in presence or in absence of the endothelium (Marshall 
and Marshall 1992), although different studies reported a prolonged contractile 
response of PASMCs in response to hypoxia only in presence of a functional 
endothelium (Holden and McCall 1984; Archer, Wu et al. 2004). It is well accepted that 
an elevation of the internal Ca2+ concentration in these cells is an early and critical 
element leading to HPV. However, the mechanism and the vasoactive mediators 
responsible for this process are still under investigation. The best documented 
hypothesis suggests that hypoxia could induce the inhibition of voltage-gated K+ 
channels (Kv channels), causing the depolarization of the PASMC membrane and the 
consequent Ca2+ entry via voltage-dependent L-type channels (McMurtry, Davidson et 
al. 1976). According with this theory, Kv channel inhibition would be determined by a 
decrease in the intracellular concentration of H2O2, due to a reduction in mitochondrial 
electron transport induced by the lack of O2. Considering the main role of 
mitochondria in O2 consumption and energy generation, they would represent an ideal 
candidate for O2 sensing, and several studies have supported this hypothesis (Mauban, 
Remillard et al. 2005; Moudgil, Michelakis et al. 2005), although others have reported 
an hypoxia-mediated increase of the levels of H2O2 and other reactive oxygen species 
(ROS) in HPV, suggesting the existence of an alternative mechanism that still needs to 
be investigated (Waypa and Schumacker 2005).  
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1.2 Pulmonary Arterial Hypertension 
1.2.1 Clinical Presentation and Classification 
Pulmonary arterial hypertension (PAH) is a disease of the small pulmonary arteries 
(PAs), characterized by vasoconstriction and vascular remodeling leading to a 
progressive increase in pulmonary vascular resistance (PVR), resulting in right 
ventricular hypertrophy and dilatation (Rich, Dantzker et al. 1987; Gaine and Rubin 
1998). The consequence of vascular obliteration is right heart failure and high 
mortality (Eddahibi, Morrell et al. 2002; Jeffery and Morrell 2002). PAH is normally 
diagnosed if mean pulmonary arterial pressure (mPAP) is higher than 25 mm Hg at 
rest. It is a rare disease that affects approximately two or three individuals per million 
per year. 
 
Transthoracic echocardiogram is usually the first diagnostic test performed in case of 
suspected PAH. This test can give an evaluation of the systolic right ventricular 
pressure (sRVP), right chamber dimension and RV function. The diagnosis is then 
normally confirmed with the measurement of the pulmonary haemodynamics and 
cardiac output, obtained through right heart catheterization (RHC). An early diagnosis 
of PAH is very important since prognosis without treatment is poor, with a median 
survival time of 2.8 years (D'Alonzo, Barst et al. 1991). However, the symptoms of this 
disease, including shortness of breath, fatigue and syncope, are often non-specific in 
the early stages of this disease, and may be attributed to stress or anxiety. For this 
reason, diagnosis can be often delayed. For a correct identification of this condition, 
particular attention should be given to previous medical conditions, drug use and 
family history. According to the last National Pulmonary Hypertension Audit Report, 
the mean age of the diagnosed patients is 56 years and the ratio of females to males is 
1.9:1 (NCASP, First Annual Report of the National Audit of Pulmonary Hypertension 
2010). After diagnosis, the clinical severity of PAH can be classified using the New York 
Heart Association (NYHA) classification for heart failure symptoms, characterized by 4 
functional classes based on the patient’s ability to function. In particular, class I 
patients are still asymptomatic and in an early stage of the disease, while class IV 
patients are substantially limited in their physical activity (Nauser and Stites 2001) 
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(Table 1-1). This classification is very important for the identification of the best 
available treatment for the patient. Another useful marker of disease severity includes 
the 6-minute walk test, used to undertake a functional assessment of exercise 
capacity. In particular, this test can reveal decreased exercise tolerance in PAH patients 
(Miyamoto, Nagaya et al. 2000). Clinical manifestations of the disease are fairly 
consistent among PAH patients, regardless of its etiology (Simonneau, Galie et al. 
2004; Voelkel and Cool 2004). In particular, HPAH and IPAH have a similar clinical 
course and a survival rate although recent reports suggest that HPAH has an earlier 
onset and more severe hemodynamic impairment at diagnosis (Sztrymf, Coulet et al. 
2008). 
 
The first classification of PAH, based on the pathophysiological mechanisms and the 
therapeutic options available at the time, was proposed in 1973 by the World Health 
Organization. Since then, there have been a series of modifications to reflect the new 
findings in the last few years. According to the latest classification, formulated during 
the 4th World Symposium on PAH held in 2008 in Dana Point, California, PAH can be 
subcategorized into i) idiopathic (IPAH), when the disease is sporadic and cannot be 
correlated with a family history or with an identified risk factor, ii) heritable (HPAH), 
when it occurs in a familial context and/or it is associated with a germline mutation, iii) 
drug- and toxin-induced, iv) associated with a known risk factor, including a congenital 
heart disease or HIV infection, and finally v) persistent pulmonary hypertension of the 
newborn (PPHN) (Rosenkranz and Erdmann 2008; Simonneau, Robbins et al. 2009). 
This classification also includes other forms of PH, subcategorized into pulmonary 
veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH), 
pulmonary hypertension owing to left heart disease, pulmonary hypertension owing to 
lung disease and/or hypoxia and chronic thromboembolic pulmonary hypertension 
(CTEPH) (Table 1-2) (Rosenkranz and Erdmann 2008; Simonneau, Robbins et al. 2009).  
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Functional Assessment of Patients with Pulmonary Hypertension
Class I Patients with pulmonary hypertension but without resulting limitation of 
physical activity. Ordinary physical activity does not cause undue dyspnea 
or fatigue, chest pain or near syncope.
Patients with pulmonary hypertension resulting in marked limitat ion of 
physical activity. These patients are comfortable at rest, but less than 
ordinary physical activity causes undue dyspnea or fatigue, chest pain or 
near syncope.
Patients with pulmonary hypertension resulting in slight limitation of 
physical activity. These patients are comfortable at rest, but ordinary 
physical activity causes undue dyspnea or fatigue, chest pain or near 
syncope.
Patients with pulmonary hypertension resulting in inability to perform any 
physical activity without symptoms. These patients manifest signs of right 
heart failure. Dyspnea and/or fatigue may be present at rest, and 
discomfort is increased by any physical activity.
Class II
Class III
Class IV
 
Table 1-1  New York Heart Association (NYHA) classification of functional status in 
patients with pulmonary hypertension. 
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Updated Clinical Classification of Pulmonary Hypertension 
(Dana Point, 2008)
1. Pulmonary arterial hypertension (PAH)
1.1. Idiopathic PAH
1.2. Heritable
1.2.1. BMPR2
1.2.2. ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia)
1.2.3. Unknown
1.3. Drug- and toxin-induced
1.4. Associated with
1.4.1. Connective tissue diseases
1.4.2. HIV infection
1.4.3. Portal hypertension
1.4.4. Congenital heart diseases
1.4.5. Schistosomiasis
1.4.6. Chronic hemolytic anemia
1.5 Persistent pulmonary hypertension of the newborn
1’. Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary 
hemangiomatosis (PCH)
2. Pulmonary hypertension owing to left heart disease
2.1. Systolic dysfunction
2.2. Diastolic dysfunction
2.3. Valvular disease
3. Pulmonary hypertension owing to lung diseases and/or hypoxia
3.1. Chronic obstructive pulmonary disease
3.2. Interstitial lung disease
3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4. Sleep-disordered breathing
3.5. Alveolar hypoventilation disorders
3.6. Chronic exposure to high altitude
3.7. Developmental abnormalities
4. Chronic thromboembolic pulmonary hypertension (CTEPH)
5. Pulmonary hypertension with unclear multifactorial mechanisms
5.1. Hematologic disorders: myeloproliferative disorders, splenectomy
5.2. Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis: 
lymphangioleiomyomatosis, neurofibromatosis, vasculitis
5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis
 
Table 1-2  Current WHO clinical classification of pulmonary hypertension, Dana Point 
2008. BMPR2, bone morphogenetic protein receptor type 2; ALK1, activin receptor like kinase-
1, HIV, human immunodeficiency virus. 
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1.2.2 PAH Pathobiology 
PAH is characterized by structural alterations of the small, peripheral arteries of the 
lung (Figure 1-2). A marked increase in vasocostriction is considered an important 
initiating factor responsible for the development of PAH, mainly due to endothelial cell 
dysfunction. In fact, in healthy subjects one of the main functions of the pulmonary 
endothelium is the maintenance of a low and stable PVR through a balance between 
vasodilator (mainly prostacyclin and nitric oxide (NO)) and vasoconstrictor (including 
endothelin-1 and serotonin) release. In contrast, it has been shown that in PAH 
patients, endothelial cells lose their capacity to preserve the normal vascular tone and 
start to produce more vasoconstrictors and less vasodilator/antiproliferative 
mediators, thereby shifting this balance, resulting in an elevation of PVR (Giaid and 
Saleh 1995; Tuder, Cool et al. 1999; Eddahibi, Humbert et al. 2001; Davies and Morrell 
2008). The second step of the disease is characterized by an abnormal proliferation of 
pulmonary artery fibroblasts (PAFs), pulmonary artery smooth muscle cells (PASMCs) 
and pulmonary artery endothelial cells (PAECs) leading to vascular remodelling, 
considered the hallmark of PAH (Hassoun, Mouthon et al. 2009). A direct consequence 
of vascular remodelling is the narrowing and eventually the obliteration of the vessel 
lumen, leading to a further increase in PVR (Humbert, Morrell et al. 2004; Tuder, 
Abman et al. 2009).  If this persists, the increased workload of the heart causes a 
compensatory hypertrophy of the right ventricle (RVH), and eventually right 
ventricular failure. The latter is the main cause of mortality in PAH patients (Guglin and 
Khan 2010).  
 
Although vascular remodelling is characterized by an increased level of cell 
proliferation, PAECs apoptosis has been observed in early stages of the process. This 
temporary reduction in EC number may stimulate PASMCs through their exposure to 
circulating mitogenic factors (Sakao, Tatsumi et al. 2009). Moreover, enhanced 
apoptosis of PAECs may create the conditions for the selection of apoptosis-resistant 
cells with increased growth potential. This hypothesis is consistent with the 
observation that few apoptotic cells have been identified in the remodeled vessels of 
patients with severe PAH (Ameshima, Golpon et al. 2003). Also, Masri et al. reported 
that PAECs isolated from IPAH patients exhibit a hyper-proliferative potential, with 
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decreased susceptibility to apoptosis (Masri, Xu et al. 2007). Since bone 
morphogenetic proteins (BMPs, section 1.2.4.1) can reduce in vitro apoptosis of PAECs 
(Hirose, Hosoda et al. 2000), the impaired BMP signaling due to mutations in the 
BMPR2 gene, observed in 80% of cases of HPAH (section 1.2.4.1), could explain this 
initial cell apoptosis (Sakao, Tatsumi et al. 2009). As already mentioned, dysfunction of 
PAECs can directly alter the balance between proliferation and apoptosis in PASMCs, 
since several vasoconstrictive agents, vasodilators and growth factors produced by 
PAECs, which act upon PASMCs proliferation and differentiation in healthy conditions, 
are dysregulated in PAH patients (Davies and Morrell 2008). Also, PASMCs isolated 
from PAH patients express decreased expression and function of potassium ion 
channels, inducing membrane depolarization and a subsequent cytosolic intake of 
calcium. This can not only further enhances vasoconstriction, but stimulates PASMCs 
migration and proliferation (Yuan, Aldinger et al. 1998; Mandegar and Yuan 2002; 
Pozeg, Michelakis et al. 2003). As a result, smooth muscle hyperplasia and thickening is 
typically observed in mild class II-III PAH vessels (Rubin 1999; Sakao, Tatsumi et al. 
2009). In particular, one of the main histopathological features common to all forms of 
PAH is the accumulation of cells expressing smooth muscle specific alpha-actin (SMA) 
in peripheral pulmonary arteries (Figure 1-3). This includes the appearance of SMA-
positive cells in the neointima, characterized by the presence of a conspicuous 
extracellular matrix, and the extension of SMA-positive cells into precapillary 
pulmonary arterioles that are normally devoid of smooth muscle (Mandegar, Fung et 
al. 2004). Also numerous macrophages can be identified within intimal lesions 
(Atkinson, Stewart et al. 2002). The cellular processes responsible for the 
muscularization of this distal part of the PA are not clear, but these observations 
suggest a central role for PASMCs in the development of PAH. 
 
Plexiform lesions represent an extreme example of vascular remodelling and can be 
usually observed in severe PAH patients. These lesions can normally develop just distal 
to bifurcation sites of small pulmonary arteries (≈ 50-300 m) predominantly as a 
result of PAECs hyper-proliferation, and cause the obliteration of the arterial lumen 
(Tuder, Groves et al. 1994) (Figure 1-3). This abnormal and uncontrolled growth of 
endothelial cells can be considered a neoplastic-like event. In 2003 Ameshima and 
colleagues reported the decreased expression of the peroxisome proliferator-activated 
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receptor (PPAR)-gamma, a tumor suppressor gene, in the plexiform lesions of patients 
with severe PAH (Ameshima, Golpon et al. 2003). PPAR-gammahas anti-proliferative, 
pro-apoptotic and anti-inflammatory functions, and it has been reported to inhibit 
angiogenesis (Chinetti, Griglio et al. 1998; Jiang, Ting et al. 1998; Tsubouchi, Sano et al. 
2000). Inflammatory cells (including T-, B-lymphocytes and macrophages) have been 
identified in the surrounding area of plexiform lesions (Humbert, Morrell et al. 2004; 
Hassoun, Mouthon et al. 2009; Pullamsetti, Savai et al. 2011). 
 
 
 
Figure 1-2  Pathobiology of PAH. The cartoon illustrates the structural alterations associated 
with PAH in comparison with normal pulmonary circulation. They include: (i) abnormal 
muscularization of distal precapillary arteries, (ii) medial thickening of large pulmonary muscular 
arteries, (iii) loss of precapillary arteries, (iv) neointimal formation and (v) formation of plexiform 
lesions in these vessels. Reported from (Rabinovitch 2008). 
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Figure 1-3  Histopathological changes associated with human PAH. Positive 
immunostaining of endothelial marker CD31 is identified in plexiform lesions (A), whereas 
supporting stroma is positive for alpha-smooth muscle actin (alpha-SMA) (B). In concentric 
intimal lesions, a single layer of PAECs is detected adjacent to vascular lumen (C, arrow) while 
concentric layers of PASMCs are identified in the vascular wall (D). Adapted from (Atkinson, 
Stewart et al. 2002). 
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1.2.3 PAH Animal Models 
Numerous animal models for the study of PAH are currently available. In particular, the 
chronic hypoxic and the monocrotaline injury model have been abundantly used in the 
last decade for the investigation of the PAH pathobiology. However, different models 
have been also introduced in the last years.  
 
1.2.3.1 Chronic Hypoxic Animals 
Hypobaric hypoxia is often used to induce PAH in a wide variety of animal species. This 
model is very reproducible, although differences can be observed between different 
species and strains (Figure 1-4). Rats and mice are the species most commonly 
exposed to chronic hypoxia to conduct PAH studies. In rats, 2 weeks of hypoxia can 
induce a moderate PAH characterized by a doubling of mRVP and a significant RVH, 
with a rare right ventricle failure. In particular, the muscularization of the small, non-
muscular arteries of the pulmonary vasculature is observed relatively rapidly, followed 
by their increased medial and adventitial thickening (Meyrick and Perkett 1989). It has 
also been reported that sustained hypoxia can induce a pulmonary artery-specific 
inflammatory response (Burke, Frid et al. 2009). In mice, the vascular remodelling 
induced by the exposure to chronic hypoxia is minimal and less evident than in rats, 
but it is possible to observe the muscularization of the non-muscular vessels and a 
poor medial thickening (Firth, Mandel et al. 2010) (Figure 1-4). Adventitial thickening 
and fibrosis of proximal pulmonary arteries has also been reported (Estrada and 
Chesler 2009). However, both in mice and rats, the disease is reversible when 
normoxia is restored. 
 
1.2.3.2 Monocrotaline-Induced PAH 
The pneumotoxic alkaloid monocrotaline can be used to generate an animal model of 
PAH. Its capacity to induce the progressive development of PAH after ingestion in 
several animal species was reported more than 40 years ago (Kay, Harris et al. 1967). 
In particular, this toxin must be activated in the liver by specific oxidases to form the 
monocrotaline pyrrole (MCTP), able to induce PAH. A single subcutaneous or 
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intraperitoneal injection can induce, by an unknown mechanism, pulmonary vascular 
remodelling, RVH and elevated mPAP over a period of one to two weeks (Hessel, 
Steendijk et al. 2006). The accumulation of mononuclear inflammatory cells in the 
adventitia of the small intra-acinar vessels has also been reported (Wilson, Segall et al. 
1989). This treatment is most commonly used in rats, whereas in mice a 
monocrotaline-induced PAH can be observed only after the injection of the active 
MCTP, since the precursor is not metabolized in the liver. However, injection of active 
MCTP is highly variable and rarely used (Dumitrascu, Koebrich et al. 2008). The 
ingestion of monocrotaline can also induce liver and kidney damage (Roth, Dotzlaf et 
al. 1981). Monocrotaline injury is severe but not irreversible. In fact, the disease can be 
prevented and in some case treated with several agents (Cowan, Heilbut et al. 2000; 
Baber, Deng et al. 2007; Csiszar, Labinskyy et al. 2009; Hsu, Ko et al. 2009). In 
particular, it is interesting to note that some agents implicated in the development of 
PAH in humans can attenuate or treat the disease in the monocrotaline model, 
including dexfenfluramine (Mitani, Mutlu et al. 2002). 
 
Since hypoxic and monocrotaline-injected animals do not represent a perfect model 
for PAH, several alternatives have been considered in recent years. In consideration of 
the association between mutations in the BMPR2 gene and this disease (Section 
1.2.4.1), PAH development in heterozygous mice (BMPR2+/-) has been evaluated. Long 
et al. studied 8 weeks old BMPR2+/- animals and observed a normal mPAP at rest. An 
additional factor such has serotonin was required to observe a significant increase in 
mPAP (Long, MacLean et al. 2006). However, West et al. recently reported that 9 
weeks old mice over-expressing a truncating mutation in the BMPR2 gene tail domain 
(R899X) developed elevated right ventricular systolic pressures (RVSP), associated with 
extensive pruning, muscularization of small pulmonary vessels, and development of 
large structural pulmonary vascular changes, approximately one-third of the time in 
normoxic conditions (West, Harral et al. 2008). Since BMPR2 homozygous KO is lethal 
in mice, a conditional KO could represent in the future an interesting option to 
evaluate.  
 
Based on the concept that vascular endothelial growth factor (VEGF) has a crucial role 
in endothelial cell differentiation, researchers assessed the effect of the inhibition of 
VEGF signaling in animals exposed to chronic hypoxia. They observed that the VEGF 
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receptor inhibitor Sugen 5416 could induce severe and irreversible PAH in chronic 
hypoxic rats. In particular several pieces of evidence showed not only the persistence, 
but also a further progression of the disease even after the removal of the hypoxic 
stimulus (Taraseviciene-Stewart, Kasahara et al. 2001). These mice present occlusive 
neointimal lesions, elevated mPAP and vascular smooth muscle/endothelial cells 
hyperproliferation, and represent for this reason a new interesting option for the 
investigation of PAH (Figure 1-5).  
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Figure 1-4  Effect of hypoxia on the pulmonary vasculature of mice, rats and calf. 
Hypoxia-induced vascular remodelling varies significantly among species, with minimal changes 
in mice and marked changes in neonatal calves. Adapted from (Stenmark, Meyrick et al. 2009). 
 
 
A. Normoxia B. Hypoxia C. Hypoxia/SU5416
 
 
Figure 1-5  Occlusive neointimal lesions in rats treated with Sugen 5416 and chronic 
hypoxia. Compared with normoxic rats (A), rats exposed to hypoxia alone display only mild 
lung vascular remodelling (B). In contrast, hypoxia/SU-5416-exposed rats show marked 
vascular remodelling with medial wall thickening and endothelial cell hyper-proliferation (C, 
inserts). Adapted from (Stenmark, Meyrick et al. 2009). 
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1.2.4 Genetic Basis of Pulmonary Arterial Hypertension 
1.2.4.1 TGF-beta Super-Family and BMPR2 Involvement in PAH 
The transforming growth factor beta (TGF-beta) super-family is one of the most 
evolutionarily conserved signal transduction pathways in the animal kingdom, 
composed by secreted polypeptides that activate cellular responses during growth and 
differentiation (Eickelberg and Morty 2007). More than 60 members of this family 
have been identified so far, with 30-40 proteins encoded by the human genome (Feng 
and Derynck 2005). This group includes three TGF-beta isoforms, five activins and at 
least eight different bone morphogenetic proteins (BMPs), able to signal through cell 
surface by binding specific type I (e.g. TGF-beta receptor 1, TGFBR1 (also named Alk5), 
activin receptor-like kinase 1, Alk1, BMP receptor 1A and 1B, BMPR1A and BMPR1B) 
and type II receptors (e.g. TGF-beta receptor 2, TGFBR2, and BMP receptor 2, BMPR2). 
In particular, both the receptor types are trans-membrane serine/threonine kinases 
that form homodimers at the cell surface in the absence of ligands but have 
heteromeric affinity for each other. Ligand binding induces the formation of a receptor 
complex composed by two homodimers (one composed by type I receptors and one 
made of type II receptors), followed by the transphosphorylation of the type I 
receptors by the constitutively active type II receptors (Figure 1-6 and Figure 1-7) (Feng 
and Derynck 2005). Active type I receptors can then phosphorylate the receptor-
associated cytoplasmic effector molecules of the TGF-beta signaling, represented by 
the Smad proteins. Three sub-groups of Smad proteins have been identified: receptor-
activated smads (R-smads), common-mediator Smad (co-Smads) and antagonistic or 
inhibitory Smads (I-Smads) (Figure 1-6) (Derynck and Zhang 2003; Shi and Massague 
2003; Feng and Derynck 2005). When ligand binds the receptor complex, type I 
receptors recruits and phosphorylate R-Smads (i.e. TGFBR1 activates Smad2 and 
Smad3 after the interaction with a TGF-beta isoform, while Alk1, BMPR1A and 
BMPR1B activate Smad1, Smad5 and Smad8 via binding with a BMP ligand, (Figure 1-6 
and Figure 1-7) leading to their conformational change and dissociation from the 
receptor. After the activation two R-Smads interact with a co-Smad (called Smad4) and 
translocate into the nucleus, where they act as transcription factors regulating genes 
that modulate cell proliferation and apoptosis (Figure 1-6) (Derynck and Zhang 2003; 
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Shi and Massague 2003). Since different combinations of type I and type II receptors 
can be formed (Figure 1-7), it is interesting to note that the same ligand can induce 
different signaling responses depending on the composition of the activated receptor 
complex. The I-Smad group is represented by Smad6 and Smad7 and it is able to 
interfere with the intracellular transmission of the signal. These proteins can in fact 
associate with type I receptors blocking R-Smad recruitment and activation (Hayashi, 
Abdollah et al. 1997; Imamura, Takase et al. 1997). Since Smad1 and Smad5 induce 
Smad6 whereas Smad3 stimulates Smad7 expression, both the TGF-beta and the BMP 
signaling are subdued to an inhibitory feedback loop. One of the main transcriptional 
targets of BMP signaling is the inhibitor of DNA binding family of proteins (id1-4) 
(Hollnagel, Oehlmann et al. 1999), characterized by the ability to bind with an high 
affinity helix-loop-helix transcription factors and inhibit their binding to target DNA 
(Sun, Copeland et al. 1991; Ruzinova and Benezra 2003). This function confers to id 
proteins an important role in cell differentiation and proliferation (Lasorella, Uo et al. 
2001; Peng, Kang et al. 2004). 
 
TGF-beta signaling has been implicated in the regulation of ECs and SMCs proliferation 
and differentiation during angiogenesis. Several in vivo studies show that depletion of 
different components of this super-family leads to abnormal formation of the vascular 
plexus and decreased vessel wall integrity. In particular, mice depleted for Alk1, 
TGFBR1 or TGFBR2 die during mid-gestation due to impaired vascular development 
(Goumans and Mummery 2000; Carvalho, Itoh et al. 2007).  
 
TGF-beta can regulate ECs proliferation and migration via interaction with Alk1 or 
TGFBR1. In fact, TGF-beta/TGFBR1 signaling inhibits ECs proliferation and migration 
through the phosphorylation of Smad2/3 and the subsequent activation of 
plasminogen activator inhibitor type 1 (PAI1), a negative regulator of EC migration 
(Deng, Curriden et al. 1996; Goumans, Valdimarsdottir et al. 2002; Goumans, 
Valdimarsdottir et al. 2003). On the contrary, TGF-beta/Alk1 signaling has been shown 
to stimulate EC migration and proliferation via activation of Smad1/5 and their target 
id1 (Goumans, Valdimarsdottir et al. 2002; Goumans, Valdimarsdottir et al. 2003). 
However, Alk1 interaction with a different ligand, BMP9, induces the opposite effect 
(David, Mallet et al. 2007). Also BMP4 and BMP6 promote EC proliferation and 
migration via Smad1/5/8 phosphorylation (Suzuki, Montagne et al. 2008).  
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TGF-beta can also stimulate vascular SMCs differentiation by activating a large set of 
SMC differentiation marker genes (Owens 2007). TGF-beta also induces inhibition of 
cellular growth via a TGFBR1-mediated Smad3 activation (Feinberg, Watanabe et al. 
2004). Also BMPs have an effect on SMCs activation state. BMP2 stimulates SMCs 
migration, while BMP7 inhibits their growth and maintain their differentiated state and 
BMP4 can induce their apoptosis via a caspase8/9-dependent mechanism (Lagna, 
Nguyen et al. 2006; Hansmann, de Jesus Perez et al. 2008). 
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Figure 1-6  The TGF-beta signaling pathway. Ligands of the TGF-beta super-family first bind 
to the type II or type I homodimers stabilizing them in a tetrameric complex, in which type II 
receptors phosphorylate type I receptors. Following receptor activation, R-Smads are recruited 
to the receptor complex and phosphorylated. Phosphorylated Smads (P-Smads) then form a 
trimeric complex with Smad4 and translocate into the nucleus, where they interact with DNA to 
regulate transcription factor expression. Reported from (Feng and Derynck 2005). 
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Figure 1-7  Heteromeric combinations of TGF-beta super-family receptors. Specific 
combinations of type II-type I heterotetramers able to bind TGF-beta ligands at the cell surface 
are indicated. Subsequent activation of R-Smads is shown on the right. Adapted from (Feng 
and Derynck 2005). 
 
 
BMPR2 gene
 
 
Figure 1-8  Schematic representation of BMPR2 functional domains. A range of BMPR2 
mutations observed in patients, indicating the nature of amino acid substitution or nonsense 
mutations (X) are showed. Adapted from (Dewachter, Adnot et al. 2009). 
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Mutations in the gene coding for the type II receptor BMPR2 are associated with the 
development of HPAH. In fact, mutations in this gene have been identified in more 
than 70% of families characterized by affected members (Machado, Aldred et al. 
2006), and also 15-40% of patients with IPAH are carriers of similar mutations 
(Thomson, Machado et al. 2000). It has been estimated that the risk of developing PAH 
for someone carrying a BMPR2 mutation is 105 higher in comparison with non-carriers 
(Morrell 2010). These mutations segregate with an autosomal dominant pattern of 
inheritance, but the penetrance of the phenotype is remarkably low, with only 20-30% 
of carriers actually developing HPAH (Newman, Wheeler et al. 2001; Newman, 
Trembath et al. 2004). This low penetrance suggests the existence of some type of 
“second hit”, of genetic or environmental nature (Morrell 2010). The BMPR2 gene is 
190 Kb long and contains 13 exons and a big 90 Kb first intron with frequent repetitive 
sequences (Johnson, Vnencak-Jones et al. 2009) (Figure 1-8). More than 200 different 
mutations, dispersed across the whole gene, have been described so far. The majority 
of them (approximately 70%) are frame-shift and nonsense mutations, resulting in 
aberrant transcripts degraded by the nonsense-mediated decay system (NMD), a 
surveillance system specifically evolved to eliminate those messenger RNA (mRNA) 
sequences containing premature termination codons (Kuzmiak and Maquat 2006; 
Machado, Aldred et al. 2006; Li, Dunmore et al. 2010). Thus, haploinsufficiency for 
BMPR2 seems to represent the main risk factor for HPAH development. Also, it is 
interesting to notice that the low penetrance of the BMPR2 mutations could be at least 
partially explained with the fact that the NMD system is not 100% efficient (Kuzmiak 
and Maquat 2006; Eickelberg and Morty 2007). In the lung vasculature, BMPR2 is 
mainly expressed in PAECs and at a lower lever in PASMCs and PAFs. It is important to 
notice that the expression of this gene is reduced in the pulmonary vasculature of 
HPAH patients carrying a mutation but also in IPAH patients in whom no mutation 
have been identified, suggesting a central role of BMPR2 in the pathogenesis of this 
pathology also in non-carriers (Morrell 2010). Moreover, a reduced phosphorylation of 
Smad1/Smad5 has been shown in patients harboring BMPR2 mutation and one study 
demonstrated increased activation of Smad2 in these category of PAH patients, 
supporting the hypothesis that BMPR2 reduction is able to significantly dysregulate the 
down-stream signaling pathway both via TGF-beta isoforms and BMP proteins (Richter, 
Yeager et al. 2004; Yang, Long et al. 2005). Since BMPR2 transduce the signal to R-
Smads by binding BMP proteins, several groups analyzed the effect of BMP stimulation 
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on pulmonary vascular cells. In primary cells obtained from unaffected controls, the 
response of PASMCs to BMP ligands is related to the site of origin of cells. In fact, BMP 
stimulation of PASMCs harvested from the main or lobar pulmonary arteries (derived 
from neural crest) (Beall and Rosenquist 1990) inhibits cell proliferation and may 
induce apoptosis (Zhang, Fantozzi et al. 2003; Yang, Long et al. 2005), while in contrast, 
in cells isolated from peripheral arteries (1 to 2 mm diameter, mainly formed by 
vasculogenesis within the developing lung mesenchyme) (Hall, Hislop et al. 2000) 
BMPs stimulate proliferation. In healthy conditions, PAECs proliferate and migrate in 
response to BMPs. This proliferation is mediated by Smad1/Smad5 activation and id 
proteins induction (Valdimarsdottir, Goumans et al. 2002). BMPs can also protect 
PAECs from apoptosis (Teichert-Kuliszewska, Kutryk et al. 2006). These specific 
responses observed in normal cells suggest that a critical reduction in BMPR2-
mediated BMP signaling may promote the increased PAECs apoptosis observed initially 
in the pathology (section 1.2.2), stimulating PASMCs through their exposition to 
circulating mitogenic factors and creating the conditions for the selection of apoptosis-
resistant cells with increased growth potential (section 1.2.2). In addition, PASMCs 
located in the underlying media, exposed to the high doses of TGF-beta released as a 
consequence of PAECs apoptosis, would be characterized by an exaggerated growth 
response due to their impaired Smad1/Smad5 signaling (Morrell 2010), explaining the 
exaggerated PASMCs proliferation observed in PAH patients. Further studies will be 
necessary to validate this hypothesis both in vivo and in vitro.  
 
Several studies analyzed the effects of an increased BMPR2 expression in rat models of 
PAH. In monocrotaline rats, adenoviral-mediated BMPR2 over-expression, obtained via 
airway delivery, did not prevent monocrotaline-induced PAH (McMurtry, Moudgil et al. 
2007), whereas a very recent study shows that vascular delivery of an adenovirus 
expressing BMPR2 attenuates monocrotaline-induced PAH (Reynolds, Holmes et al. 
2011). In hypoxic rats a targeted gene delivery of BMPR2 to the pulmonary vascular 
endothelium significantly reduced RVP and RVH (McMurtry, Moudgil et al. 2007; 
Reynolds, Xia et al. 2007). 
 
Because of the enhanced TGF-beta signaling observed in IPAH patients (Richter, Yeager 
et al. 2004) and in monocrotaline-induced rat PAH (Long, Crosby et al. 2009), the effect 
of TGFBR1 blocking has been evaluated in rats. Three different studies showed 
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beneficial effects of TGFBR1 inhibition on PAH development and progression (Long, 
Crosby et al. 2009). 
 
1.2.4.2 Serotonin and SERT Involvement in PAH 
The serotonin system has also been involved in the pathobiology of PAH. In particular, 
the “serotonin hypothesis of PAH” was formulated for the first time in 1960s, and then 
proposed again the 1980s, after the observation that obese patients treated with 
appetite suppressants such as aminorex and dexfenfluramine had an increased risk of 
developing PAH (Abenhaim, Moride et al. 1996; Kramer and Lane 1998). Both 
aminorex and dexfenfluramine are in fact serotonin transporter (SERT) substrate and 
are able to increase the extracellular concentration of serotonin (Rothman, Ayestas et 
al. 1999). Further studies focused on the role of serotonin in PAH revealed its capacity 
to induce proliferation of both PAFs and PASMCs and to promote vasoconstriction and 
remodelling of the pulmonary vasculature (MacLean, Herve et al. 2000; Welsh, Harnett 
et al. 2004). Moreover, it has been observed that PASMCs isolated from PAH patients 
proliferate faster than normal cells in response to serotonin, and elevated levels of 
serotonin itself can be detected in affected patients (Eddahibi, Humbert et al. 2001).  
 
Since tryptophan hydroxylase 1 (Tph1) is the rate-limiting enzyme in the synthesis of 
serotonin in the periphery, its expression level in PAH patients has been evaluated. 
Analysis of lung tissue and PAECs revealed an increased expression of Tph1 in IPAH 
patients in comparison with unaffected controls (MacLean, Herve et al. 2000). Also, 
hypoxia-induced increases in RVP and vascular remodelling are ablated in Tph1 
deficient mice, suggesting a central role for serotonin synthesis in the development of 
hypoxia-induced PAH (Morecroft, Dempsie et al. 2007).  
 
Several studies identified the SERT coding gene (named solute carrier family 6 member 
4, SLC6A4) as another genetic risk factor for PAH development. SERT is an integral 
membrane protein that belongs to the Na+/Cl- family of transporters and it is able to 
transport serotonin across the membrane using Na+ concentration gradient as driving 
force. The promoter region of SLC6A4 is characterized by the presence of repetitive 
elements of varying length, with a common allele composed of 14 repeats (short 
variant, S) and another common allele composed of 16 repeated elements (long 
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variant, L). The L allele results in a higher expression of SERT with a consequent 
increased uptake activity. In a study based on the analysis of a small cohort of IPAH 
patients, a high percentage (65%) of patients homozygous for the L allele was 
identified, suggesting the involvement of SERT enhanced expression in PAH 
development (Eddahibi, Humbert et al. 2001). Also, a predominance of the L allele 
variant has been associated with exaggerated PAH in patients with chronic obstructive 
lung disease and with an increased RVP in patients affected by heart failure (Eddahibi, 
Chaouat et al. 2003). However, subsequent studies based on larger cohorts of PAH 
patients failed to confirm these findings, although affected patients with the L allele 
may present an earlier onset of the pathology (Willers, Newman et al. 2006). It is also 
important to note that an increased expression of the SLC6A4 gene has been observed 
in IPAH patients, with no correlation with the genotype (Eddahibi, Humbert et al. 
2001). Several in vivo studies suggested an involvement of SERT in PAH pathobiology. 
In fact, mice over-expressing SERT (SERT+) exhibit an enhanced RVP and vascular 
remodelling, and develop an exaggerated PAH in response to hypoxia (MacLean, 
Deuchar et al. 2004). A targeted over-expression of SERT in PASMCs induces a similar 
effect in mice (Guignabert, Izikki et al. 2006). On the contrary, mice deficient for SERT 
expression are less susceptible to hypoxia-induced PAH and the pharmacological 
inhibition of SERT via citalopram attenuates the severity of hypoxia-induced PAH in WT 
and SERT+ mice (Eddahibi, Hanoun et al. 2000; Morecroft, Pang et al. 2010). Since 
SERT+ mice show high expression levels of Rho kinase (ROCK), involved in cellular 
proliferation and migration, and also an increased ROCK-dependent vascular 
remodelling, it has been suggested that serotonin could promote cell proliferation via 
activation of the ROCK pathway (Liu, Ren et al. 2009; McMurtry, Abe et al. 2010; 
Connolly and Aaronson 2011). Also, in the previously mentioned Long et al. study 
(section), animals heterozygous for BMPR2 expression (BMPR2+/-) exhibited a 
significant increase in RVP only after serotonin infusion, suggesting that serotonin 
could represent the “second hit” required to uncover a PAH phenotype in case of 
BMPR2 haploinsufficiency (Long, MacLean et al. 2006). 
 
48 
1.2.5 Treatment Options 
Through the 1980s, PAH prognosis was very poor, with only 30% of survivors after 3 
years from the diagnosis. However, over the last decade, several new therapies for the 
treatments of PAH have been introduced, with the intent to improve the 
hemodynamics, the functional NYHA class and the exercise capacity of the patients. 
The next sections will summarize these treatments (Figure 1-9), but it is important to 
remember that although they can substantially improve symptoms and quality of life, 
they do not treat PAH directly, and patient survival still remains poor. 
 
1.2.5.1 Calcium Channel Blockers  
Calcium channel blockers (CCB), also called calcium antagonists, are a class of drugs 
able to slow down the rate at which calcium passes through voltage-gated calcium 
channels (VGCCs) in cardiac muscle and blood vessels. This decreases the intracellular 
concentration of calcium, leading to cellular hyper-polarization and reduction in 
muscle contraction. In particular, in blood vessels a decrease in calcium results in less 
contraction of the vascular smooth muscle and therefore in an increase in arterial 
diameter inducing vasodilatation. In 1991/1992, Rich et al. reported that the use of 
CCB could dramatically improve the survival in PAH patients. However, this positive 
effect was characteristic of those patients showing a favorable response to acute 
administration of a vasodilator, tested during right heart catheterization (Rich and 
Kaufmann 1991; Rich, Kaufmann et al. 1992). In Rich studies, acute vasodilator 
response was assessed through the administration of an high dose of CCB (Rich and 
Kaufmann 1991; Rich, Kaufmann et al. 1992), but subsequent studies documented that 
such a treatment could result in serious adverse effects, especially in non-responders 
(Sitbon, Humbert et al. 1998; Sitbon, Humbert et al. 2005). Different agents are 
therefore recommended for the evaluation of the pulmonary vasoresponsiveness, 
including inhaled nitric oxide (NO), intravenous adenosine and epoprotenol (Galie, 
Ussia et al. 1995; Sitbon, Humbert et al. 1998; Badesch, Champion et al. 2009). A 
pulmonary vasodilator test is considered positive when it is possible to observe a 
decrease in the mPAP of at least 10 mm Hg to reach an absolute value of 40 mm Hg or 
less without a decrease in cardiac output. Unfortunately, such a response is observed 
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only in 10% of patients with PAH and only half of them normally experience long-term 
benefits after CCB administration, suggesting that other factors can influence the 
efficacy of this treatment (Sitbon, Humbert et al. 2005; Montani, Savale et al. 2010). In 
case of negative test, the administration of CCB can result in systemic hypotension, 
worsening right heart failure and death (Partanen, Nieminen et al. 1993; Galie, Torbicki 
et al. 2004), and this treatment is never recommended for patients with severe PAH 
because of the potential high mortality rate observed in this group (Sitbon, Humbert et 
al. 2005). 
 
1.2.5.2 Prostanoids 
Prostacyclin (PGI2) is a natural prostanoid (prostanoids are a group of complex fatty 
acids) produced by the vascular endothelium. It is a potent vasodilator able to reduce 
PVR and it has also antiplatelet aggregator properties. Moreover, it attenuates VSMC 
proliferation through signal transduction following ligand binding to its receptor 
(Shirotani, Yui et al. 1991). Several studies reported that a deficiency in prostacyclin 
production may contribute to the pathogenesis of PAH (Christman, McPherson et al. 
1992; Tuder, Cool et al. 1999; Humbert, Morrell et al. 2004).  
 
Intravenous epoprostenol was the first prostacyclin analogue approved by the Food 
and Drug Administration (FDA) for the treatment of severe PAH in 1995 and it is still 
used with NYHA class III and class IV patients (Badesch, Abman et al. 2004; Badesch, 
Abman et al. 2007). Data obtained from different clinical trials show that a continuous 
intravenous infusion of epoprostenol can significantly improve the 6-minute walk test 
results and the quality of life of patients reducing the mPAP and the PVR (Rubin, 
Mendoza et al. 1990; Barst, Rubin et al. 1996; Badesch, Tapson et al. 2000). However, 
this is an expensive therapy (Highland, Strange et al. 2003), also complicated by the 
need of a continuous administration (obtained via a central venous catheter) due to its 
very short half-life (≈ 3 min). Any interruption of the infusion can result in severe 
rebound PAH. Epoprostenol administration should be avoided in case of concomitant 
use of antiplatelet agents or anticoagulants, which could increase the risk of bleeding, 
or with medications that lower blood pressure. Common adverse effects include jaw 
pain, diarrhea, flushing, nausea and headaches. 
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Treprostinil is another prostacyclin analogue and its use has been approved in 2002 for 
the treatment of NYHA class II-IV PAH. Data obtained from the first clinical trial 
demonstrated that treprostinil administration can substantially improve the 6-minute 
walk test result, the dyspnea fatigue rating and pulmonary hemodynamics including 
mPAP and PVR (Simonneau, Barst et al. 2002). Having a longer half-life than 
epoprostenol (≈3 hours), it can be administrated by subcutaneous infusion, eliminating 
the need for a surgically inserted central venous catheter, with a consequent reduction 
of infection and thrombosis. However, this kind of infusion often induces in patient 
injection-site pain and erythema and also the same adverse effects of epoprostenol 
can be observed (Simonneau, Barst et al. 2002). For this reason, this therapy is 
normally reserved for patients with a severe disease that result refractory to oral 
therapies (Badesch, Abman et al. 2004). 
 
Iloprost is the last synthetic analogue of prostacyclin approved by FDA for the 
treatment of severe PAH (Badesch, Abman et al. 2004). It can be administered by 
inhalation and represents for this reason an attractive option for PAH patients. 
However, the first clinical trials showed a reduced efficacy in comparison with 
epoprostenol and treprostinil, suggesting a potential role for iloprost as an adjunctive 
agent (Hoeper, Schwarze et al. 2000; Olschewski, Simonneau et al. 2002; Opitz, Wensel 
et al. 2005). The adverse effects of this therapy include cough, headache, flushing and 
jaw pain but also syncope, tachycardia, pneumonia and dyspnea. 
 
1.2.5.3 Endothelin Receptor Antagonists 
Endothelins are a class of strong vasoconstrictors mainly produced by endothelial cells 
that play a central role in vascular homeostasis. Endothelin-1 (ET-1) is the most 
abundantly expressed isoform in the pulmonary circulation and it is over-expressed in 
the plasma and the lung of PAH patients (Giaid, Yanagisawa et al. 1993). It has been 
shown that an increase in the expression of this peptide not only results in 
vasoconstriction, but can induce an abnormal growth of endothelial cells, smooth 
muscle cells and fibroblasts and inhibit the apoptosis of smooth muscle and 
endothelial cells (Shichiri, Kato et al. 1997; Jankov, Kantores et al. 2006). ET-1 interacts 
with two different G protein-coupled receptors, named ETA and ETB. ETA is expressed in 
smooth muscle cells and fibroblasts (Evans, Cobban et al. 1999), while ETB is abundant 
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in endothelial and smooth muscle cells (Hori, Komatsu et al. 1992). Both the receptors 
are involved in smooth muscle cells contraction and proliferation (McCulloch, Docherty 
et al. 1996; Davie, Haleen et al. 2002), but ETB also mediates the release of vasodilators 
and antiproliferative factors including prostacyclins and NO from endothelial cells  
(Fukuroda, Nishikibe et al. 1992; Dupuis, Goresky et al. 1996). Consequently, a 
selective blockade of the ETA receptor has been suggested as a potential therapeutic 
agent for the treatment of PAH, and studies conducted with animal models of PAH 
showed that such a treatment result in a 25% reduction of the severity of the 
pathology (Black, Mata-Greenwood et al. 2003). Controversially, another study 
demonstrated that a combined blockage of both the receptors can better antagonize 
the ET-1-induced vasoconstriction (Sato, Oka et al. 1995), suggesting that more studies 
will be necessary to identify the best strategy. At the moment, three endothelin 
receptor antagonists (ERAs) are in clinical use: bosentan, effective in the inhibition of 
both ETA and ETB, sitaxsentan and ambrisentan, selective for the ETA receptor 
(Badesch, Feldman et al. 2011; Klinger, Oudiz et al. 2011; Sandoval, Torbicki et al. 
2011). 
 
Bosentan is an orally active ERA indicated for the treatment of class III-IV PAH. Clinical 
trials completed so far showed that a bosentan-based therapy can significantly 
decrease PVR and improve the exercise capacity (Rubin, Badesch et al. 2002; Galie, 
Hinderliter et al. 2003; McLaughlin, Sitbon et al. 2005).  The most common side effects 
of bosentan are represented by headache, dizziness, flushing and syncope, but also an 
abnormal hepatic function has been observed (Rubin, Badesch et al. 2002). 
Both ambrisentan and sitaxsentan are ERAs specific for ETA with a longer half-life than 
bosentan, which allows once a day dosing. Data obtained from the first clinical trials 
report encouraging improvements in hemodynamics and exercise capacity, but their 
efficacy is still under evaluation (Girgis, Frost et al. 2007; Oudiz, Galie et al. 2009). 
 
1.2.5.4 Phosphodiesterase Type 5 Inhibitors 
Phosphodiesterases are a super-family of enzymes involved in the hydrolysis of cyclic 
nucleotides, and have a specific tissue distribution. In particular, phosphodiesterase 
type 5 (PDE-5) is selectively expressed in the lung and it is implicated in endothelial 
dysfunction because of its capacity to inactivate cyclic guanosine monophosphate 
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(cGMP), the second messenger of the NO pathway in the pulmonary vasculature 
(Moncada and Higgs 1993; Wharton, Strange et al. 2005). Different studies reported an 
increased PDE-5 gene expression and activity in PAH patients, resulting in an impaired 
antiproliferative and vasodilating effect of endogenous NO (Badesch, Abman et al. 
2004; Corbin, Beasley et al. 2005). As we mentioned in section 1.2.5.1, inhaled NO is 
recommended for acute vasodilator testing, but its therapeutic use in the treatment of 
PAH is limited by its very short half-life. For this reason, PDE-5 inhibitors have been 
tested instead as therapeutic agents. In particular, sildenafil, an orally active highly 
specific PDE-5 inhibitor (already used in the treatment of erectile dysfunction) was 
approved by the FDA in 2005. Its use is recommended in patients with mild to 
moderate symptoms (Michelakis, Tymchak et al. 2002; Tantini, Manes et al. 2005; 
Ghofrani, Osterloh et al. 2006). The clinical trials conducted so far show the capacity of 
sildenafil to improve exercise tolerance and RVH (Bhatia, Frantz et al. 2003; Michelakis, 
Tymchak et al. 2003; Sastry, Narasimhan et al. 2004). Also, experiments conducted 
with rats demonstrated an increased percentage of survivals in monocrotaline-induced 
PAH (Schermuly, Kreisselmeier et al. 2004) and an in vitro study showed that this 
treatment can efficiently reduce PASMCs proliferation induced by platelet-derived 
growth factor (Tantini, Manes et al. 2005). Wilkins et al. study compared the efficacy of 
sildenafil versus bosentan as first-line therapy for PAH, showing a comparable effect of 
the two treatments (Wilkins, Paul et al. 2005). In comparison with other treatments 
(i.e. prostanoids), Phosphodiesterase type 5 inhibitors are less expensive and therefore 
more affordable for patients. However, not only common side effects of sildenafil use 
(including headache, flushing, palpitations and back pain) have been observed, but 
also death due to worsening PAH, to pulmonary embolism or myocardial infarction has 
been reported with low frequency (Galie, Ghofrani et al. 2005; Wilkins, Paul et al. 
2005).   
 
1.2.5.5 Combined Therapy 
Considering that none of the therapies reported in the previous sections represent a 
definitive “cure” for PAH, the use of a combination therapy is at the moment 
attractive. Several efficacy studies have been conducted or are in process  (Humbert, 
Barst et al. 2004; Kayser 2005; Paul, Gibbs et al. 2005; Hoeper, Leuchte et al. 2006; 
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Mathai, Girgis et al. 2007), but the most efficacious combination for specific subgroups 
of patients still need to be evaluated.  
 
Lung transplantation represents at this time the only “cure” for PAH, and it is reserved 
for those patients unable to respond to other therapies. 
 
 
 
 
 
 
 
 
 
 
Figure 1-9  Major molecular pathways for PAH which are currently approved for medical 
treatments. Reported from (Ghofrani and Grimminger 2009; Humbert 2010). 
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1.3 Non Coding RNAs 
At the beginning of this century it was generally thought that the amount of DNA in a 
genome correlated with the complexity of an organism. In fact, the human genome is 
about 30 times bigger than that of simpler organism such as Caenorhabditis elegans or 
Drosophila melanogaster, and 250 times bigger than that of the yeast Saccharomyces 
cerevisiae (Griffiths-Jones 2007). For this reason many geneticists predicted that the 
human genome should contain around 100,000 protein-coding genes (Roest Crollius, 
Jaillon et al. 2000), assuming that such a substantial quantity of DNA could explain the 
differences between a human and a roundworm in term of quantity of proteins that 
could be produced. However, the human genome consists approximately of 25,000 
protein-coding genes, only a few thousand more than worms or flies (Griffiths-Jones 
2007; Taft, Pheasant et al. 2007). Moreover, the analysis of the genome of our closest 
relative, the chimpanzee, showed that almost 30% of all the orthologous proteins 
encoded in human and in this primate are identical, without any correlation between 
proteins number/structure and complexity of the species (Watanabe, Fujiyama et al. 
2004). This paradox, known as G-value paradox (Hahn and Wray 2002; Taft, Pheasant 
et al. 2007), remained without any explanation for years, and the non-coding portion 
of the genome, representing in the most evolved organisms the vast majority, was 
named “junk DNA” or “transcriptional noise”. However over the past decade it has 
been observed that the percentage of the genome coding for proteins decreases 
linearly with the biological complexity, starting with almost 90% in prokaryotes, 
decreasing to almost 68% in yeast, almost 25% in nematodes and 17% in insect, and 
reaching 1% in mammals (Taft, Pheasant et al. 2007; Costa 2008). Therefore many 
researchers started to analyse more in detail this “junk” portion of the genome, 
identifying several different classes of small non-coding RNAs essential for many vital 
functions. They includes transfer RNAs (tRNAs), responsible for the transport of 
specific amino acids to the ribosomes during protein translation (RajBhandary and 
Kohrer 2006; Soll and RajBhandary 2006), ribosomal RNAs (rRNAs), identified in the 
small and the large subunits of ribosomes (Nissen, Hansen et al. 2000; Beringer and 
Rodnina 2007; Rodnina, Beringer et al. 2007), spliceosomal RNAs (also called small 
nuclear RNAs, snRNAs), part of the spliceosome complex and therefore involved in 
mRNA splicing (Padgett, Grabowski et al. 1986), and small nucleolar RNAs (snoRNAs), 
responsible for guiding a series of site-specific post-transcriptional modifications of the 
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other classes (Smith and Steitz 1997). However, the most abundant and studied class 
of small non-coding RNAs is represented by small silencing RNAs, including PIWI-
interacting RNAs (piRNAs), small interfering RNAs (siRNAs) and microRNAs (miRNAs), 
all able to inhibit specifically gene expression through complementary recognition of 
RNA targets. 
 
1.3.1 Piwi-Interacting RNAs 
piRNAs are 24-32 nucleotides long non-coding RNAs obtained from single-stranded (ss) 
RNA precursors mainly transcribed from specific intergenic repetitive elements called 
piRNA clusters (Siomi, Sato et al. 2011). They have been identified in the germ line of 
several animal species, where their main role is to silence transposable elements (TEs) 
(Malone and Hannon 2009), genomic parasites able to move from site to site in the 
genome by insertion or transposition potentially disrupting coding genes of the host 
organism (Kazazian 2004). To protect the integrity of the genome, these short RNAs 
associate with PIWI proteins, germline-specific members of the Argonaute family, to 
form an active piRNA-induced silencing complex (piRISC), able to silence specific target 
RNA sequences (Girard, Sachidanandam et al. 2006). In fact, like other members of the 
Argonaute family (Section 1.3.3.6), PIWI proteins exhibit endonuclease activity and can 
therefore cleave target TEs that are complementary to the guide piRNA (Brennecke, 
Aravin et al. 2007; Gunawardane, Saito et al. 2007). It has been hypothesized that the 
piRISC could also guide the de novo methylation machinery to specific TE loci 
(Kuramochi-Miyagawa, Watanabe et al. 2008), and even direct heterochromatin 
protein 1A (HP1A) localization to target sequences to induce their conversion to 
heterochromatin (Brower-Toland, Findley et al. 2007), however further investigation 
will be necessary to validate these theories.  
 
1.3.2 Short Interfering RNAs 
siRNAs are 20-25 nt long perfectly complementary duplexes able to bind specific 
mRNA targets and silence them. They were identified for the first time in the 1990’s 
after the observation that in plants transgenes identical to host genes can sometimes 
cause silencing of both the transgene and the homologous endogenous gene through 
the formation of aberrant double stranded (ds) RNAs, a phenomenon named co-
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supression (Napoli, Lemieux et al. 1990; van der Krol, Mur et al. 1990; Hamilton and 
Baulcombe 1999). In the same period a similar discovery was made in animals, when 
Guo et al. injected antisense ss-RNAs into Caenorhabditis elegans to down regulate 
specific genes, discovering that surprisingly the long dsRNA used as a negative control 
could reduce efficiently the expression of their gene of interest (Guo and Kemphues 
1995; Fire, Xu et al. 1998).  SiRNAs can be experimentally introduced in the cell as 
synthetic dsRNAs or can be virally derived (exogenous siRNAs), but they can also derive 
from more extended dsRNAs obtained from bidirectional transcription at a single locus 
or complementary transcripts produced from distinct loci in the nucleus (endogenous 
siRNAs), as reported in mouse and in Drosophila melanogaster (Chung, Okamura et al. 
2008; Czech, Malone et al. 2008; Ghildiyal, Seitz et al. 2008; Okamura, Chung et al. 
2008; Tam, Aravin et al. 2008; Watanabe, Totoki et al. 2008). Another source of 
endogenous dsRNAs, found in the yeast Saccharomyces pombe, in plants and in 
Caenorhabditis elegans is transcription from an RNA-dependent RNA polymerase 
(RdRP) (Herr, Jensen et al. 2005; Xie and Qi 2008; Grewal 2010). These long 
endogenous transcripts are then processed by the class III RNase III enzyme Dicer 
(Section 1.3.3.6) in a shorter ds and loaded onto different effector ribonucleoprotein 
(RNP) complexes, able to mediate different small RNA functions including mRNA 
cleavage and translational repression (mediated by the RNA-induced silencing 
complex, RISC (Section 1.3.3.6), but also regulation of chromatin structure (mediated 
by the RNA-induced transcriptional gene silencing, RITS, complex) (Grewal 2010). In 
fact, in association with the Argonaute protein Ago1, the chromodomain protein Chp1 
and the self-associated adaptor protein Tas3, siRNAs can target specific 
pericentromeric regions of Saccharomyces pombe inducing formation of 
heterochromatin (Reinhart and Bartel 2002; Volpe, Schramke et al. 2003; Verdel, Jia et 
al. 2004).  
 
1.3.3 miRNAs 
1.3.3.1 Discovery 
The first miRNA was identified in 1993, when two different groups of researchers 
discovered in Caenorhabditis elegans a short RNA transcript, named lin-4, able to 
inhibit the expression of another gene, lin-14, by binding to its 3’untranslated region 
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(UTR) (Lee, Feinbaum et al. 1993; Wightman, Ha et al. 1993). This discovery was 
considered a nematode idiosyncrasy until 2000, when a second RNA with such a 
function was characterized. It was named let-7 and it was reported to be able to 
repress lin-41, lin-14, lin-28, lin-42, and daf-12 expression during specific stages of 
development of Caenorhabditis elegans (Reinhart, Slack et al. 2000). Since let-7 was 
soon found to be conserved in many species (Pasquinelli, Reinhart et al. 2000), the 
ability of short non-coding RNAs to silence target genes started to be considered a 
wider phenomenon, and the interest on this kind of gene regulation grew rapidly.  
However, in consideration of the role of these short RNAs in developmental timing, 
they were first named short temporal RNAs (stRNAs), and the term microRNA (miRNA) 
was not introduced until 2001 (Lagos-Quintana, Rauhut et al. 2001). 
Over the last decade, the number of miRNA publications and registered new 
sequences in miRBase (Section 1.3.3.2) have grown exponentially (miRBase 17, 
released in April 2011, contains 16772 entries representing hairpin precursor miRNAs, 
expressing 19724 mature miRNA products, in 153 species), testifying the enormous 
importance of these small sequences in the current research world.  
 
1.3.3.2 Nomenclature 
miRNA nomenclature, sequence data, annotation and predicted targets are collected 
in the miRNA database, called miRBase (Griffiths-Jones, Grocock et al. 2006; Griffiths-
Jones, Saini et al. 2008; Griffiths-Jones 2010). In particular, names have been assigned 
by the miRBase registry based on a strict convention established by prominent miRNA 
researchers with the aim to prevent duplication (Ambros, Bartel et al. 2003).  
 
miRNAs are named using the prefix “miR” (while the precursor hairpins are labeled 
“mir”) and an identifying number, assigned sequentially when the discovery of a new 
miRNA is described in a manuscript accepted for publication and it is therefore 
included in miRBase (Griffiths-Jones, Grocock et al. 2006). Each miRNA also have a 3 or 
4 letter prefix to designate its species, such as “hsa” for human (Homo sapiens) or 
“mmu” for mouse (Mus musculus) sequences (Griffiths-Jones, Grocock et al. 2006; 
Griffiths-Jones, Saini et al. 2008). MiRNAs with identical sequences in different species 
are normally given the same number, while miRNAs that differ only in one or two 
positions in the same organism present a lowercase letter as suffix (e.g. rno-miR-19a 
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and rno-miR-19b). These miRNAs are considered members of the same family 
(Griffiths-Jones, Grocock et al. 2006). When identical mature miRNAs are coded by 
distinct loci, they are given numbered suffixes (e.g. dme-miR-281-1 and dme-miR-281-
2). After miRNA identification and the first manuscripts about their activity, it was 
generally believed that only one strand of the mature miRNA could interact with its 
targets. However, now we know that (rarely) both strands can be incorporated in the 
RISC complex (Section 1.3.3.6) and regulate gene expression (Guo and Lu 2010; Yang, 
Phillips et al. 2011). Since these two complementary mature miRNAs originated from 
the same precursors contain different (but complementary) seed sequences, they have 
also been named in a different way. When one single strand is less active than the 
other, it is distinguished by an asterisk (e.g. hsa-miR-21 and hsa-miR21*) and it is 
named passenger strand (the other strand, normally included in the miRISC complex, is 
named guide strand), while when the two single stranded mature miRNAs are equally 
active on targets (or when their relative expression levels are not known) they are 
named with the same number followed by the name of the hairpin arm from which 
they are originated (-3’p for the 3’arm and -5’p for the 5’arm, e.g. rno-miR-10a-3p and 
rno-miR-10a-5p). 
 
MiRNA coding genes are also named using the same 3 or 4 letter prefix and the same 
identifying number, but in capital letters or italics according to the conventions of the 
organism (for example, mir-1 in Caenorhabditis elegans and Drosophila melanogaster, 
MIR-156 in Arabidopsis thaliana).  
 
1.3.3.3 Biogenesis: miRNA Transcription 
MiRNAs are initially transcribed as long transcripts (their length can vary between few 
hundreds and several thousands of nucleotides), known as pri-miRNAs. The majority of 
these precursors contains cap structures and a poly(A) tail, and can therefore be 
classified as class II genes, transcribed by polymerase-II (pol-II), along with all protein-
coding genes and specific non-coding genes including U1, U2, U4 and U5 snRNAs (Lee, 
Kim et al. 2004). However, over 20% of human miRNAs, including those located in the 
chromosome 19 miRNA cluster (C19MC), resides within repetitive elements such as 
Alu repeats and were reported to be therefore transcribed from their polymerase-III 
(pol-III) promoters (Borchert, Lanier et al. 2006). However Bortolin-Cavaillé et al. 
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recently questioned this hypothesis suggesting that C19MC miRNAs would be 
originated instead from a non-protein-coding Pol-II (and not Pol-III) transcript 
(Bortolin-Cavaille, Dance et al. 2009). 
 
 miRNAs can be localized within introns of known coding genes (intronic) or between 
clusters of genes (intergenic) (Schanen and Li 2011) (Figure 1-10). Intronic miRNAs can 
be transcribed from the host gene promoter, while intergenic miRNAs are normally 
derived from independent transcription units (Lee, Jeon et al. 2002; Bartel 2004). 
Unfortunately, very little is still known about the promoter structure and the 
transcriptional regulation of these miRNAs, but the characterization of the promoter of 
the miRNA gene cluster miR-23a ≈27a ≈24-2 showed that this region lacks the TATA 
box, the initiator element, the down-stream promoter element (DPE) and the TFIIB 
recognition element (BRE), all essential for messenger RNA (mRNA) transcription (Lee, 
Kim et al. 2004). 
 
Pri-miRNAs are characterized by the presence of stem and loop structures, with 
imperfect complimentary regions. This precursor can encode a single miRNA 
(monocistronic unit) or several miRNAs (polycistronic unit) (Figure 1-10). All the 
miRNAs generated from the same polycistronic unit are members of the same cluster, 
transcriptionally regulated in the same way (Bartel 2004). 
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A.  Intergenic miRNA, Monocistronic Unit
B.  Intergenic miRNA, Polycistronic Unit
C.  Intronic miRNA
Intergenic Region
Gene Intron
Gene Exon
Intergenic Region
 
 
Figure 1-10  miRNA gene models. Canonical miRNA genes can be found in intergenic regions 
as independent transcriptional units, where they can encode for one (A) or several miRNAs (B), 
or they can be localized in introns of host genes (C), where they may be transcribed 
independently or as part of host gene transcripts. 
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1.3.3.4 Biogenesis: the Drosha/DGCR8 Complex in Primary miRNA 
Processing 
MiRNA maturation begins in the nucleus with cleavage of the pri-miRNA to release a 
60-70 nt long stem loop intermediate called pre-miRNA (Figure 1-11). This step is 
mediated by Drosha, a 160 kDa Class II type RNase III enzyme able to cleave the pri-
miRNA in an asymmetric way to leave a 5’ phosphate and a 2 nt 3’ overhang. This also 
facilitates the other steps of miRNA maturation since protruding 3’ ends are 
recognized more efficiently by Exportin 5 and Dicer (Lee, Ahn et al. 2003; Lund, 
Guttinger et al. 2004). 
 
RNase III proteins are dsRNA-specific endonucleases able to cut both sides of a RNA 
helix and they are grouped into three classes based on their domain organization (Han, 
Lee et al. 2004). Class one proteins contain one RNAse III domain (RIIID) and one ds-
RNA binding domain (dsRBD). They can be found in yeast and bacteria. Class II 
enzymes like Drosha have two RNase III catalytic sites with a dsRBD, both required for 
pri-miRNA processing. In addition, Drosha also has a proline-rich domain and 
arginine/serine-rich domain at the N terminus, which is important in protein-protein 
interactions (Figure 1-12) (Tsunetsugu-Yokota and Yamamoto 2010). Drosha homologs 
can be found only in animals. Class III proteins include Dicer, which will be described in 
detail in a separate section (section 1.3.3.6). In a first moment Drosha was only known 
for being implicated in pre-ribosomal RNA processing (Wu, Xu et al. 2000), but in 2003 
its role in miRNA maturation was made clear by the observation that its depletion in 
cultured cells resulted in the dramatic accumulation of pri-miRNAs (Lee, Ahn et al. 
2003) with a very low detection of mature miRNAs. One year after that, the mode of 
action of this step of miRNA maturation was better understood with the identification 
of a complex, termed microprocessor, containing Drosha and the dsRNA binding 
protein DGCR8 (also known in Drosophila melanogaster as Pasha, partner of Drosha) 
(Denli, Tops et al. 2004; Gregory, Yan et al. 2004; Han, Lee et al. 2004). This is an 
evolutionary conserved protein which has two dsRBDs and a WW domain containing 
two conserved tryptophan (W) residues, known to interact with proline-reach peptides 
such as the N-terminal domain of Drosha  (Gregory, Yan et al. 2004) (Figure 1-12). 
DGCR8 is a 120 kDa protein and it is one of the 30 genes in the chromosomal region 
22q11.2 whose heterozygous deletion result in the DiGeorge syndrome, a disease 
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characterized by congenital heart defects, immunodeficiency and developmental and 
behavioural problems (Gregory and Shiekhattar 2005). Its role in miRNA processing is 
to recognize the substrate and  bind the base of the pri-miRNA hairpin, positioning 
Drosha in the right position to cleave the pri-miRNA stem at a distance of 11 base pairs 
(bp) from the junction between the dsRNA stem and the flanking ssRNA regions (Han, 
Lee et al. 2006) (Figure 1-13). 
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Figure 1-11  miRNA biogenesis. The primary transcripts of miRNAs, called pri-miRNAs, are 
transcribed as individual miRNA genes, from introns of protein-coding genes, or from 
polycistronic transcripts. The RNase Drosha further processes the pri-miRNA into 70–100 
nucleotides, hairpin-shaped precursors, called pre-miRNA, which are exported from the nucleus 
by exportin 5. In the cytoplasm, the pre-miRNA is cleaved by Dicer into a miRNA:miRNA* 
duplex. Assembled into the RISC, the mature miRNA negatively regulates gene expression by 
either translational repression or mRNA degradation.  
Obtained from http://eugenemaster.wordpress.com/what-is-microrna/ 
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Figure 1-12  Structure of the miRNA processing enzymes. The common domains are 
indicated in the same colour. See the text for further details about the function of each domain. 
Reported from (Tsunetsugu-Yokota and Yamamoto 2010).  
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Figure 1-13  DGCR8 role in Pri-miRNA processing. DGCR8 can recognize the Pri-miRNA 
substrate and anchor Dicer in the right position. The processing centre (yellow circle) of Drosha 
is placed then at ≈11 bp from the basal segments. Adapted from (Han, Lee et al. 2006). 
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As already mentioned, no homologous proteins to Drosha can be found in plants, 
where this stage of miRNA biogenesis seem to be different (Chen 2009; Voinnet 2009). 
In fact, both the pri-to-pre-miRNA conversion and mature miRNA processing are made 
in plants by DCL1, a nuclear Dicer-like protein, together with the ds-RNA-binding 
protein HYPONASTIC LEAVES1 (HYL1) and the C2H2-zinc finger protein SERRATE (SE). 
The mature miRNA duplex is then methylated by the RNA methyltransferase HEN1 and 
the miRNA is loaded into an AGO1 complex (Figure 1-14) (Chen 2009; Voinnet 2009). 
 
Recent studies show that pri-miRNA processing might be a co-transcriptional process. 
In fact, in intronic miRNAs, Drosha is able to process the miRNA precursor before the 
intron is excised. Thus, miRNA maturation and mRNA splicing might be coordinated 
mechanisms (Kim and Kim 2007; Kim, Han et al. 2009) (Figure 1-15A). 
 
In 2007 a new class of small intronic hairpins was identified first in Drosophila 
melanogaster and Caenorhabditis elegans (Okamura, Hagen et al. 2007; Ruby, Jan et 
al. 2007) and then also in mammalian (Berezikov, Chung et al. 2007). They were named 
mirtrons. These small RNA precursors are characterized by the presence of introns and 
flanking exonic sequences and their nuclear biogenesis can bypass Drosha cleavage, 
requiring instead the splicing machinery and the lariat-debranching enzyme (Ldbr) 
(Okamura, Hagen et al. 2007). The pre-mirtron so generated can be exported to the 
cytoplasm by Exportin-5 (Section 1.3.3.5) and cleaved by Dicer (Section 1.3.3.6), 
generating an active miRNA (Okamura, Hagen et al. 2007) (Figure 1-15B).  
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Figure 1-14  miRNA biogenesis in plants. As in animals, a miRNA is transcribed in the 
nucleus in a long pri-miRNA. However, no homologous proteins to Drosha can be found in 
plants, and this precursor is then processed by DCL1 together with HYL1 and SE. The mature 
miRNA duplex is then methylated by HEN1 and loaded into an AGO1 complex. See the text for 
further details. Reported from (Chen 2009). 
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A. Canonical intronic miRNA processing (Dicer-mediated)
B. mirtron processing (Dicer-independent) 
 
Figure 1-15  Maturation of canonical intronic miRNAs and mirtrons. (A) Canonical intronic 
miRNAs are processed by Drosha. In particular, this enzyme might be recruited together with 
the spliceosome complex and process the miRNA precursor before the intron is excised. On the 
contrary, non canonical pre-mirtrons are produced from spliced introns and debranching (B). 
This mechanism is mediated by Ldbr and bypasses the Drosha-processing step. Reported from 
(Kim, Han et al. 2009). 
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1.3.3.5 Biogenesis: Exportin-5 Mediates the Nuclear Export of Pre-
miRNAs 
Pre-miRNAs processed by Drosha and DGCR8 are then exported to the cytoplasm 
where the last steps of miRNA maturation take place. This nuclear export is efficiently 
mediated by Exportin-5 (Exp5), a member of the karyopherin family of nucleo-
cytoplasmic transport factors (Yi, Qin et al. 2003) (Figure 1-13).  
 
Several members of this family are involved in the nuclear export of non-coding RNAs, 
including tRNAs, snRNAs and rRNAs (Lei and Silver 2002; Cullen 2003), and Exp5 in 
particular can also mediate the export of adenovirus VA1 and tRNAs (Lee, Jiko et al. 
2011). All these receptors possess a RanGTP-binding site (Ran is a GTPase enzyme), 
and the RanGTP gradient across the nuclear envelope is used as an energy source 
(Bohnsack, Czaplinski et al. 2004). Exp5 binds efficiently RanGTP and the pre-miRNA in 
the nucleus to form a hetero-trimeric complex and pass through the nuclear pore (Yi, 
Qin et al. 2003; Zeng and Cullen 2004; Wang, Xu et al. 2011) (Figure 1-16). Then, once 
in the cytoplasm, the Ran-GTP is hydrolysed to Ran-GDP resulting in the release of the 
pre-miRNA, further processed by Dicer. It is interesting to notice that Exp5 binding 
requires a ›14 bp RNA stem with a base-paired 5’and a short 3’ overhang (Gwizdek, 
Ossareh-Nazari et al. 2003; Zeng and Cullen 2004) (Figure 1-16), while it shows a weak 
interaction with extended-pre-miRNAs that give incorrect mature miRNAs after Dicer 
processing in vitro (Lund, Guttinger et al. 2004; Zeng and Cullen 2004). 
 
As expected, antibodies directed against Exp5 block pre-miRNA export decreasing its 
cytoplasmic concentration (Bohnsack, Czaplinski et al. 2004), but this doesn’t result in 
pre-miRNA accumulation in the nucleus, suggesting that this miRNA precursor is 
relatively unstable (Bohnsack, Czaplinski et al. 2004; Zeng and Cullen 2004). 
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Figure 1-16  Schematic representation of Exp-5:RanGTP:pre-miRNA. Adapted from (Lee, 
Jiko et al. 2011). 
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1.3.3.6 Biogenesis: Cytoplasmic Processing and miRISC 
Once exported to the cytoplasm, the pre-miRNA is loaded into the RISC (RNA Induced 
Silencing Complex) Loading Complex (RLC) (Figure 1-13 and Figure 1-17). The core of 
this complex is represented by the RNase III enzyme Dicer, TAR RNA-binding protein 
(TRBP), protein activator of PKR (PACT) and an Argonaute protein (AGO). This complex 
processes the pre-miRNA and selects the guide strand of the obtained ds mature 
miRNA to direct target-miRNA interaction (Gregory, Chendrimada et al. 2005). 
 
As every typical class III RNase III enzyme, Dicer is characterized by the presence of two 
RNase III domains, one dsRBD, a DUF283 (domain of unknown function) and a PAZ 
(Piwi-Argonaute-Zwille) domain in the middle and a helicase/ATPase domain at the N-
terminus (Figure 1-14). The PAZ domain binds specifically to the 3’ two nucleotide 
overhang structure of the pre-miRNA (Song, Liu et al. 2003), anchoring the enzyme on 
the miRNA precursor with the right orientation allowing in this way its cleavage at a 
fixed distance from that end. The dsRNA generated by Dicer is normally 21 to 25 
nucleotides (nt) long and contains a miRNA guide strand and a passenger strand. It has 
been shown in Drosophila melanogaster that loss of function mutations in this enzyme 
prevent the conversion of the pre-miRNA in its mature form (Lee, Nakahara et al. 
2004), and double Knock-out (KO) mice die in early stages of development (Bernstein, 
Kim et al. 2003), proving its fundamental role in miRNA biogenesis. Moreover, it has 
been demonstrated the presence of a physical interaction of Dicer with Argonaute 2 
(AGO2), responsible for the miRNA mediated post-transcriptional gene silencing, 
suggesting a role for this enzyme not only in miRNA maturation, but also in the 
formation of the RISC complex (Gregory, Chendrimada et al. 2005). In consideration of 
these evidences it is not surprising that Dicer levels are kept strictly under control in 
the cell, but it is interesting to observe that this regulation is miRNA mediated. In fact it 
has been reported that the let-7 miRNA family, and in particular let-7d, is able to 
regulate Dicer expression, constituting in this way a negative feedback loop, since 
Dicer is involved in let-7 maturation (Tokumaru, Suzuki et al. 2008). 
 
Both the dsRNA-binding proteins TRBP and PACT have similar structures, with three 
dsRBDs that directly interact with each other and with Dicer (Figure 1-14). They do not 
have a direct role in miRNA processing like Dicer, but they both play a role in the 
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recruitment of the pre-miRNA and in the RISC assembly. In fact, their depletion only 
reduces the efficiency of miRNA maturation (Grishok, Pasquinelli et al. 2001; Haase, 
Jaskiewicz et al. 2005; Lee, Hur et al. 2006)  
 
After the cleavage of the pre-miRNA, the 22 nt duplex miRNA remains associated with 
RISC, and the complex identifies the guide strand (Figure 1-13 and Figure 1-17). The 
mechanism behind miRNA unwinding, probably ATP-dependent, and the recruitment 
of the right strand is still largely unknown. However, the selection of a specific strand 
could be at least partially explained by the thermodynamic properties of the two ends 
of the duplex. In fact, the strand with a less stable 5’ end (often due to the presence of 
uracils) is the one that is normally incorporated in the active RISC complex and 
represent the guide strand, while the passenger strand is degraded (Khvorova, 
Reynolds et al. 2003; Schwarz, Hutvagner et al. 2003). Another theory states that the 
two strands can be distinguished using their nucleotide sequence and secondary 
structure (Ahmed, Ansari et al. 2009). However, both the strands of the duplex are 
sometimes functional and can be incorporated in the RISC complex to target different 
mRNAs, as it has been recently described (Packer, Xing et al. 2008). 
 
The active RISC complex forms with the selected ss mature miRNA the miRNA-induced 
silencing complex (miRISC), also called micro-ribonucleoproteins (miRNPs) complex 
(Filipowicz, Bhattacharyya et al. 2008) (Figure 1-13 and Figure 1-17). The main protein 
of the complex is again a member of the Argonaute family.  This highly conserved 
family of proteins is characterized by a PAZ domain, which binds to the 3’ end of guide 
RNA (Wang, Sheng et al. 2008; Jinek and Doudna 2009), a MID domain which provides 
a binding pocket for the 5’-phosphate end of the miRNA (Boland, Tritschler et al. 
2010), and a PIWI domain, similar to RNase H, with endonuclease activity (also named 
“slicer” activity) (Jinek and Doudna 2009) (Figure 1-14). In humans there are 4 different 
Argonaute proteins (named AGO 1-4), and even if all of them show the same affinity to 
miRNAs, only AGO2 has endonuclease activity (Liu, Carmell et al. 2004; Meister, 
Landthaler et al. 2004) and can therefore cleave a target mRNA. However, if there is 
not perfect complementarity between the miRNA and the target, the mRNA may be 
physically unreachable by the active “slicer” domain of AGO2, resulting instead in 
mRNA destabilization or translational repression. Because of the low degree of 
complementarity observed in animals, it was suggested that translational repression is 
73 
more prevalent in animals than in plants (Rhoades, Reinhart et al. 2002; Jones-
Rhoades, Bartel et al. 2006; Bartel 2009). The reason why a specific member of the 
AGO family is recruited in the active miRISC complex instead of the others still need to 
be clarified.  
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Figure 1-17  Cytoplasmic miRNA processing, RISC loading complex and miRISC. After 
export to the cytoplasm, pre-miRNA associates with the endonuclease Dicer and several other 
regulatory proteins, such as TRBP and PACT and a member of the Argonaute family. Dicer 
mediated cleavage results in production of about 20-nt-long miRNA/miRNA* duplex. After 
processing, the guide strand of the miRNA/miRNA* duplex is incorporated into the miRNA-
induced silencing complex (miRISC), whereas the passenger strand (miRNA*) is degraded. In 
some cases, also the passenger strand may be included in the miRISC to function as mature 
miRNA. 
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1.3.3.7 miRNA-Mediated Gene Silencing 
The most important part of a miRNA in its interaction with a mRNA target is the 5’ 
portion. This has been hypothesize for the first time after the observation that in the 
3’UTR of the target gene lin-14 there is a “core element” of complementarity to the 5’ 
region of the lin-4 miRNA (Wightman, Ha et al. 1993), and the theory was confirmed 
when it became clear that residues 2-8 of miRNAs are the most conserved among 
homologous metazoan miRNAs (Lewis, Shih et al. 2003; Lim, Glasner et al. 2003). This 
miRNA portion was called “seed sequence” since it mediates target binding, and the 
introduction of mismatches in this core region can inhibit initial target recognition 
even if there is perfect complementarity elsewhere (Doench and Sharp 2004; 
Brennecke, Stark et al. 2005). Mostly miRNAs target sites located in the 3’UTR of a 
target gene, often in multiple copies (Jackson and Standart 2007). 
 
A large number of bioinformatics databases can predict miRNA:mRNA interaction (i.e. 
TargetScan, EMBL, PicTar and Mirnada) using several criteria including stringent seed 
pairing, site number, site accessibility and overall predicted pairing stability (Bartel 
2009). MiRNA target prediction in mammals show that about one third of genes might 
be miRNA regulated and each miRNA can regulate an overage of 100-200 target genes 
(Lewis, Burge et al. 2005; Lim, Lau et al. 2005). Moreover, different miRNAs can act in a 
cooperative way to regulate the same target, creating a miRNA network more difficult 
to figure out. 
 
The mechanism behind miRNA ability to silence gene expression is still quite 
controversial. Two main models have been proposed, each of them supported by 
several evidences: mRNA degradation or mRNA translation repression. Moreover, both 
the initiation and the post initiation steps of translation have been identified as 
potential target of mRNA activity. Next sections summarize the experimental 
evidences supporting each model. 
 
1.3.3.8 miRNA Activity: Inhibition of Translation Initiation 
The hypothesis that miRNAs could block translation at some point of the initiation step 
was formulated for the first time in 2005, when Pillai et al. studied the activity of 
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endogenous let-7a in HeLa cells using a luciferase construct with three bulged target 
sites for this miRNA in its 3’ UTR (Pillai, Bhattacharyya et al. 2005). 48 h after 
transfection they observed an 80-90% reduction in luciferase expression, but the 
mRNA abundance was decreased only of a 20%, suggesting that protein translation 
was somehow inhibited (Pillai, Bhattacharyya et al. 2005). Analyzing a sucrose gradient 
of polysome, they also observed the target mRNA in the same fraction of the 40s small 
ribosomal subunit, the first recruited during ribosome assembling, strongly suggesting 
an inhibition of the transcription initiation (Pillai, Bhattacharyya et al. 2005). The same 
result was obtained one year later in a study focused on miR-122 repression of the 
endogenous cationic amino acid transporter-1 in HuH7 cells (Bhattacharyya, 
Habermacher et al. 2006). Moreover, the Pillai et al. study showed that an active 
luciferase repression was obtained only in presence of a 7-methylguanosine 
(m7GpppG)-capped polyadenylated target mRNA, while uncapped targets where 
completely resistant (Pillai, Bhattacharyya et al. 2005). This result was further 
investigated by Humphreys et al. in a study showing that not only uncapped mRNAs, 
but also nonpolyadenylated targets could not be efficiently repressed (Humphreys, 
Westman et al. 2005). They hypothesized that miRNA could block translation 
interfering with the formation of the “closed loop”, a structure assumed by the mRNA 
to facilitates translation (Lomakin, Hellen et al. 2000; Kahvejian, Svitkin et al. 2005) and 
formed by the interaction of poly(A) binding proteins (PABPs), bound to the mRNA tail, 
with eIF (eukaryotic initiation factor) proteins, associated with the m7GpppG-cap 
(Figure 1-18) (Humphreys, Westman et al. 2005). This theory was supported by the 
discovery that AGO2 is able to bind directly the m7GpppG-cap with its MID region 
(Figure 1-19), homologous with a domain of the cap-binding eIF (eIF4E), antagonizing 
in a competitive way the interaction between the target mRNA and eIF4E (Kiriakidou, 
Tan et al. 2007). However this result has been recently challenged by two different 
manuscript (Eulalio, Huntzinger et al. 2008; Kinch and Grishin 2009), and for this 
reason this model will require further validations. 
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Figure 1-18  Schematic representation of the “closed loop”. In this structure, PABPs, bound 
to the mRNA tail, interact with eIF proteins, associated with the m7GpppG-cap, to facilitate 
translation. Reported from (Filipowicz, Bhattacharyya et al. 2008). 
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Figure 1-19  Possible mechanisms of the microRNA-mediated post-transcriptional gene 
regulation. After binding the 3’UTR of the target gene, a miRNA can induce deadenylation and 
decay of target (A), blocking of the translation initiation step (B), proteolytic cleavage of nascent 
polypeptides (C) or blocking of the translation elongation step (D). mRNAs repressed by 
deadenylation or at the translation-initiation stage are moved to P-bodies for either degradation 
or storage. Reported from (Filipowicz, Bhattacharyya et al. 2008). 
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1.3.3.9 miRNA Activity: Inhibition of Translation after Initiation 
The first evidences of a possible miRNA-mediated inhibition of mRNA translation at 
some point after initiation were reported for the first time by Olsen et al., in a study 
focused on lin-4, the first discovered miRNA (Olsen and Ambros 1999). They observed 
that in the L2 and L3 larval stages of Caenorhabditis elegans development, when the 
expression of this miRNA is at its maximum, the amount of the target protein LIN-28 is 
reduced of a 90%, while the abundance of its mRNA is essentially unchanged (Olsen 
and Ambros 1999). For this reason they validated the hypothesis of a translational 
repression. However, when they analyzed a sucrose gradient of polysomes at L2-L3 
stage, they identified the repressed lin-28 mRNA in the same fraction as in L1 extracted 
polysomes (when it is actively translated), suggesting that in both cases this mRNA is 
associated with active ribosomes and then active translation is already in progress 
when protein expression is inhibited (Olsen and Ambros 1999).  Similar evidences were 
also obtained in 293T cells transfected with a luciferase construct with 6 bulged sites 
for let-7a in its 3’UTR (Petersen, Bordeleau et al. 2006). Cosedimentation of several 
miRNAs with polysomes has been considered a further confirmation of this theory 
(Kim, Krichevsky et al. 2004; Nelson, Hatzigeorgiou et al. 2004). A more detailed model 
was proposed by Petersen at al., suggesting that miRNAs could promote the 
premature termination of protein translation by inducing the dissociation of the 
ribosome from the mRNA (ribosome “drop-off”) (Petersen, Bordeleau et al. 2006) 
(Figure 1-19). However, they failed to detect any nascent protein chain, introducing 
the hypothesis that miRNAs could also recruit specific protease to degrade newly 
synthesized peptides (Nottrott, Simard et al. 2006; Petersen, Bordeleau et al. 2006) 
(Figure 1-19). 
 
1.3.3.10 miRNA Activity: Target mRNA Degradation 
miRNA are often able to affect substantially the expression of their target despite 
marginal changes in the abundance of their mRNA are observed (Olsen and Ambros 
1999; Pillai, Bhattacharyya et al. 2005). For this reason, for several years it was 
concluded that miRNA ability to regulate gene expression was only due to its capacity 
to interfere with mRNA translation. However, in the last years different publications 
reported a substantial decrease of target mRNA levels due to changes in miRNA 
78 
expression (Giraldez, Mishima et al. 2006; Rehwinkel, Natalin et al. 2006; Guo, Ingolia 
et al. 2010). First of all, repetition of some of the experiments originally performed in 
Caenorhabditis elegans (Olsen and Ambros 1999; Seggerson, Tang et al. 2002) 
surprisingly showed that lin-4 and let-7 are both able to promote extensive 
degradation of lin-14, lin-28 and lin-41 target mRNAs (Bagga, Bracht et al. 2005; 
Valencia-Sanchez, Liu et al. 2006). In addition, microarray analysis of mRNAs extracted 
from HeLa cells showed that expression of the brain-specific miR-124 and the muscle-
specific miR-1 results in changes in the abundance of subsets of 100 to 200 different 
mRNAs in each case (Lim, Lau et al. 2005). miRNAs can induce such a decrease in 
mRNA abundance mediating the acceleration of target mRNA degradation through 
deadenylation followed by decapping (Behm-Ansmant, Rehwinkel et al. 2006; 
Schmitter, Filkowski et al. 2006; Wu, Fan et al. 2006; Wu, Thivierge et al. 2010) (Figure 
1-19). In particular, deadenylation is able to destabilize a mRNA through disruption of 
the “closed loop” already described in section 1.3.3.8 (Figure 1-18), while decapping 
results in the degradation of the body of the mRNA by 5’-3’ exonuclease activity 
(Behm-Ansmant, Rehwinkel et al. 2006; Schmitter, Filkowski et al. 2006; Wu, Fan et al. 
2006). 
 
AGO proteins, miRNAs and target mRNAs accumulate and can be detected in 
cytoplasmic foci known as P-bodies, or processing bodies (Liu, Valencia-Sanchez et al. 
2005). These foci are composed by several different proteins, always including 
enzymes involved in mRNA decapping and decay (Sheth and Parker 2003). P-bodies are 
able to move within the cell cytoplasm, and can fluctuate in size and number. For 
example, inhibition of translation initiation can induce their increase in size and 
number, suggesting that only ribosomes-free mRNAs can localize to P-bodies 
(Brengues, Teixeira et al. 2005). In fact, it has been shown that mRNAs, and in 
particular mRNA decay intermediates are required for P-bodies integrity (Teixeira, 
Sheth et al. 2005). Thus, deadenylated mRNAs are internalized into P-bodies and 
therefore degraded (Kulkarni, Ozgur et al. 2010). However, entry of a mRNA into P-
bodies not always leads to its degradation. This reversibility has been showed for the 
cationic amino acid transporter (CAT-1) mRNA, regulated by miR-122. In normal 
conditions miR-122 is able to reduce CAT-1 expression by a 65%, and both this miRNA 
and CAT-1 mRNA can be detected in P-bodies. However, if cells are amino acid starved, 
the mRNA cannot be longer detected in these loci, with a rapid increase in the amount 
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of CAT-1 protein (Bhattacharyya, Habermacher et al. 2006). This mRNA release 
requires a particular AU-rich element (ARE) in its 3’UTR, and the presence of the ARE 
binding protein HuR (Bhattacharyya, Habermacher et al. 2006). P-bodies can therefore 
be considered temporary repository for untranslated mRNAs, increasing the ability of 
miRNAs to finely regulate gene expression. 
 
All the evidences presented in the previous sections suggest that mRNA degradation 
and inhibition of translation both contribute to miRNA-mediated gene silencing, and 
probably the relative importance of each mechanism is different in different systems 
and cell types.  
 
1.3.3.11 miRNA Turnover 
Considering the involvement of miRNAs in regulation of gene expression, it is not a 
surprise that their turnover is finely regulated too. First of all, during miRNA 
maturation only one of the two strands of the short RNA is preserved, the guide 
strand, while the passenger strand is normally rapidly degraded. It has been suggested 
that AGO proteins can stabilize the strand required for gene silencing, leading to 
degradation of the non-targeting strand (Kai and Pasquinelli 2010).  
 
Very little it is known at the moment about miRNA half-life and degradation. However, 
decay of mature miRNAs in animals seem to be mediated by the 5´-to-3´ 
exoribonuclease XRN2, known as Rat1p in plants (Chatterjee and Grosshans 2009). 
Also 3´-to-5´ exoribonucleases have been identified in mammals, but their involvement 
in miRNA turnover still needs to be evaluated (Kai and Pasquinelli 2010). Several type 
of post-transcriptional modification can alter miRNA stability, including 3’ methylation 
in plants with some evidences emerging in animals too, a mechanism able to block the 
addition of uracil (U) residues associated with miRNA degradation, and 3’ adenylation 
in mammals and plants. This has been reported in particular for  miR-122, a miRNA 
abundantly expressed in the liver and important in Hepatitis C, stabilized by the 
addition of an extra A to its end (Kai and Pasquinelli 2010). Alterations in the 
expression/stability of miRNAs are often associated with the development of different 
pathologies. 
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1.3.3.12 Effect of miRNA Dysregulation  
1.3.3.12.1 miRNAs and Cancer 
 
Cancer is nowadays considered the leading cause of death in the developed world, and 
even if several treatments are now available depending upon the specific type of 
malignancies, they are often damaging for the rest of the body (i.e. chemotherapy, 
radiation therapy) and not always effective for all the patients. In order to evaluate 
miRNA role in tumor development and growth, during the last years many groups of 
researchers focused their attention on alterations of non-coding sequences in cancer. 
Interestingly, several studies showed evidences of a global repression of miRNAs in 
different malignancies (Calin, Ferracin et al. 2005; Lu, Getz et al. 2005; Calin and Croce 
2006; Cummins, He et al. 2006; Yanaihara, Caplen et al. 2006; Zhang, Volinia et al. 
2008). The causes for this down-regulation are multifactorial and can involve each step 
of miRNA biogenesis. For example, a reduced expression of Dicer has been observed in 
lung cancer and adenocarcinoma (Karube, Tanaka et al. 2005; Chiosea, Jelezcova et al. 
2007), while more recently Melo et al. identified mutations in the gene coding for Exp5 
(XPO5) within different cancer cell lines harboring microsatellite instability (Melo, 
Moutinho et al. 2010). Re-introduction of a wild type form of the gene in these cells 
resulted in the up-regulation of several miRNAs previously repressed (Melo, Moutinho 
et al. 2010). Moreover, transcriptional factors can contribute to the down-regulation of 
specific miRNAs, including miR-17-92 cluster, regulated by the oncogene c-Myc 
(amplified in several types of human tumors) (O'Donnell, Wentzel et al. 2005; Chang, 
Yu et al. 2008). 
 
One of the first evidences of an involvement of miRNA dysregulation in cancer was 
presented in 2002 by Calin et al. They showed that two miRNAs, miR-15a and miR-16-
1, transcribed in cluster from human chromosome 13, are down-regulated in 68% of 
patients with chronic lymphocytic leukemia (CLL) (Calin, Dumitru et al. 2002). Further 
analysis demonstrated that this cluster can efficiently regulate the expression of Bcl2, 
an apoptosis regulator protein, and an increase in miR-15a/16-1 expression can lead 
cells to apoptosis (Cimmino, Calin et al. 2005). 
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Even if the majority of miRNAs is down-regulated in cancer, different examples of 
selective miRNA up-regulation have been reported as well. In breast cancer, an 
elevation in miR-103/107 expression has been associated with high metastatic 
phenotype, due to a functional targeting of Dicer (Martello, Rosato et al. 2010), while 
in lung cancer miR-21 up-regulation results in the silencing of different tumor 
suppression factors including PDCD4. A targeted deletion of miR-21 significantly 
reduces in vivo lung tumorigenesis (Hatley, Patrick et al. 2010). 
 
The examples presented in this section show clearly that miRNAs can alter biological 
processes involved in cancer development. However, further studies will be necessary 
to evaluate if the manipulation of these short non-coding RNAs can be used to treat 
this complex disease. 
 
1.3.3.12.2 miRNAs and Cardiovascular Diseases 
 
The importance of miRNAs in cardiovascular development was demonstrated for the 
first time in mice, after the observation that a selective deletion of Dicer or DGCR8 
coding genes in myocardial and vascular cells leads to a lethal phenotype (Chen, 
Murchison et al. 2008; Rao, Toyama et al. 2009). Despite that, no specific miRNA 
ablation has been found to be fully lethal in rodents, suggesting a redundancy in 
miRNA function. A thorough analysis of miRNA expression in the cardiovascular system 
revealed the existence of a relatively small group of miRNAs highly expressed in the 
heart, including miR-1, let-7, miR-133, miR-126-3p, miR-143, miR-30c and miR-22 
(Lagos-Quintana, Rauhut et al. 2002). Between them, miR-1 was the first miRNA 
implicated in heart development, and together with the related miR-133, it shows a 
cardiac- and skeletal muscle-specific expression. miR-1 and miR-133 are transcribed 
from a common bicistronic precursor, and they are encoded from multiple, highly 
conserved loci in the genome. In particular, in the cardiac muscle they expression is 
regulated by serum response factor (SRF) and myocardin (Myocd) (Zhao, Samal et al. 
2005), while in skeletal muscles they are controlled by myogenic differentiation factor 
(MyoD) and the myocyte enhancer factor-2 (MEF2) (Chen, Mandel et al. 2006; Rao, 
Kumar et al. 2006; Liu, Williams et al. 2007). This suggests an important role for 
transcription factors in the tissue-specific expression of miRNAs within the 
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cardiovascular system, composed by multiple cell lineages that must present peculiar 
physiological, electric and anatomic properties for a correct functionality of each 
region of the heart. Although many groups investigated the role of miR-1 and miR-133, 
their function is still unclear. For example, they have been shown to act synergistically 
to promote mesoderm differentiation of embryonic stem (ES) cells (Ivey, Muth et al. 
2008), while in cultured myoblasts, miR-1 promotes differentiation and miR-133 
induces proliferation (Chen, Mandel et al. 2006). 
 
Considering the involvement of miRNAs in the development of a normal heart, it is not 
a surprise that miRNA expression is specifically altered in heart diseases. An example 
of this is represented by cardiac hypertrophy, characterized by an extensive 
remodelling of the heart. In fact, a significant up-regulation in miR-195 expression has 
been identified in human and mouse hypertrophic hearts, and a further increase in the 
expression of this miRNA leaded to heart failure in mice within 2 weeks of birth (van 
Rooij, Sutherland et al. 2006). Also, transgenic over-expression of miR-208a in the 
heart was sufficient to induce hypertrophic growth in mice (van Rooij, Sutherland et al. 
2007; Callis, Pandya et al. 2009).  
 
miR-21 has been identified as a target for heart failure, being increased selectively in 
cardiac fibroblasts extracted from the failing heart. In particular, miR-21 regulates the 
ERK–MAP kinase signaling pathway through inhibition of sprouty homologue 1 (Spry1), 
and in vivo silencing of this miRNA leads to an attenuation of cardiac dysfunction 
(Thum, Gross et al. 2008). 
 
miRNA dysregulation has also been reported in cardiac fibrosis, a dysfunction induced 
by an inappropriate secretion of extracellular matrix from cardiac fibroblasts. A 
substantial down-regulation of miR-29 was observed in affected tissues, suggesting a 
potential beneficial effect of the up-regulation of this miRNA (van Rooij, Sutherland et 
al. 2008). 
 
Finally, also angiogenesis, responsible for the adequate blood supply to the tissues, is 
affected by miRNA dysregulation. First of all, Dicer deficiency is lethal in mice, leading 
to abnormalities in the development of the blood vessel network (Kuehbacher, Urbich 
et al. 2007). In particular, 3 miRNAs (miR-21, miR-143 and miR-145) have been 
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implicated in the last years in vascular smooth muscle cell (VSMC) differentiation and 
proliferation, acting on specific targets. Cheng et al. reported that miR-21 (more 
information about it will be reported in chapter 5), is up-regulated in vessels during 
neointima lesion formation and is able to increase VSMC proliferation and reduce 
apoptosis in vitro. Two main targets of this miRNA have been involved so far in this 
process, the tumor suppressor gene PTEN (Phosphatase and tensin homolog) (Ji, Cheng 
et al. 2007) and PDCD4 (Programmed cell death protein 4) (Zhang 2009). On the other 
hand, miR-143 and miR-145 (described in details in chapter 4) are selectively expressed 
in VSMCs of arterial walls, and they have been recently presented as novel biomarkers 
and modulators of VSMC phenotype (Cheng, Liu et al. 2009). Their targets include 
Kruppel-like factor 4 and 5 (KLF4 and KLF5), and also the angiotensin-converting 
enzyme (ACE), all implicated in the effect of miR-143 and miR-145 on VSMCs behavior 
(Boettger, Beetz et al. 2009; Cheng, Liu et al. 2009; Cordes, Sheehy et al. 2009). Two 
different studies reported a dedifferentiated state of VSMCs in miR-143/miR-145 
deficient mice (Boettger, Beetz et al. 2009; Elia, Quintavalle et al. 2009), and a 
decreased blood pressure was observed in these animals, due to a reduced contractile 
ability of the vessels (Boettger, Beetz et al. 2009; Xin, Small et al. 2009). However, 
while Boettger et al. observed a substantial neointima lesion formation in miR-
143/miR-145 KO mice (Boettger, Beetz et al. 2009), Xin et al. reported a reduced 
neointima formation after carotid artery ligation in the same mouse model (Xin, Small 
et al. 2009), suggesting that further studies will be necessary to better understand the 
role of these miRNAs in VSMC differentiation and angiogenesis. 
 
1.3.3.12.3 miRNAs as Biomarkers 
 
An early detection of cancer is often crucial to improve treatment outcomes. For this 
reason, during the last few years a big effort has been placed in the identification of 
novel, easily accessible, non-invasive biomarkers.  
 
The possibility to extract and analyze miRNAs from body fluids including serum was 
shown for the first time in 2008 (Lawrie, Gal et al. 2008). The analysis of these short 
non-coding RNAs proved their capacity to resist to harsh treatments such as boiling, 
low/high pH and freeze-thaw cycles and also to resist to Rnase A digestion (Chen, Ba et 
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al. 2008; Gilad, Meiri et al. 2008; Mitchell, Parkin et al. 2008). Although the origin of 
cell-free miRNAs is still unclear, two theories have been formulated. The first theory 
suggests that tissue injury could lead to a passive release of miRNAs in the body fluids. 
This has been observed for miR-208, normally expressed selectively in the heart, but 
detected also in the serum after a heart injury (Ji, Takahashi et al. 2009). The second 
theory derives from the recent observation that mRNAs and miRNAs can be 
transported from a cell to another within microvesicles known as exosomes to regulate 
gene expression (van Niel, Porto-Carreiro et al. 2006; Valadi, Ekstrom et al. 2007). This 
hypothesis could explain the reason why cell free miRNAs are protected against Rnase 
activity. 
 
While in healthy individuals cell free miRNA levels stay stable in the serum (Chen, Ba et 
al. 2008; Mitchell, Parkin et al. 2008), selective dysregulations have been identified in 
specific malignancies. For example, high levels of miR-21 have been detected in the 
serum of patients with B-cell lymphoma (Lawrie, Gal et al. 2008), while analysis of 
serum from leukemia patients showed a substantial reduction in miR-92a detection 
(Tanaka, Oikawa et al. 2009). A significant dysregulation of circulating miRNAs has also 
been detected in early stage colon cancer patients, suggesting that these new 
biomarkers could become very important for the detection of tumors when they are 
still clinically asymptomatic (Huang, Huang et al. 2010). More recently, dysregulation 
of specific miRNAs has been observed in the serum of patients affected by 
cardiomyopathy (i.e. miR-1 and miR.133a) and cardiovascular diseases such as 
coronary artery disease (i.e. miR-133a, miR.208a and miR-92a) suggesting that 
circulating miRNAs could become important biomarkers for the diagnosis of 
cardiovascular pathologies and heart failure (Fichtlscherer, De Rosa et al. 2010; 
Kuwabara, Ono et al. 2011). 
 
Unfortunately, miRNA extraction from serum is still technically challenging, mainly due 
to the low concentration of circulating miRNAs often observed in fluids. In fact, several 
miRNAs are extremely low concentrated in serum, and the extracted material results  
therefore difficult to quantify (Chen, Ridzon et al. 2005). Moreover, due to the absence 
of validated endogenous controls, the normalization of Real-Time PCR analysis of these 
cell-free miRNAs is often a critical issue. Several studies selected miR-16 as the most 
appropriate endogenous control because of its stable and widespread expression in 
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many tissues and in serum (Wang, Chen et al. 2009; Heneghan, Miller et al. 2010), but 
its dysregulation in specific malignancies has been reported too (Lodes, Caraballo et al. 
2009), suggesting that an improvement in circulating miRNAs extraction and analysis is 
still needed.  
 
1.3.3.12.4 miRNA-Based Therapies 
 
In the previous sections we have described the deep involvement of miRNAs in post-
transcriptional gene regulation and we have reported several examples of miRNA 
dysregulation in severe pathologies. Despite that, the specific role of most miRNAs is 
still unclear. Loss of function studies have always been considered very helpful to 
improve our knowledge about a genomic sequence, however generating genetic KOs 
for specific miRNAs is often difficult, in particular for those non-coding sequences 
expressed from multiple genomic loci or coded in the intronic region of a gene. For this 
reason, alternative strategies have been developed in the last few years to regulate 
post-transcriptionally a miRNA. 
 
The first strategy developed to efficiently repress the activity of a miRNA requires the 
use of ss-antisense oligonucleotide (ASOs) complementary to the miRNA sequence and 
therefore able to sequester it (Figure 1-20). Multiple steps of miRNA maturation can 
be targeted in this way, with the design of ASOs directed against the Pri-, the Pre- or 
the mature miRNA of interest (Esau 2008). Several modifications to protect ASOs 
against nuclease degradation and to improve affinity for the target miRNA have been 
tested, including 2’ sugar or 2’fluoro modifications (Esau 2008). DNA oligonucleotides 
containing locked nucleotides (LNAs) have also been shown to efficiently inhibit miRNA 
activity. In particular, these LNA/DNA mixmer can form highly stable and sequence 
specific duplexes with their targets due to their higher melting temperature (Tm) 
(Orom, Kauppinen et al. 2006). A third class of oligonucleotides used for miRNA 
silencing is then represented by the “antagomiRs”, cholesterol-conjugated single-
stranded RNA analogues complementary to a miRNA target (Krutzfeldt, Rajewsky et al. 
2005). All these sequences can be efficiently transfected in vitro but also intravenous 
(i.v.) (Krutzfeldt, Rajewsky et al. 2005) or intraperitoneally (i.p.) (Esau 2008) injected in 
vivo for miRNA silencing. The efficiency of ASOs has also been demonstrated in vivo 
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when delivered to the lung by inhalation (Duan, Chan et al. 2005). Alternatively, a 
stable loss of function can be achieved by virus-mediated transfer (Scherr, Venturini et 
al. 2007). 
 
A different strategy has been recently developed to efficiently silence entire miRNA 
seed families through the use of competitive inhibitors called “miRNA sponges”. These 
competitive inhibitors are represented by transgene sequences expressed from a 
strong promoter and containing multiple, tandem binding sites to a miRNA of interest 
in their 3’UTR (Ebert, Neilson et al. 2007). These chemically synthesized RNAs can be 
expressed transiently from transfected plasmids or stably inserted in the genome by 
lentiviral vectors (Gentner, Schira et al. 2009). Since the binding sites can interact 
efficiently only with the seed sequence, all the miRNAs sharing the same seed region 
will be efficiently sequestered by the sponge. Alternatively, combinations of seed 
binding sites for two or more miRNAs of interest can be cloned in the 3’UTR of the 
transgene for a multiple silencing effect (Ebert, Neilson et al. 2007). The existence of 
natural endogenous miRNA sponges able to fine-tune the activity of a miRNA was first 
showed in plants and recently also in mammalian (Franco-Zorrilla, Valli et al. 2007; 
Ebert and Sharp 2010; Poliseno, Salmena et al. 2010). 
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Figure 1-20  ASOs pharmacologically modulate microRNAs activity. The antisense 
oligonucleotide (black) binds the mature microRNA (red), blocking its function within the cell. 
Obtained from PharmTech (http://pharmtech.findpharma.com/pharmtech/article/). 
 
1.4 Aims 
The principle research aim of this work was to investigate the role of miRNAs in the 
development of PAH. This may offer insight into the pathobiology and the genetic basis 
of PAH, generating the possibility of new treatments. This was evaluated through 
investigation of the following experimental study aims: 
 In vivo and in vitro characterisation of global miRNA expression profile in two 
different rat models of PAH and identification of specific miRNAs potentially 
involved in the development of the pathology; 
 In vivo analysis of the effects of the genetic ablation of specific miRNAs (i.e. 
miR-145 and miR-21) in the development of PAH; 
 Evaluation of the role of the TGF-beta superfamily on miRNA regulation via in 
vitro TGF-beta/BMP4 stimulations and BMPR2 manipulation. 
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2. Materials and methods 
2.1 Chemicals 
All chemicals, unless otherwise stated, were obtained from Sigma-Aldrich (Poole, UK) 
and were of the highest grade obtainable. All cell culture reagents were obtained from 
Gibco (Invitrogen, Paisley, UK) unless otherwise indicated. Dulbecco’s calcium and 
magnesium free phosphate buffered saline (PBS) was obtained from Lonza (Lonza 
Group Ltd, Basel, Switzerland). All oligonucleotides were obtained from MWG-Biotech 
(Edersberg, Germany). 
 
2.2 Cell Culture 
All tissue culture work was performed using a biological safety class II vertical laminar 
flow cabinet in sterile conditions. Cell lines were grown as a monolayer, maintained in 
the appropriate cell culture media (described below in detail) and incubated at 37°C in 
a 5% CO2 atmosphere. Cells were routinely passaged when monolayer cell growth 
reached 90% confluency, to prevent cell growth arrest via contact inhibition. Briefly, 
cells were washed twice in PBS and incubated in a minimal volume of trypsin-EDTA at 
37°C, 5% CO2 for approximately 5 min in order to detach cells. The action of trypsin-
EDTA was inhibited by the addition of an equal volume of media containing fetal calf 
serum (FCS). Cells were harvested by centrifugation at 500 × g for 5 min and 
resuspended in fresh media for passaging or plating. 
 
2.2.1 Isolation and Culture of Primary Rat Pulmonary Artery 
Fibroblasts  
Rat pulmonary artery fibroblasts (RPAFs) were extracted from male Wistar rats 
(specific pathogen free, Harlan UK Ltd, 6 weeks old; 300-400g) using the technique of 
Freshney as previously described (Peacock, Dawes et al. 1992). Cells were maintained 
in Dulbecco’s modified Eagle medium (DMEM) containing 10% (v/v) FCS, 
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supplemented with penicillin/streptomycin (100 U/ml and 100 g/ml respectively) and 
L-glutamine (27 mg/ml) and used at passage 4.  
 
2.2.2 Isolation and Culture of Primary Rat Pulmonary Artery 
Smooth Muscle Cells  
Rat pulmonary artery smooth muscle cells (RPASMCs) were derived from small 
precapillary pulmonary arterioles using an iron oxide magnetic separation method, as 
previously described (Sobolewski, Jourdan et al. 2004). Cells were maintained in 
DMEM containing 10% (v/v) FCS, supplemented with penicillin/streptomycin (100 U/ml 
and 100 g/ml respectively) and used at passage 4. 
 
2.2.3 Primary Culture of Human Pulmonary Artery Endothelial 
Cells  
Human Pulmonary Artery Endothelial Cells (HPAECs) were obtained from Lonza (Lonza 
Group Ltd, Basel, Switzerland) and cultured by following the supplier’s instructions. 
Briefly, cells were maintained in EGM®-2 Endothelial Cell Growth Medium-2 (Lonza 
Group Ltd, Basel, Switzerland) containing 2% (v/v) FCS, supplemented with 
penicillin/streptomycin (100 U/ml and 100 g/ml respectively) and used at passage 3. 
 
2.2.4 Primary Culture of Human Pulmonary Artery Fibroblasts  
Human Pulmonary Artery Fibroblasts (HPAFs) were obtained from ScienCell (Carlsbad, 
CA, USA). Cells were cultured by following the Supplier’s instructions. They were 
maintained in Fibroblast Medium (ScienCell, Carlsbad, CA, USA) containing 2% (v/v) 
FCS and supplemented with penicillin/streptomycin (100 U/ml and 100 g/ml 
respectively). Cells were used at passage 3. 
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2.2.5 Isolation and Culture of Primary Human Pulmonary 
Artery Smooth Muscle Cells  
Human pulmonary artery smooth muscle cells (HPASMCs) were kindly provided by Prof 
N.W Morrell, University of Cambridge, UK. They were explanted from peripheral 
arteries as previously described (Yang, Long et al. 2005). Smooth muscle cell lines were 
obtained from 4 patients with PAH known to harbour a mutation in BMPR2. These 
included: 1 patient with a mutation in the kinase domain of BMPR2 in which arginine is 
substituted for cysteine at position 347 (C347R); 1 patient with a missense mutation in 
the cytoplasmic tail of BMPR2, leading to a serine in place of asparagine at position 
903 (N903S); 1 patient with a truncating mutation at amino acid position 9 (W9X) and 
1 patient with a truncating mutation at amino acid position 899 (R899X). Three further 
PASMC preparations were obtained from macroscopically normal lung biopsies excised 
from non-PAH donors as unaffected controls. Cells were cultured as previously 
described (Yang, Long et al. 2005). Briefly, cells were maintained in DMEM containing 
10% (v/v) FCS, supplemented with 2 mM L-glutamine and penicillin/streptomycin (100 
U/ml and 100 g/ml respectively) and used at passage 4. 
 
2.2.6 Cell Freezing/Thawing 
Cells were harvested as described in Section 2.2 and then resuspended in 1 ml of 
Cryopreservation Medium (DMEM containing 10% (v/v) FBS and 10% (v/v) dimethyl 
sulphoxide (DMSO) for RPAFs, RPASMCs and HPASMCs. EGM®-2 Endothelial Cell 
Growth Medium-2 containing 2% (v/v) FBS and 10% (v/v) DMSO for HPAECs). The 
resuspended cells were placed in a 2 ml cryo-preservation vial and left on ice for 1 h 
followed by a -80°C freezer overnight. The cryo-preservation vials were then 
transferred in liquid nitrogen for long term storage. Frozen cells were removed from 
liquid nitrogen and thawed rapidly in a water bath at 37°C, then transferred in a 15 ml 
centrifuge tube containing the appropriate pre-warmed cell culture media (as specified 
above). The tubes were centrifuged at 500 × g for 5 min to pellet the cells and remove 
the DMSO. Cells were then resuspended in 10 ml of fresh growth media and seeded 
onto T-25 flasks. The following day they were placed in fresh media. 
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2.2.7 Growth of cells in a hypoxic environment 
A humidified temperature-controlled incubator (LEEC model GA156; Colwick, 
Nottingham, UK) was used as a hypoxic chamber. This incubator allows control of 
internal oxygen levels between 0 and 21% while CO2 level is simultaneously controlled 
at 5%. For the experiments of chapter 3, RPAF, RPASMCs, HPAFs and HPAECs were 
transferred to 6-well plates at approximately 80% confluence and kept in 5% oxygen 
for 24 h before extracting total RNA for checking miRNAs expression level. 
 
2.2.8 TGF-beta and BMP4 RPASMCs stimulation  
Passage 4 RPASMCs were cultured in 6-well plates in the appropriate growth media (as 
specified in Section 2.2.2). After 24 h the media was replaced with 0.1% FCS media and 
cells incubated for a further 24 h. Wells were then incubated with 1 ng/ml of TGF-beta 
(R&D Systems, Minneapolis, MN, USA) or 10 ng/ml of BMP4 (R&D Systems, 
Minneapolis, MN, USA) or with DMEM containing 0.1% FCS as a negative control. Total 
RNA was extracted after 5 and 24 h of stimulation and stored for TaqMan® Real-Time 
PCR analysis of miRNA expression.  
 
2.2.9 Down-regulation of BMPR2 expression with a si sequence 
PASMCs were seeded in 6-well plates (1.5 x 105 cells/well) and grown for two days in 
DMEM/10% FBS. Prior to transfection, PASMCs were incubated in Optimem I for 3 h. 
PASMCs were transfected with a final concentration of 10 nM siRNA (Dharmacon™ On-
TARGETplus siRNA for BMPR2, or siControl Nontargeting Pool, Perbio Science UK Ltd) 
in complex with DharmaFECT1™ (4ml/well) diluted in Optimem I. The Dharmafect was 
incubated in half the final volume (200 l for 1 well) of Optimem I for 5 min followed 
by addition of Optimem I (200 l for 1 well) containing 10X final concentration of the 
relevant siRNA, making the siRNA at 5X final concentration. The mix was incubated for 
20 min at room temperature to allow lipoplexes to form. The Transfection mix (400 
l/well) was dropped onto cells in fresh Optimem I (1.6ml/well), ensuring full coverage 
of the well. Cells were incubated with the complexes for 4 h at 37°C, followed by 
replacement with DMEM/10% FBS for 24h. RNA was extracted after 72 h. 
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2.3 Development of hypoxia-induced PAH in rats and 
mice 
The development of hypoxia-induced PAH was obtained in rats and mice using a 
hypobaric hypoxic chamber. Following acclimatization, mice were exposed to 550 
mbar for a continuous period of 14 days and rats up to 21 days. As a consequence of 
atmospheric depressurization from ≈ 1000 mbar (ambient room pressure) to 550 
mbar, oxygen availability is decreased from 21% O2 to 10% O2, inducing the 
development of PAH. Temperature (21-23 °C) and relative humidity (30-50%) were 
maintained within a normal range and all the animals were re-housed with clean 
bedding and food/water every week. 
 
2.4 Animals, treatments and tissue collection 
For the rat study of chapter 3, WT male Sprague-Dawley rats (6-7 weeks old; 250-300 
g) were used throughout.  All protocols and surgical procedures were approved by the 
local animal care committee and performed under the project license held by Dr 
Nicholas W. Morrell (University of Cambridge, UK).  For the induction of PAH due to 
chronic hypoxia, groups of rats were maintained in a normobaric hypoxic chamber (as 
described in the previous paragraph) for up to 21 days. In the monocrotaline model, 
animals received a single subcutaneous injection of monocrotaline (60 mg/kg). To 
characterize miRNAs expression in PAH, animals were sacrificed at 2, 7 and 21 days 
immediately after the rats were anesthetized (intramuscular ketamine 75 mg/kg and 
zylazine 6mg/kg). Rats were exsanguinated and the lungs were removed and snap 
frozen in liquid nitrogen for further analysis. 
For the experiments based on BMPR2 mutated mice in chapter 4 and chapter 5 
(Sections 4.2.6 and 5.2.4), mice harbouring a heterozygous truncating mutation in 
BMPR2 were used to further determine the regulation of miR-143, miR-145 and miR-
21 and kindly provided by Dr Nicholas W. Morrell (University of Cambridge, UK). These 
mice, similar to previously described R899X transgenic mice (West, Harral et al. 2008) 
develop spontaneous pulmonary hypertension. Lung tissue was harvested from 
R899X+/- mice (strain C57BL/6J, 6 months of age, 25 to 30 g body weight) and WT 
littermates for miR-143, miR-145 and miR-21 expression and for in situ hybridization 
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studies. Animal experiments were reviewed and approved by the local animal care 
committee and performed under the project license held by Dr Nicholas W. Morrell 
(University of Cambridge, Cambridge, UK). To assess miRNA expression level, animals 
were sacrificed with an injection of Euthatal (Chemindustry, Monrovia, CA, USA). The 
solution is administered at the rate of 1 ml per 1.4 Kg body weight (≈ 150 mg/Kg body 
weight). Then the thoracic cavity was opened to expose heart and lung, isolated after 
the excision of the carotid. Lungs were dissected out and snap frozen in liquid nitrogen 
for RNA extraction or fixed in 10% (v/v) neutral-buffered formalin (NBF, 10% (v/v) 
formalin, 33 mMol/L NaH2PO4, 45 mMol/L Na2HPO4) for three days, under gentle 
agitation and then embedded in paraffin for histological analysis. 
For the miR-145 KO mouse study of chapter 4 and the miR-21 KO mouse study of 
chapter 5, mice were generated as previously described (Xin, Small et al. 2009; Patrick, 
Montgomery et al. 2010) and kindly provided by Dr Olson (University of Texas 
Southwestern Medical Center, Dallas, Texas, USA). All the experiments were reviewed 
and approved by the local animal care committee in Glasgow, UK, and performed 
under the project license held by Prof. Margaret R MacLean (University of Glasgow, 
UK), Licence No. 60/3773. Briefly, the genomic region coding for the pre-miR-145 or 
the pre-miR-21 was replaced with a neomycin resistance cassette flanked by loxP sites 
through homologous recombination. The neomycin resistance cassette was then 
removed by breeding these mice with mice expressing the Cre transgene. Homozygous 
aged matched miR-145-/- (or miR-21-/-) female mice or WT matching controls (strain 
C57BL6J/129SVEV, 8 weeks of age, 25 to 30 g body weight) were exposed to chronic 
hypoxia for 14 days (as described in section 2.3) or maintained in normoxic conditions 
and analyzed at 10 weeks of age. To assess vascular remodelling and miRNA/target 
expression, animals were sacrificed with an injection of Euthatal (Chemindustry, 
Monrovia, CA, USA) and the lung isolated as previously described in this section. The 
extralobar branch of the pulmonary artery (PA) was excised from its insertion into 
heart and lungs and snap frozen in liquid nitrogen. Lungs, hearts, kidneys, brains and 
spleens were collected and snap frozen in liquid nitrogen or fixed in 10% (v/v) neutral-
buffered formalin (NBF, 10% (v/v) formalin, 33 mMol/L NaH2PO4, 45 mMol/L Na2HPO4) 
for three days, under gentle agitation and then embedded in paraffin for histological 
analysis. 
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2.5 Assessment of PAH 
2.5.1 Haemodynamic Measurements 
The induction of general anaesthesia was performed via exposure to 3% (v/v) 
isoflurane supplemented with O2. Mice were immediately weighed and 1-2% (v/v) 
isoflurane continuously administered via a facemask to maintain general anaesthesia. 
General anaesthesia was confirmed by the absence of a hind-limb and tail reflex. These 
reflexes were also routinely assessed throughout surgery. Following confirmation of 
general anaesthesia, both right ventricular pressure (RVP) and systemic arterial 
pressure (SAP) were measured. 
 
2.5.2 Right Ventricular Pressure Measurement  
RVP was measured via a transdiaphragmatic approach. The continuous measurement 
of RVP was assessed via a heparinised saline-filled calibrated 25-gauge needle attached 
to an Elcomatic E751A pressure transducer connected to a MP100 data acquisition 
system (BIOPAC Systems Inc, Santa Barbra, USA). Briefly, the anterior sternum was 
exposed removing a portion of skin from the ventral chest. The 25-gauge needle was 
then advanced through the mid-portion of the sternum, into the abdomen. A negative 
pressure reading was obtained in consequence of the entry into the diaphragm, then 
the needle was advanced directly into the right ventricle via puncture through the right 
ventricular free wall. This was confirmed by the characteristic pressure waveform 
typically observed inside the right ventricle (Figure 2-1). From this recording, kept 
stable for up to 20 min, systolic RVP (sRVP) was deduced and used as an index of PAH. 
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Figure 2-1  Representative recording of right ventricular pressure. Representative 
measurement of right ventricular pressure in mice. Y-axis expressed in mmHg. 
 
 
 
 
2.5.3 Systemic Arterial Pressure Measurement  
Systemic Arterial Pressure (SAP) was measured via cannulation of the left common 
carotid artery. Briefly, the trachea was exposed via skin incision through the ventral 
neck. Lateral blunt dissection was performed through the muscle lying inferior to the 
trachea. The left common carotid artery is typically positioned ≈ 2 mm lateral (left) and 
less than 1 mm posterior to the trachea. The artery was carefully separated from both 
the vagus nerve and the recurrent laryngeal nerve. Distal suture (7-0 silk non-braided) 
was used for isolation of the artery and an arterial clip positioned at the most proximal 
arterial segment to temporarily occlude blood flow through the lumen. Following 
incision through the arterial wall, a heparinised saline-filled polypropylene cannula 
(Harvard Apparatus, Boston, USA) was proximally inserted 4-5 mm into the lumen and 
secured using suture. As for the RVP measurement, the systemic arterial cannula was 
also attached to an Elcomatic E751A pressure transducer connected to a MP100 data 
acquisition system (BIOPAC Systems Inc, Santa Barbra, USA) allowing the recording of 
the SAP (Figure 2-2). Following measurement of RVP and SAP, mice were killed by 
cervical dislocation. 
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Figure 2-2  Representative recording of systemic arterial pressure. Representative 
measurement of systemic arterial pressure in mice. Y-axis expressed in mmHg. 
 
 
 
 
 
2.5.4 Right Ventricular Hypertrophy Measurement 
The atria, large blood vessels and pericardial fat were dissected free from the 
ventricles. The right ventricular free wall (RV) was dissected from the left ventricle plus 
septum (LV+S) and both were weighted in order to assess right ventricular hypertrophy 
(RVH). The ratio RV/LV+S has been used as an index of PAH (MacLean, Deuchar et al. 
2004; Morecroft, Pang et al. 2010). 
 
2.5.5 Pulmonary Vascular Remodelling Assessment 
Three 5 μm sagittal sections of lung were elastic-Van Gieson stained and 
microscopically assessed for the muscularisation of pulmonary arteries (<80 μm 
external diameter) in a blinded fashion. The presence of double elastic laminae 
allowed the individuation of the remodelled arteries. Lung sections from 5 mice for 
each group were analyzed. Approximately 150 arteries from each sagittal lung section 
were assessed. This was expressed as a percentage of pulmonary vascular remodelling 
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(remodelled vessels/total pulmonary vessels x 100 = % pulmonary vascular 
remodelling). 
 
2.6 DNA extraction from mouse tissue 
In order to verify the genotype of miR-145 (or miR-21) KO mice used in chapter 4 (or 
chapter 5), genomic DNA was isolated from tissue samples using the QIAamp DNA Mini 
Kit (Qiagen, CA, USA) following the manufacturer’s instructions. Briefly, mouse ear 
clips were placed in 200 μl SDS-containing lysis buffer with proteinase K and incubated 
overnight at 55°C. 200 μl of ethanol were added to the samples, mixed and then 
loaded onto a QIAamp Spin Column. Samples were centrifuged for 1 minute at 6000 x 
g to adsorb the DNA onto the silica-gel membrane of the spin column. The spin column 
was washed with buffers AW1 and AW2 and then DNA was eluted in 50 μl of deionised 
water by centrifugation at 6000 x g for 1 minute. The concentration of DNA in each 
sample was quantified using the NanoDrop ND-1000 Spectrophotometer (Nano-Drop 
Technologies, Wilmington, DE, USA) as described in detail in Section 2.8.2. 
 
2.7 Polymerase Chain Reaction (PCR) 
The absence in the genome of the DNA sequence coding for pre-miR-145 or pre-miR-
21 in the KO mice was assessed by PCR, a technique used to amplify a DNA sequence 
using two oligonucleotides that are complementary to the 3' (three prime) ends of 
each of the sense and anti-sense strand of the DNA target, generating millions of 
copies. In particular, during a first step DNA is heated to break all the hydrogen bonds 
and separate the two DNA strand, after that it is cooled down to consent the annealing 
of the primer and then heated again for the elongation step obtained through the 
action of a thermostable DNA polymerase. The final step is the re-annealing of the new 
DNA strands. This steps are repeated several times (30 to 40 generally) in order to 
amplify the DNA template. In this case, specific oligonucleotides allowed the 
amplification of a sequence flanking the pre-miR coding region of each miRNA of 
interest, absent in the KO mice. If the analyzed animal is a KO, the amplified DNA 
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fragment will have a different size than a WT, depending by the strategy used for 
creating the KO, previously described (Xin, Small et al. 2009; Patrick, Montgomery et 
al. 2010). In particular, for miR-145 samples, a 145 bp fragment was obtained for the 
WT animals and a 200 bp for the mutants, while for miR-21 samples, a 469 bp 
fragment was obtained for the WT animals and a 330 bp for the mutants (Figure 
2-3and Figure 2-4). For each sample analyzed, 5 ng of DNA were incubated with a mix 
containing 5 l of 5X Go Taq Flexi Buffer (Promega, Southampton, UK), 3 mM MgCl2, 
400 nM forward and reverse primers (sequence and annealing temperature are 
indicated in Table 2-1) and 0.6 U of Taq DNA polymerase (Promega, Southampton, UK). 
Reactions were then incubated in a 96-well plate at 95°C for 2 min (denaturation), 
following by 35 cycles of 95°C for 15 s (amplification), 62°C or 61°C (for miR-21 or miR-
145 KO mice respectively) for 35 s (annealing) and 72°C for 30 s (extension). PCR 
products were analyzed in an agarose gel (Figure 2-3 and Figure 2-4). Briefly, A 1% 
(w/v) agarose gel for miR-21 KO samples (or 2% for miR-145 KO samples) was prepared 
in 1X Tris/Borate/EDTA (TBE, 10 mM Tris, 10 mM boric acid, 10 mM EDTA, pH 8.3) 
containing ethidium bromide (10 ng/ml). Samples were subjected to electrophoresis at 
80V for 1 h alongside a DNA ladder (100 bp or 1 Kb as indicated, Promega, 
Southampton, UK).  
 
 
 
 
 
PCR Primers Sequence Melting Point
miR-145
Forward
Reverse
miR-21
Forward
Reverse
GCACGTGCTGAAGGCATCTCTC                        
GGGTGGGAGGGAGACAGATCC
GGGCGTCGACCCGGCTTTAACAGGTG
GGGCGTCGACGATACTGCTGCTGTTACCAAG
59°C 
60°C 
66°C 
67°C 
 
Table 2-1  Oligo nucleotides used for PCR reactions. 
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200 bp
100 bp
200 bp
145 bp
HT KO WTL
 
 
Figure 2-3  Representative PCR showing the specific fragments amplified from 
heterozygous (HT), miR-145 KO or WT mice. In the first lane the fragments of the 100 bp 
DNA ladder are shown (L). 
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469 bp
330 bp
500 bp
400 bp
300 bp
HT KO WTL
 
 
Figure 2-4  Representative PCR showing the specific fragments amplified from 
heterozygous (HT), miR-21 KO or WT mice. In the first lane the fragments of the 100 bp DNA 
ladder are shown. 
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2.8 Total RNA extraction from frozen tissues, PASMCs, 
PAFs, PAECs and human serum  
Total RNA (including miRNAs) from tissues and cells was obtained using the miRNeasy 
kit (Qiagen, Hilden, Germany). In particular for the extraction from frozen tissues, 700 
l of QIAzol Lysis Reagent (Qiagen, Hilden, Germany) were added to each sample while 
it was still frozen, and the tissue were disrupted using the TissueLyser system (Qiagen, 
Hilden, Germany) by rapid agitation in the presence of a 5 mm tungsten carbide bead 
(Qiagen, Hilden, Germany) for 4 cycles of 30 s each at 20 Hz. After that the 
homogenates were carefully transferred to a fresh 1.5 ml centrifuge tube. The addition 
of 140 l of chloroform allowed RNA separation from DNA and proteins in an upper 
phase after a 15 min centrifugation at 12,000 x g at 4°C. 500 μl of ethanol were then 
added in order to facilitate RNA binding to the column and the samples were loaded 
into RNeasy spin columns and centrifuged at 8,000 x g for 15 s. The RNA bounded to 
the column was then washed 3 times (1X with 700 μl of RWT buffer and 2X with 500 μl 
of RPE buffer) and finally eluted with 40 μl of Diethylpyrocarbonate (DEPC) treated 
water. DEPC is a strong inhibitor of RNases and avoid RNA degradation. Samples were 
stored at -80°C.  
 
For RNA extraction from cells the same protocol was used with the exception of the 
first step. 700 l of QIAzol Lysis Reagent (Qiagen, Hilden, Germany) were added 
directly to the 6-well plates used for the experiments. The solution was then collected 
in a micro centrifuge tube for each sample.  
 
 
2.8.1 DNAse treatment 
In order to eliminate the genome DNA contamination the DNAse 1, amplification grade 
(Sigma-Aldrich, Poole, UK) was used following the manufacturer’s instructions. Briefly, 
4 l of 10X reaction buffer were added to the purified RNA, previously eluted in 40 l 
of DEPC water as described above in detail. Then 2 l of amplification grade DNAse I (1 
U/l) were added to each sample and the reaction was incubated for 15 min at RT. 1 
unit of amplification grade DNAse I completely digests 1 g of plasmid DNA to 
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oligonucleotides in 10 min at 37°C. Re-suspended stop solution was then added to 
each sample (0.1 volumes) and incubated for 19 min at 70°C to inactivate the DNase I. 
Heating also denatures RNA secondary structure, so the RNA can be used directly in 
reverse transcription reaction. After the treatment, the RNA was stored at -80°C in 
order to prevent degradation. 
 
2.8.2 RNA quantification and quality assessment 
Total RNA was quantified using the NanoDrop ND-1000 Spectrophotometer (Nano-
Drop Technologies, Wilmington, DE, USA). This instrument is able to calculate the 
concentration of a nucleic acid exposing a sample to ultraviolet light at 260 nm, and 
measuring the light that passes through the sample. The more light is absorbed by the 
sample, the higher is the nucleic acid concentration. In particular, the correlation 
between the amount of light absorbed and the nucleic acid concentration is calculated 
using the Beer–Lambert law as follows: 
c = A/( x l) 
Where: 
c = nucleic acids concentration 
A = absorbance  
 = molar absorptivity 
l = length of solution the light passes through  
 
The molar absorptivity is a measurement of how strongly a chemical species absorbs 
light at a given wavelength (260 nm in this case), and it is an intrinsic property of the 
species. For nucleic acids, the used values are 50 ng/l for double-stranded DNA, 33 
ng/l for single-stranded DNA and 40 ng/l for RNA. 
For assessing RNA quality, absorbance of the RNA samples was quantified at 260 and 
280 nm, and the 260/280 ratio was calculated. The samples showed a 260/280 ratio ≥ 
1.9, which was assumed as an indicator of RNA purity. In order to further determine 
RNA quality, when enough RNA was extracted from tissues or cells, agarose gel 
electrophoresis was used. RNA samples (700 ng) and 1 kb DNA marker plus 6X loading 
buffer (0.02% bromophenol blue, 0.02% xylene cyanole and 2.5% glycerol, Promega, 
Southampton, UK) were loaded onto a 1% (w/v) agarose gel in 1X Tris/Borate/EDTA 
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(TBE) (10 mM Tris, 10 mM boric acid, 10 mM EDTA, pH 8.3) and ethidium bromide (10 
ng/mL). Gels were electrophoresed at a constant voltage of 80/90 V with TBE as a 
running buffer and visualized under UV light (260 nm). This allows the visualization of 
28S and 18S ribosomal RNA (rRNA) as two separate bands (Figure 2-5). 
 
 
 
 
 
 
28S
18S
L HeLa1 HeLa2 HeLa3
 
 
Figure 2-5  Example of an RNA gel. Total RNA was extracted in triplicate from HeLa cells. 1 
μg was loaded in each well. 
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2.8.3 Reverse transcription 
Complementary DNA (cDNA) specific for each miRNA was synthesized from total RNA 
using stem-loop reverse transcription primers according to the TaqMan® MicroRNA 
Assay protocol (Chen, Ridzon et al. 2005) (Applied Biosystems, Foster city, CA, USA). 
The assays specific for each miRNA and control are shown in Table 2-2. Each reaction 
contained 5 ng of extracted total RNA, 50 nM stem-looped RT primer, 0.75 l of 10X RT 
buffer, 0.25 mM each of deoxyribonucleotide triphosphates (dNTPs), 0.5 l of 50 U/l 
Multiscribe reverse transcriptase and 0.095 l of 20 U/l RNase inhibitor. The 15 l 
reactions were incubated in a 96-well plate for 30 min at 16°C (preannealing), 30 min 
at 42°C (reverse transcription), 5 min at 85°C (reverse transcription inactivation) and 
then stored at -20°C. 
 
Total cDNA for gene expression analysis was obtained from total RNA using the 
SuperScript II Reverse Transcriptase (Invitrogen, Paisley, UK). Briefly, 1 g of RNA from 
each sample to reverse transcribe was diluted in DEPC treated water up to a final 
volume of 10 l and denatured at 70°C for 10 min. In the meantime, a master mix 
reaction was made up in 10 l according to the following recipe: 4 l of 5X SuperScript 
II buffer (Invitrogen, Paisley, UK), 200 U of SuperScript II RT (Invitrogen, Paisley, UK), 3 
g of random hexamer primers (Invitrogen, Paisley, UK), 20 U of RNase inhibitor 
(Promega, Southampton, UK), 0.125 mM each of dNTPs mixture, nuclease free water 
up to 10 l. After the denaturation step the master mix was added to each sample to 
give a final reaction volume of 20 μl. Cycling conditions were the following: 10 min at 
25°C (preannealing), 30 min at 48°C (reverse transcription), 5 min at 95°C (reverse 
transcription inactivation). cDNA was stored at -20°C. 
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Assay Mature miRNA Sequence Product Code
miR-21
miR-451
miR-22
miR-30c
miR-143
miR-145
miR-322
let-7f
let-7a
let-7d
UAGCUUAUCAGACUGAUGUUGA 000397 
AAGCUGCCAGUUGAAGAACUGU 000398 
UGUAAACAUCCUACACUCUCAGC 000419 
UGAGAUGAAGCACUGUAGCUC 002249 
GUCCAGUUUUCCCAGGAAUCCCU 002278 
AAACCGUUACCAUUACUGAGUU 001141 
AAACAUGAAGCGCUGCAACA 001059 
UGAGGUAGUAGAUUGUAUAGUU 000382 
UGAGGUAGUAGGUUGUAUAGUU 000377
AGAGGUAGUAGGUUGCAUAGUU 002283
Assay Control Sequence Product Code
ACAATGATGACTTATGTTTTTGCCGTTTAC
CCAGCTGAGGGTTTCTTTGAAGAGAGAAT
TTAAGACTGAGC
001712
GTGCTCGCTTCGGCAGCACATATACTAAA
ATTGGAACGATACAGAGAAGATTAGCATG
GCCCCTGCGCAAGGATGACACGCAAATTC
GTGAAGCGTTCCATATTTT
001973 
001006GATGACCCCAGGTAACTCTGAGTGTGTCG
CTGATGCCATCACCGCAGCGCTCTGACC
U87
U6
Rnu-48
 
Table 2-2  TaqMan® probes used for miRNA reverse transcription and Real-Time PCR. 
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2.9 Two-channel microarray experiment  
For the microarray assay showed in Chapter 3, total RNA extracted from control, 
hypoxic and monocrotaline-treated rats was sent to LC sciences (Houston, Texas, USA) 
for a two-channel microarray experiment. 5 g of each RNA sample were used. For 
shipping, 0.1 volume of 3 M NaOAc (pH 5.2) and 3 volumes of 100% ethanol were 
added, mixed and placed in RNase-free 1.5 ml tubes. The samples were packed in dry 
ice for shipping. Figure 2-6 gives a design of the miRNA microarray study investigating 
PAH in the rat. Each circle represents a “condition”, with each hypoxia treatment being 
in red and each monocrotaline treatment in blue.  Each arrow represents a two-
channel microarray experiment. For the experiment, the RNA was labeled with a 
fluorescent dye then hybridized overnight onto a microfluidic chip containing 
complementary probes for 723 human miRNAs and other RNA controls. The chip was 
imaged using a GenePiz 4000B laser scanner and digitized using Array-Pro image 
analysis software. Raw data matrix was then subtracted from the background matrix. 
To assess the statistical significance of intergroup differences, rank products were used 
(Breitling, Armengaud et al. 2004). Significance was assessed using the false discovery 
rate multiple testing correction method (Reiner, Yekutieli et al. 2003), with a false 
discovery rate cutoff of 5%. 
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Figure 2-6  Design of the miRNA microarray study investigating PAH in hypoxic or 
monocrotaline-exposed rats. Each circle represents an animal group (minimum n = 5/group), 
with each hypoxia treatment being in red and each drug treatment in blue. The control group is 
represented in green. Each arrow shows a two-channel microarray experiment.  
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2.10 TaqMan® Quantitative Real-Time PCR analysis of 
mature, pre- and pri- miRNAs and mRNAs 
For the Real-Time PCR step, amplification was carried out using TaqMan® MicroRNA 
(Chen, Ridzon et al. 2005) or mRNA specific primers (Table 2-2 and Table 2-3) (Applied 
Biosystems, Foster city, CA, USA) on the Applied Biosystems 7900 HT real-time PCR 
system. The 10 l reaction included 0.7-2 l of template cDNA, 5 l of 2X TaqMan® 
Universal PCR Master Mix or SYBR® Green PCR Master Mix (Applied Biosystems, Foster 
city, CA, USA), 0.5 l of 20X concentrated FAM or VIC labeled probe for Pri/mature-
miRNA or gene expression analysis (Applied Biosystems, Foster city, CA, USA) or 4 pmol 
of forward and reverse oligos of Pre-miRNA detection, nuclease-free water up to 10 l. 
The quantity of template cDNA to use in each experiment was carefully chosen 
according to the expression level of the specific miRNA/mRNA, in order to have cycle 
threshold (Ct) values in a range of 20-30. In fact, with Ct values smaller than 20, the 
fluorescence (that is a measure of the expression level of the transcript of interest) is 
so high that the identification of differences between samples is not precise, while vice 
versa,  in case of Ct values too low, the consistency of the result can be difficult to 
determine. Reactions were incubated in a 384-well optical plate at 95°C for 10 min 
(denaturation), following by 40 cycles of 95°C for 15 s (amplification) and 60°C for 1 
minute (annealing). U87, U6, RNU-48 and GAPDH were used as endogenous controls 
for rat miRNAs, mouse miRNAs, human miRNAs and mRNAs respectively. Ct values 
were exported directly into EXCEL worksheets for analysis and the relative 
quantification was made using the 2- Ct method (Livak and Schmittgen 2001; Cikos, 
Bukovska et al. 2007). Briefly, the Ct values, defined as the number of cycles it takes 
for a sample to reach the level where the rate of amplification is the greatest during 
the exponential phase, were obtained for every miRNA/gene and for the 
correspondent endogenous control. The Ct value was calculated using the equation: 
[miRNA/mRNA Ct  = miRNA/mRNA Ct − control Ct].  
The fold change for every miRNA/mRNA expression was finally obtained from the 
formula 2−CT, where the CT value was the difference between the control group 
CT and every other stimulated/mutated group CT values. The value of 2−CT for the 
control group was 1. Each experiment was run in triplicate and results are presented as 
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the mean + standard deviation of the sample. To assess the statistical significance of 
intergroup differences, student’s t tests, one-way or two-way ANOVA were performed 
as specified.  
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Assay Species Product Code
Kcnj6
Ywhaz
Nfat5
Ppp2r5e
Tacc1
Tnrc6a
Adarb1
Tgfbr1
TGFBR1
Tgfbrap1
Amplicon Lenght
Rat 70 Rn00755103_m1
Rn01762487_m1Rat 65
Rat 68 Rn01769637_m1 
Rat 61 Rn01163358_m1 
Rn00755072_m1 
Rn00563671_m1
Rat 104
Rat 92
Rn00562811_m1
Hs00610320_m1 
Rat 86
Human 73
Rn01437728_m1 Rat 71
Rat 113Rbpsuh Rn01457013_g1 
Rat 100 Rn01478432_m1 
Gapdh Rat Rn01775763_g1 174
GAPDH Human 93 Hs02758991_g1 
Gapdh Mouse 107 Mm99999915_g1 
Smad4 Mouse 71 Mm03023996_m1 
MouseSmad5
Klf4
Klf5
Mouse
Mouse
77
Mm03024001_g1 
Mm00516104_m1 
Mm00456521_m1 
159
140
 
Assay Species Product Code
Pri-miR-21
Amplicon Lenght
Human 101 Hs03302625_pri
 
PCR Primers Sequence
Pre- miR-145
Forward
Reverse
Pre- miR-21
Forward
Reverse
CACCTTGTCCTCACGGTCCA        
AACCATGACCTCAAGAACAG
GCGCAGCGCCCTGTCTCCCA
GCTGCAGAACAACTTCTCTC
Pre- miR-143
Forward
Reverse
TGTCGGGTAGCTTATCAGAC                  
TGTCAGACAGCCCATCGACT
Species
Human
Human
Human
 
 
Table 2-3  TaqMan
®
 probes used for gene expression/Pri-miRNA Real-Time PCR and 
oligos used for SYBR
®
 Green-based Real-Time PCR analysis. 
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2.11 Northern blot analysis  
In order to detect and visualize miR-145, miR-143 or miR-21 in mouse and human 
samples, northern blotting assays were performed. Briefly, 2 g (for miR-21 detection) 
or 3 g (for miR-143 and miR-145 detection) of mouse or human total RNA mixed with 
5X loading dye (Sigma-Aldrich, Poole, UK) were denatured at 90°C for 5 min and then 
separated on a 15% TBE-Urea gel (Invitrogen, Paisley, UK) at 150 V for approximately 1 
h in running buffer (Invitrogen, Paisley, UK) and transferred to an uncharged nylon 
membrane, Hybond-NX (Amersham Bioscience UK Ltd, Buckingham, UK) using a trans-
blot semi-dry system (Bio-Rad Laboratories, Hemel Hempstead, UK) at 10 V for 1 h and 
30 min. After this step, the membrane was EDC-UV cross-linked for 1 h at 60°C in a 
cross-linking solution composed of 122.5 l of 1-methylhymidazole (Sigma-Aldrich, 
Poole, UK), 0.3 g of EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, Sigma-
Aldrich, Poole, UK) and DEPC-treated water up to 12 ml. Pre-hybridization was carried 
out at 55°C for 30 min with hybridization buffer (50% (v/v) de-ionized formamide, 5X 
SSPE, 5X Denhardt’s solution, 0.1% (v/v) SDS, and 2 mg of heat-denatured herring 
sperm DNA). Then 25 pmol of miR-21, miR-145, miR-143 or U6 miRCURY LNA™ 
Detection probe, 5`-digoxigenin (DIG) labeled (Exiqon, Denmark), were added over 
night at the same pre-hybridization temperature. Following hybridization, the 
membrane was washed 30 min at 50°C with the low stringency wash solution 
(Invitrogen, Paisley, UK) followed by a 30 min wash with the high stringency wash 
solution (Invitrogen, Paisley, UK) and a 5 min wash in a washing buffer composed of 
0.1 M maleic acid, 0.15 M NaCl pH 7.5 and 0.3% (v/v) of Tween 20.  After that, the 
membrane was blocked for 30 min in blocking solution (1% (w/v) blocking reagent, 
Roche Diagnostics, West Sussex, UK, in maleic acid) with shaking and incubated 30 min 
with an anti-DIG antibody (Roche Diagnostics, West Sussex, UK) diluted 1:5000 in the 
same blocking solution at RT. Then, the membrane was washed two times for 15 min 
with the wash buffer followed by 5 min incubation with the detection buffer (0.1 M 
Tris-HCl) with shaking. The CDP Star Chemiluminescent Substrate (Sigma-Aldrich, 
Poole, UK) was used to detect the presence of the miRNA of interest on the 
membrane. miRNA quantification was performed with the Scion Image software 
(www.scioncorp.com): band intensities of the miRNA of interest were established and 
normalized to the relative U6 signal. 
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2.12 Prediction of potential miRNAs targets 
In order to identify a list of targets for miR-21, miR-22, miR-30c, miR-451 and miR-322 
(Chapter 3) and miR-145 (Chapter 4), we screened 3'UTRs of mRNAs for the seeds of 
the miRNAs of interest. The seed is the Watson-Crick consecutive pairing between 
mRNAs and the miRNA at positions 2-7 counted from its 5'end. It has recently been 
demonstrated that the seed in 3'UTRs is the primary motif associated with miRNA-
mediated regulation (Selbach et al, 2008). All seed-based prediction algorithms have 
the highest overlap with pulsed SILAC data, and the accuracy was only topped by three 
methods that use evolutionary conservation (PicTar, TargetScanS, Diana).  However, 
the false-positive rate of this target prediction method is still around 40%. In addition, 
multiple non-conserved seeds, in particular those located at optimal distances of less 
than 40 nt (Grimson et al, 2007; Selbach et al, 2008) seem to exert the same effect as 
single conserved seeds (R. Khanin, unpublished observations). Therefore, in this work 
we opted to simply search for seeds for a miRNA of interest in 3'UTRs of rat, mouse or 
human mRNAs (downloaded from USCS Genome Browser http://genome.ucsc.edu/). 
In particular, for miR-21, miR-22 and miR-30c we focused on those targets with 
multiple seeds for one or two miRNAs. Using the same criteria, we also generated a 
preliminary list for miR-451/miR-322 targets in order to compare the proteins 
potentially regulated by the down-regulated and the up-regulated miRNAs of chapter 
3. These lists were then used for identifying those targets potentially both regulated in 
a significant way and involved in the pathology. 
 
2.13 Protein extraction 
Rat and mouse lung tissues were homogenated using the TissueLyser system (Qiagen, 
Hilden, Germany) by rapid agitation in the presence of a 5 mm tungsten carbide bead 
(Qiagen, Hilden, Germany) for 4 cycles of 30 s each at 20 Hz in lysis buffer containing 
150 mM NaCl, 50 mM Tris HCl pH 7.4, 1 mM EDTA, 1% (v/v) triton X 100, 1 mM 
phenylmethylsulfonylfluoride (PMSF), 0.25% (w/v) Na-deoxycholate, and 1X Roche 
Complete Protease Inhibitor Cocktail Tablets (Roche Diagnostics, West Sussex, UK). The 
homogenates were sonicated for 30 s and incubated 20 min on ice. Lysed tissues were 
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centrifuged at 14,000 rpm at 4°C for 15 min and the supernatant containing protein 
was then transferred to a fresh 1.5 ml centrifuge tube and stored at -20°C. 
 
2.13.1 Protein quantification 
The protein content was determined using the bicinchoninic acid (BCA) Protein Assay 
Kit (Pierce, Rockford, IL, USA) according to the manufacturer’s instructions. Briefly, a 
standard curve was generated using the following BSA dilutions: 2000 g/ml, 1500 
g/ml, 1000 g/ml, 750 g/ml, 500 g/ml, 250 g/ml, 125 g/ml and 25 g/ml. In a 
96-well plate, 200 l of working reagent were added to 25 l of each sample or 
standard in duplicate, and the plate was then covered to protect from light and 
incubated at 37°C for 30 min. After that the plate was cooled to RT and the absorbance 
from each well was read at 560 nm using a Wallac Victor2 plate reader (Wallac, Turku, 
Finland). The concentration of each sample was then obtained according to the linear 
equation based on the standard curve generated from the analysis of the standards 
absorbance.  
 
2.13.2 Western Blot Analysis 
In order to determine the expression level of TGFBR1 in control and 7 day 
monocrotaline rat lung (Chapter 3, Section 3.2.9), and of KLF4 and KLF5 in WT and miR-
145 KO mice (Chapter 4, Section 4.2.4), sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) and western blotting were performed. To separate 
TGFBR1, which is 56 KDa, KLF4  and KLF5, which are both 50 KDa, reducing conditions 
and a 12% polyacrylamide gel (containing 40% (v/v) polyacrylamide (30%), 11.25 mM 
Tris pH 8.8, 0.1% (v/v) SDS, 300 μl ammonium persulphate (APS) and 30 μl N,N,N′,N′-
tetramethylethylenediamine (TEMED)) were used. 20 g for TGFBR1 and 50 g for 
KLF4 and KLF5 of total proteins were mixed with an equal volume of 2X reducing 
loading dye (125 mM Tris pH 6.8, 4% (v/v) SDS, 10% (v/v) glycerol, 0.006% (v/v) 
bromophenol blue, 2% (v/v) -mercaptoethanol). Samples were heated at 95°C for 5 
min before the gel was loaded. 40 μl of rainbow ladder (Amersham Bioscience UK Ltd, 
Buckingham, UK) were also added to the gel as a marker of protein size. Samples were 
electrophoresed at 200 V in running buffer (0.025 M Tris-HCl, 0.2 M glycine, 0.001 M 
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SDS) for approximately 3 h. Proteins were transferred onto Hybond-P membrane 
(Amersham Bioscience UK Limited, Buckingham, UK) overnight at 0.9 mAmps at 4°C in 
transfer buffer (0.025 M Tris, 0.2 M glycine, 20% (v/v) methanol, 0.01% (v/v) SDS). The 
membranes were then blocked in TBS-T (150 mM NaCl, 50 mM Tris, 0.1% (v/v) Tween-
20) + 10 % (w/v) fat-free milk powder (blocking buffer) for 1 h with shaking. After 
blocking, the filter was incubated with a rabbit polyclonal anti-TGFBR1, anti-KLF4 or 
anti-KLF5 antibody (Abcam, Cambridge, UK) diluted 1:750 for TGFBR1 detection and 
1:500 for KLF4 and KLF5 detection in blocking buffer for 3 h at RT with shaking. After 
that, the filter was washed twice in TBS-T for 5 min. The membrane was then 
incubated with a horseradish peroxidase (HRP) secondary antibody (dilution 1:1000, 
goat anti-rabbit Abcam, Cambridge, UK) in blocking buffer for 1 h at RT and then 
washed four times in blocking buffer for 15 min at RT followed by two 15 min washes 
with TBS-T. The ECL Western Blotting detection kit (Amersham Bioscience UK Ltd, 
Buckingham, UK) was used to detect the presence of the protein of interest on the 
membrane. Equal sample loading was verified by stripping the blot in stripping buffer 
(100 mM 2-mercaptoethanol, 2% (v/v) SDS, 62.5 mM Tris-HCL pH6.8) at 50°C for 30 
min with occasional agitation, washing it two times, 10 min each, in TBS-T with 
agitation, and then reprobing it with an anti-beta-actin antibody (Abcam, Cambridge, 
UK) for TGFBR1 and an anti-GAPDH antibody (Abcam, Cambridge, UK) for KLF4 and 
KLF5. Protein quantification was performed with the Scion Image software 
(www.scioncorp.com): band intensities of the protein of interest were established and 
normalized to the relative beta-actin or GAPDH signal. 
 
2.14 Histology 
Tissues were excised and immediately fixed in 10% (v/v) neutral-buffered formalin 
(NBF, 10% (v/v) formalin, 33 mMol/L NaH2PO4, 45 mMol/L Na2HPO4) for three days, 
under gentle agitation. Formalin-fixed tissues were then paraffin-embedded. For in situ 
and immunohistochemistry experiments, single tissue sections with 3 and 5 μm 
thickness respectively were mounted onto sialanised glass slides. Slides were baked at 
65°C for 3 h, then at 40°C overnight. For haematoxylin and eosin and elastic Vann 
Gieson staining, 5 μm sections were cut and mounted onto non sialanised slides. Slides 
were then left overnight at RT to dry. 
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2.14.1 Slide silinisation 
Blank glass slides were placed in a solution of 2% 3-amino-propyltriethoxysaline (APES) 
in 100% acetone for 30 s. Slides were then rinsed in acetone for 10 s, followed by two 
5 min rinses in deionised water before being left to air dry overnight at 37°C. 
 
2.14.2 Immunohistochemistry 
Rat, mouse and human lungs were fixed as described in details in the previous section. 
After deparaffinization with two 7 min washes in Histoclear (Thermo Fisher Scientific, 
UK), sections were rehydrated by passing through an alcohol gradient 100%, 95% and 
70% ethanol for 7 min each and washed in deionised water for 5 min. Following 
hydration, antigen retrieval was performed by the incubation of lung sections in boiling 
0.1 M/L Sodium citrate pH 8.0 for 30 min. Sections were then cooled to RT. Slides were 
then immersed in 3% (v/v) H2O2 in PBS for 30 min at RT to block endogenous 
peroxidase activity. After that, they were washed twice in deionised water for 5 min 
and incubated with a blocking solution (10% (v/v) normal goat serum, 5% (w/v) bovine 
serum albumin (BSA) in PBS) for 1 h in a humidified chamber to reduce non-specific 
background staining. Sections were then incubated with rabbit anti-TGFBR1 antibody 
(Abcam, Cambridge, UK), mouse monoclonal antibody against alpha-smooth muscle 
actin (anti-SMA, DaKo, Clone 1A4, High Wycombe, UK), or isotype matched mouse IgG 
nonimmune control (DaKo, High Wycombe, UK), in 5% (w/v) BSA and 10% (v/v) normal 
goat serum in PBS overnight at 4°C in a humidified chamber.  Slides were washed three 
times in PBS for 5 min each. Sections were then incubated with appropriate 
biotinylated secondary antibody (DaKo, High Wycombe, UK) diluted 1:200 in 5% (w/v) 
BSA and 10% (v/v) normal goat serum in PBS, and then with horseradish peroxidase-
labelled ExtravidinTM (Sigma-Aldrich, Poole, UK) diluted 1:200 in 1% (w/v) BSA in PBS. 
Color was developed using 3.3 diaminobenzidine-nickel and the nuclei were 
counterstained with Mayer’s haematoxylin. 
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2.14.3 In situ hybridization for detection of miRNA localization 
For the detection of miR-143 and miR-145 in mouse lung, sections were rehydrated 
with histoclear and graded concentrations of ethanol as previously described. Slides 
were then boiled for 10 min within 10 mM sodium citrate pH 6.0, cool to RT, incubated 
with 10 g/ml proteinase K at 37°C for 15 min and finally fixed in 4% 
paraformaldehyde (PFA) for 10 min at RT in order to allow probe-miRNA interaction.   
Following antigen retrieval, slides were incubated with hybridisation buffer (50% (v/v) 
formamide, 4X SSC, 2.5X Denhadrt’s solution, 2.5 mg/ml salmon DNA, 0.6 mg/ml yeast 
tRNA, 0.025% (v/v) SDS and 0.1% (w/v) blocking reagent) at 60°C for 1 h followed by a 
60°C overnight incubation with 40 nM of miR-143, miR-145 or scramble miRCURY 
LNA™ Detection probe, 5`-DIG labeled (Exiqon, Denmark) in the same buffer. 
Immunodetection was performed blocking the sections in 1% (w/v) blocking reagent in 
PBS and 10% (v/v) FCS for 1 h at RT followed by a 4°C overnight incubation with an 
anti-DIG antibody (Roche Diagnostics, West Sussex, UK) diluted 1:1000. Slides were 
then incubated with 0.1 M Tris pH 9.0 for 5 min. In order to stain miR-143 or miR-145, 
BM purple solution AP substrate (Roche Diagnostics, West Sussex, UK) was added to 
each section and left at RT for 3 days.  
 
2.14.4 Haematoxylin and eosin staining 
After deparaffinization and rehydration of slides (described above in details), slides 
were stained in Harris haemotoxylin for 2 min, washed in running tap water for 5 min 
and then placed in eosin for two min in order to counterstain nuclei. After that, 
sections were washed again for 5 min in running tap water. Slides were dehydrated 
using increasing concentrations of ethanol (75%, 95% and 100%) for 7 min each and 
then cleared by two 7 min washes in histoclear. Sections were then mounted in 
Histomount. Nuclei appeared blue/purple whereas cytoplasm was stained pink. 
 
2.14.5 Elastin Van Gieson Stain 
After deparaffinization and rehydration (described above in details), slides were 
incubated in 0.5% (w/v) KMnO4 for 5 min and then rinsed in running tap water. 
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Sections were then decolorized in 1% (w/v) oxalic acid for 2-3 min and washed again in 
running tap water. After that, slides were rinsed in 95% ethanol and stained in elastic 
stain for 2 h. The stain in excess was removed rinsing again the sections in 95% ethanol 
and washing them in running tap water. The counterstain was obtained placing the 
slides in Van Gieson for 30 s. Sections were then dehydrated as described above and 
mounted in Histomount. Elastic fibers appeared in black, collagen in deep red, while 
cytoplasm, muscles and fibrin in yellow. 
 
2.15 Statistical analysis  
Statistical analysis was performed using Prism 4.0 Graph Pad software. All results are 
expressed as mean ± standard error of the mean (SEM). Data were analyzed using a 
two-way ANOVA followed by Bonferroni’s post-hoc test, one-way ANOVA followed by 
Bonferroni’s post-hoc test or unpaired t-test as appropriate, and described in Figure 
legends. 
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3. Dynamic Changes in Lung MicroRNA Profiles During 
the Development of Pulmonary Hypertension Due to 
Chronic Hypoxia and Monocrotaline 
3.1 Introduction 
Pulmonary arterial hypertension (PAH) is a complex disorder characterized by the 
obstructive remodeling of pulmonary arteries (PAs) leading to a progressive elevation 
in pulmonary arterial pressure and subsequent right heart failure and death (Rich, 
Dantzker et al. 1987). The elevation in pulmonary arterial pressure is due to 
adventitial, medial and intimal thickening that results from fibroblast, smooth muscle 
and endothelial cells proliferation (Chapter 1, Section 1.2.2).  
 
Familial PAH is associated with diverse heterozygous mutations in the gene encoding 
bone morphogenic protein-receptor 2 (BMPR2), involved in cartilage and bone growth 
and repair (Lane, Machado et al. 2000), and has been shown to be related to 
mutations in the activin-receptor kinase-like 1 (ALK1) gene (Harrison, Flanagan et al. 
2003) in some severe forms of the pathology. Moreover, reductions in the expression 
level of BMPR2 and BMP type 1A receptor (BMPR1A) and a dysfunctional Smad1/5 
signaling have been observed in PASMCs isolated from patients with idiopathic PAH, 
supporting the theory of a critical involvement of the TGF-beta super-family in the 
pathobiology of PAH (Chapter 1, Section 1.2.4.1). 
 
In order to study in detail the characteristics and the development of this pathology, 
different animal models can be used (although each of them presents similarities with 
the human disease but also limitations, Chapter 1, Section 1.2.3) (Stenmark, Meyrick et 
al. 2009). In particular, exposure to hypoxia in mice and rats or injection with the toxin 
monocrotaline all  lead to the development of pulmonary arterial changes correlated 
with PAH, including remodeling and elevation in pulmonary arterial pressure (Wilson, 
Segall et al. 1992; Brusselmans, Compernolle et al. 2003; Stenmark, Fagan et al. 2006; 
Stenmark, Meyrick et al. 2009). The signaling and gene expression downstream of BMP 
and TGF-beta receptors in the two rat models have been recently characterized in 
detail (Morty, Nejman et al. 2007; Long, Crosby et al. 2009). In particular, the analysis 
of wild type (WT) animals exposed to chronic hypoxia or treated with a single injection 
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of monocrotaline for 2, 7 or 21 days showed a reduced BMP and enhanced TGF-beta 
signaling. Moreover, hypoxic and monocrotaline-treated animals showed a down-
regulation of BMPR2, suggesting the involvement of this pathway in the pathology 
(Long, Crosby et al. 2009) (Chapter 1, Section 1.2.4.1).  
 
miRNAs are small non coding transcripts of 16–29 nt that regulate gene expression 
post-transcriptionally by targeting mRNAs (Ambros 2004; Jackson and Standart 2007). 
Approximately 30% of all the human genes are suggested to be regulated by miRNAs 
(Lewis, Burge et al. 2005) and, importantly, a single miRNA is able to target potentially 
hundreds of proteins involved in different pathways within a given cell (Boyd 2008) 
(Chapter 1, Section 1.3). miRNA involvement in many critical cellular process including 
apoptosis, differentiation and proliferation suggests their potential implication in the 
development and progression of several pathologies (Croce 2009; Condorelli, Latronico 
et al. 2010; Varol, Konac et al. 2010; Qin and Zhang 2011; Small and Olson 2011). In 
cancer, many recent studies have reported distinct miRNA signatures in cancer cells 
(Ambs, Prueitt et al. 2008; Lujambio, Calin et al. 2008; Yang, Kong et al. 2008) (Chapter 
1, Section 1.3.3.12.1). In the heart and vasculature, miRNAs are associated with 
remodeling and development of hypertrophy and failure (Rao, Toyama et al. 2009; 
Topkara and Mann 2011; van Almen, Verhesen et al. 2011) (Chapter 1, Section 
1.3.3.12.2). 
 
Here, in order to evaluate the involvement of miRNAs in the development of PAH in 
the monocrotaline and the hypoxic rat models, the lung tissue dissected from the 
same rats analyzed in the Long et al. study (Long, Crosby et al. 2009) was assessed by 
miRNA profiling. In vitro experiments confirmed the dysregulation of a specific group 
of miRNAs after treatment with chronic hypoxia. The analysis of mice exposed to 
hypoxia and human samples obtained from affected patients confirmed miRNA 
dysregulation in pathological samples from both animal models and PAH patients. 
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3.2 Results 
3.2.1 Global miRNA Profiling of the Lungs of Hypoxia- and 
Monocrotaline-Exposed Rats 
Total RNA (including miRNAs) was isolated from the whole lung of control rats and rats 
subjected to hypoxia or monocrotaline and harvested at 2, 7 and 21 days post insult. 
Hemodynamic studies conducted by Prof. Nicholas W. Morrell and his group in 
Cambridge (Long, Crosby et al. 2009) had already demonstrated the development of 
PAH in these animals, as described in the introduction of this chapter. In order to verify 
the involvement of specific miRNAs in the hypoxic- and the monocrotaline induced 
PAH, the expression level of 350 miRNAs in the lung was investigated using a two-
channel microarray experiment. This allowed us to identify their expression signature 
during the first stages of pathogenesis in both hypoxic- and monocrotaline-induced 
PAH. In particular, the microarray was designed to allow comparison between time 
points and also comparison of miRNAs regulated between each injury (Chapter 2, 
Figure 2.7).  
 
We confirmed the prominent expression of miR-195 and miR-200c in rat lung of 
control animals (Table 3-1), consistent with the previous identification of these 
miRNAs as the only lung specific miRNAs (Wang, Weng et al. 2007). Poorly expressed 
miRNAs were excluded from the analysis, even if they were significantly altered when 
statistically assessed, since the obtained results were considered not reliable enough 
when the obtained signal was too low. Moreover, a low absolute expression value for a 
nucleotidic sequence in a microarray often results in its undetectable expression in a 
TaqMan® Real-Time PCR assay, making the validation of the microarray result very 
difficult. For these reasons and in consideration of the relatively high number of 
miRNAs identified as dysregulated in the samples and characterized by more elevated 
expression levels, potentially interesting miRNAs, detected with absolute values lower 
than 500 AU (arbitrary unit), were excluded from the next steps of the project as 
recommended by LC Sciences (Houston, Texas, USA). This group of miRNAs included 
miR-204, down-regulated in PAH-affected animal models and human patients, and 
very recently implicated in the development of PAH. This miRNA acts through a direct 
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modulation of SRC homology region 2 domain-containing phosphatase-2 (SHP2), an 
activator of the proto-oncogene tyrosine- protein kinase Src (Courboulin, Paulin et al. 
2011). We analyzed miRNA regulation considering both time-fold variation and 
statistically significant differences between either the hypoxic or monocrotaline groups 
compared to the control group. This analysis revealed the dysregulation of ~8% of the 
assessed miRNAs. Within this group, ~80% of miRNAs were down-regulated and ~20% 
showed an up-regulation. Expression levels of miR-322, miR-451, miR-21, miR-22, 
miR30c, let-7f and let-7a were the most significantly altered (Table 3-2) and were, 
therefore, selected for further analysis.  
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3,062
2,4192,8643,2723,4943,0253,0262,512
1,9752,9313,2512,8222,9253,0503,077
3,7302,3233,8793,8043,1273,2582,968
1,6883,0243,6934,3773,3682,5043,819
2,2702,9992,5313,8502,3743,3452,962
2,4343,0443,0052,6163,3292,9743,035rno-miR-195
M day 21M day 7M day 2H day 21H day 7H day 2CTR
1,295
1,1951,2231,3841,0961,5649471,629
1,4239261,4736901,058911975
1,0961,3271,0181,2038154671,249
1,0511,0091,1161,4391,3821,2601,691
1,2851,3359428942,8949021,200
1,1181,5161,1471,2521,6701,1931,028rno-miR-200c
M day 21M day 7M day 2H day 21H day 7H day 2CTR
173
352137241333181147
123
7011091134363140
 
Table 3-1  Absolute levels of miR-195 and miR-200c during the progression of PAH. All the absolute intensities are shown, with the mean values in black bold 
and SEM in red bold at the end of each column (n = 5 or 6/group). To assess the statistical significance of intergroup differences, rank products were used but no 
significant differences were identified.
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1.27E-032.44E-021.65E-02
2,8813671,2762,2431,3401,2621,686
9.44E-037.02E-05
2412108328349311,1091,066
1.53E-031.39E-025.67E-031.40E-022.50E-04
4791,3351,0081,5399961,528467rno-miR-451
M day 21M day 7M day 2H day 21H day 7H day 2CTR
p-value
rno-miR-322
rno-miR-21
5.48E-034.55E-024.50E-02
6661,107570680638720333
3.46E-02
2.61E-02 2.20E-02
2,9183,3004,1202,6733,1814,2854,085
rno-miR-22
rno-miR-30c
1.00E-04
6,3592,5607,4016,0358,2577,0948,290rno-let-7f
1.01E-05
8,4144,0388,9268,37010,9838,5739,747rno-let-7a
Mean 
SEM 77 181 174 415 207 201 84
p-value
Mean 
SEM 133 154 216 242 138 37 288
p-value
Mean 
SEM 24163266471504265302
p-value
Mean 
SEM 85611595619913592
p-value
Mean 
SEM 124179209341438408346
p-value
Mean 
SEM 8872171253145710261271355
p-value
Mean 
SEM 5062621262150812771347534
 
 
Table 3-2  Expression levels of selected miRNAs in the two-channel microarray study. Mean raw values and SEM for miRNAs up- and down-regulated in PAH 
rats are shown. To assess the statistical significance of intergroup differences, rank products were used. Significant P-values are shown. 
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3.2.2  Validation of miRNA Dysregulation 
In order to validate the microarray analysis, the expression level of miR-322, miR-451, 
miR-21, miR-22, miR30c, let-7f and let-7a, selected as described above, plus a control 
miRNA that was not altered in the lungs of treated male animals compared to controls 
(miR-145) were analyzed by TaqMan® Real-Time PCR in the total RNA used in the 
microarray study. As expected, and in agreement with the profiling data, mir-145 
levels were not altered under either condition (Figure 3-1). In contrast, miR-451, miR-
322, let-7f, miR-21, miR-22 and miR-30c were significantly altered following induction 
of PAH (Figure 3-1). In particular, miR-451 expression showed a substantial up-
regulation in the lung of male rats exposed to hypoxia, and reached a maximum in 7 
days monocrotaline rats. MiR-322 was significantly up-regulated just 7 days after the 
injury for both the models before returning back to control levels by day 21. miR-22 
presented opposite trends in the two models resulting in maximal down-regulation 
after 21 days in hypoxic conditions and 2 days after a monocrotaline injection. MiR-21 
and miR-30c showed a significant down-regulation in the monocrotaline and in the 
hypoxic model alone, respectively (Figure 3-1). Let-7f expression was down-regulated 
in both the models at early time points in the hypoxic model (2 and 7 days after 
induction of hypoxia) and later time points in the monocrotaline model (21 days after 
the injection), while let-7a showed a significant down-regulation only 21 days after 
monocrotaline injection (Figure 3-1). 
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Figure 3-1  Validation of miRNA dysregulation. TaqMan
®
 Real-Time PCR analysis of hypoxic 
and monocrotaline-injected rats after 2, 7, and 21 days of exposure. Total RNA was extracted 
from hypoxic (light grey bars) or monocrotaline-injected (black bars) male rats at the age of 6 
weeks and analyzed in triplicate. Results were normalized to U87 values and expressed as 
relative fold change, with an arbitrary value of 1 assigned to the control (CTR) group. Raw Ct 
values for the target miRNAs are indicated above each column. Data are expressed as mean ± 
SEM and analysed by two way ANOVA followed by Bonferroni’s post-hoc test. *P<0.05, 
**P<0.01, ***P<0.001 compared to control rats. N = 5/group. 
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3.2.3 Analysis of the miR-17–miR-92a Cluster in the 
Monocrotaline and the Hypoxic Rat Models 
The expression level of the miR-17–miR-92a cluster (miR-17, miR-19b, miR-20a, and 
miR-92) was quantified in hypoxic and monocrotaline treated rats, in consideration of 
its recently described involvement in the regulation of BMPR2 (Brock, Trenkmann et al. 
2009). In particular, a screening based on a computational algorithm (TargetScan, 
www.targetscan.org) identified several miRNAs encoded by the cluster as potential 
regulators of the gene, and the ectopic over-expression of miR-17/92 resulted in a 
strong reduction of the BMPR2 protein (Brock, Trenkmann et al. 2009). For this reason, 
taking account of the high number of false positive and false negative results of this 
type of experiment and of the higher precision of the real-time PCR technique (Chapter 
2, Section 2.10), a TaqMan® Real-Time PCR validation of the miRNAs included in this 
cluster was performed despite the microarray analysis showed no significant changes 
between control animals and hypoxic/monocrotaline-injected mice (Table 3-3). MiR-
18a and miR-19a were not assessed because they showed very low expression on the 
array (lower than 100 AU) (Houston, Texas, USA). TaqMan® Real-Time PCR validations 
showed a up-regulation of miR-17, miR-19b, miR-20a, and miR-92 in the samples 
(Figure 3-2), consistent with the Brock et al. study, even if it is important to notice that 
miR-17 and miR-20a, described as direct regulators of BMPR2 in the paper, resulted 
up-regulated only in the monocrotaline model (Figure 3-2). 
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CTR H day 2 H day 7 H day 21 M day 2 M day 7 M day 21
rno-miR-17 180 234 161 130 217 249 225
184 164 338 201 260 246 272
197 169 227 155 160 194 278
214 323 352 184 158 314 175
169 308 202 232 172 242 218
250
rno-miR-18a 29 21 28 16 8 28 23
23 13 23 28 20 37 41
16 26 30 25 25 21 30
19 35 32 40 30 30 21
22 31 25 24 18 16 40
28
rno-miR-19a 12 11 15 7 9 27 12
12 33 17 12 11 16 17
10 8 9 23 16 16 12
9 39 14 21 17 10 14
13 13 14 11 15 8 23
16
rno-miR-20a 268 272 241 216 239 284 264
236 175 235 219 272 233 353
214 257 263 300 238 267 281
276 271 277 210 220 247 212
216 302 316 108 225 252 248
259
rno-miR-19b 94 109 156 118 138 203 44
83 14 90 199 194 80 113
80 132 73 161 170 218 67
39 479 51 102 166 79 141
56 251 181 121 109 158 76
100
rno-miR-92a 418 487 519 500 490 438 509
573 371 1,294 401 391 390 268
922 524 708 380 454 415 392
531 337 599 372 413 316 451
553 507 453 249 670 444 553
405
240 256 180 193 249 234
199 34 38 18 20 19 19
12
25 27 27 20 26 31
23 4 2 4 4 4 4
2
21 14 15 14 15 15
12 6 1 3 1 3 2
1
255 330 211 239 257 272
245 21 15 31 9 9 23
11
223 110 140 155 148 88
75 68 25 18 15 30 17
10
445 715 380 484 401 435
567 38 151 40 50 23 50
77
 
 
Table 3-3  Absolute levels of miR-17/92 cluster in the two-channel microarray study. All 
the absolute intensities are shown, will the mean values in black bold and SEM in red bold at 
the end of each column (n = 5 or 6/group). To assess the statistical significance of intergroup 
differences, rank products were used but no significant differences were identified. 
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Figure 3-2  TaqMan
®
 Real-Time PCR analysis of the miR-17/92 cluster in hypoxic and 
monocrotaline-treated rats. Total RNA was extracted from the lung of hypoxic (light grey bars) 
or monocrotaline-injected (black bars) six weeks old male rats. Time points and samples were 
tested in triplicate. Results were normalized to U87 values and expressed as relative fold 
change, with an arbitrary value of 1 assigned to the control group. Raw Ct values for the target 
miRNAs are indicated above each column. Data are expressed as mean ± SEM and analysed 
by two way ANOVA followed by Bonferroni’s post-hoc test. *P<0.05, ***P<0.001 compared to 
CTR rats. N = 5/group. 
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3.2.4 In Vitro Validation of miRNAs Expression Level 
As next step, the expression level of the dysregulated miRNA group, identified in the 
microarray study and validated by TaqMan® Real-Time PCR, was assessed in in vitro 
models of hypoxic injury to determine whether the hypoxic insult in vitro paralleled 
the effect of miRNA profiles in vivo. For this purpose, total RNA was extracted from 
normoxic and 24 h hypoxic rat PAFs and rat PASMCs and analyzed by TaqMan® Real-
Time PCR for miRNA levels (Figure 3-3A and B). The inability to isolate PAECs from rat 
PAs did not allow us to analyze this cell type under the same experimental conditions. 
From the analysis of the data, miR-451 was slightly up-regulated, although this was not 
significant, in hypoxic PASMCs but undetectable in PAFs (Figure 3-3A and B). MiR-322, 
the only other up-regulated miRNA of our group of interest, showed a significant 
dysregulation in PASMCs, suggesting a potential involvement of both these miRNAs in 
the cellular changes resulting from a hypoxic insult in this pulmonary artery cell type 
(Figure 3-3A). On the other hand, the expression pattern for the down-regulated 
miRNAs of the group was quite similar to the in vivo analysis. In PAFs, miR-22, let-7f, 
and miR-30c were significantly down-regulated, whereas let-7a was not down-
regulated and miR-21 showed a similar expression level in both normoxic and hypoxic 
cells (Figure 3-3B). It is important to remember that miR-21 showed a significant down-
regulation in vivo only in the monocrotaline model, while no changes in miR-21 
expression could be detected after exposure to hypoxia in male rats. In PASMCs, both 
miR-22 and miR-30c showed a significant down-regulation, whereas miR-21, let-7a and 
let-7f did not show altered expression after hypoxic treatment (Figure 3-3A). Thus in 
general the exposure of rat PAFs and PASMCs to hypoxia in vitro correlated with the 
changes in miRNAs observed in vivo. 
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3.2.5 Analysis of Genes Critical for miRNA Biogenesis in Rat 
Models of PAH 
mRNA levels for genes critical to miRNA biogenesis (i.e. Dicer, Drosha, DGCR8, and 
Exp5, Chapter 1, Sections 1.3.3.4-1.3.3.6) were assessed by TaqMan® Real-Time PCR 
analysis in the same experimental samples used for miRNA analysis. In particular, 
GAPDH was chosen as housekeeping gene for the normalization of the genes of 
interest after the evaluation of its stability in hypoxic conditions. In fact, different 
studies reported in the past the capacity of hypoxia to induce up-regulation of GAPDH 
in different systems (Graven, Troxler et al. 1994; Zhong and Simons 1999). However, 
more recent studies proved that this dysregulation cannot be observed in several 
types of malignancies including human hepatocellular carcinoma, mouse hepatoma, 
human colon cancer and glioblastoma (Said, Hagemann et al. 2007; Said, Polat et al. 
2009). In our experiments GAPDH didn’t show any significant change under hypoxic 
conditions (Figure 3-4) and was therefore selected as housekeeping gene. The stability 
of the selected housekeeping gene has been evaluated in every TaqMan® Real-Time 
PCR performed in this and in the next result chapters (data not shown). Interestingly, 
in vivo exposure to hypoxia induced a marked and sustained decrease in lung mRNA 
level of Dicer (Figure 3-5A). Monocrotaline injury showed a significant effect on Dicer 
expression only 21 days post-injection (Figure 3-5A). We also quantified Dicer, Drosha, 
DGCR8, and Exp5 mRNA expression in 24 h hypoxic rat PAFs. In vitro, Dicer expression 
was significantly down-regulated by hypoxia (Figure 3-5B). Considering the important 
role played by Dicer in the maturation of a miRNA from its pre-form to its mature and 
active form (Murchison and Hannon 2004; Tijsterman and Plasterk 2004; Macrae, Zhou 
et al. 2006) (Chapter 1, Section 1.3.3.6), the significant down-regulation of this factor is 
consistent with the high number of down-regulated miRNAs identified in this study. It 
is also interesting to notice the differential response of Dicer to hypoxia and 
monocrotaline injection, consistent with the differences in pathogenesis observed 
between these two models (Meyrick and Perkett 1989; Wilson, Segall et al. 1989; 
Hessel, Steendijk et al. 2006; Firth, Mandel et al. 2010) (Chapter 1, Section 1.2.3). 
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Figure 3-3  miRNA expression is regulated by hypoxia in vitro. TaqMan
®
 Real-Time PCR 
analysis of hypoxic rat PASMCs (A) and PAFs (B) showing the expression level of miR-21, miR-
22, miR-30c, let-7f, let-7a, miR-322 and miR-451 after 24 h of hypoxic conditions. These 
experiments were performed with total RNA extracted from both the control (CTR, dark grey 
bar) and the hypoxic cells (light grey bars) and tested in triplicate. Results were normalized to 
U87 values and expressed as relative fold change, with an arbitrary value of 1 assigned to the 
CTR group. Raw Ct values for the target miRNAs are indicated above each column. Data are 
expressed as mean ± SEM and analysed by unpaired t-test. *P<0.05, **P<0.01, ***P<0.001 
compared to CTR rats. N = 4/group. 
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Figure 3-4  GAPDH row Ct values in hypoxic and monocrotaline-treated rats in 
comparison with untreated rats (CTR). GAPDH expression level was evaluated in hypoxic 
and monocrotaline-treated rats and compared with untreated animals in order to assess 
weather hypoxia can induce its expression as previously reported. Raw data are indicated for 
each sample analyzed in triplicate by TaqMan
®
 Real-Time PCR, with a lane representing the 
mean value for each group. 
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Figure 3-5  In vivo and in vitro expression level of Dicer, Exp5, Drosha, and DGCR8 in 
hypoxic and monocrotaline-treated rats. (A) TaqMan
®
 Real-Time PCR analysis of hypoxic 
and monocrotaline-injected male rats after 2, 7, and 21 days of exposure. Total RNA was 
extracted from hypoxic (light gray bars) or monocrotaline-injected (black bars) rats at the age of 
6 weeks (N = 4/group), and tested in triplicate. Results were normalized to GAPDH values and 
expressed as relative fold change, with an arbitrary value of 1 assigned to the control (CTR) 
group. (B) TaqMan
®
 Real-Time PCR analysis of hypoxic rat PAFs showing the expression level 
of Dicer, Exp5, DGCR8, and Drosha after 24 h of exposure. This experiment was performed 
with total RNA extracted from CTR and hypoxic cells (n = 4/group). Results were normalized to 
GAPDH values. Raw Ct values for the target genes are indicated above each column. Data are 
expressed as mean ± SEM and analyzed by: (A) two way ANOVA followed by Bonferroni’s post-
hoc test. *P<0.05, **P<0.01 compared to CTR rats, or (B) unpaired t-test. ***P<0.001 compared 
to CTR rats. 
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3.2.6 Assessment of let-7d Expression Level in Hypoxic and 
Monocrotaline-Treated Rats and in Hypoxic Rat Cells 
Considering that Dicer, despite its role in miRNA biogenesis (Murchison and Hannon 
2004; Tijsterman and Plasterk 2004; Macrae, Zhou et al. 2006), can itself be the target 
of specific miRNAs, we decided to assess the expression of let-7d, identified as a 
miRNA regulator of Dicer expression (Tokumaru, Suzuki et al. 2008) (Chapter 1, Section 
1.3.3.6), in the two analyzed rat models of PAH and in 24 h hypoxic rat PAFs. TaqMan® 
Real-Time PCR analysis of the samples revealed a significant up-regulation of this 
miRNA in hypoxic conditions both in vivo and in vitro (Figure 3-6A and B). 
Monocrotaline-injection led to an altered let-7d expression but only after 2 days of 
treatment, with normal levels detected 7 and 21 days after the injury (Figure 3-6A and 
B).  
 
3.2.7 Effects of TGF-beta and BMP4 Stimulations on miRNA 
Expression in Rat PASMCs 
The significant down-regulation occurring in Dicer expression after both a hypoxic and 
a monocrotaline injury (even if with different timing) correlates well with the down-
regulation observed in specific miRNAs, but cannot explain the substantial up-
regulation characteristic of miR-451 in both the models. A recent study demonstrates  
the existence of functional binding sites for SMAD3 (GTCTGGCCT) and SMAD4 
(GTCTAGTCT) in the upstream region of this miRNA, suggesting that miR-451 may be 
activated by the SMAD pathway (Gal, Pandi et al. 2008). Long et al. study (Long, Crosby 
et al. 2009) showed an increased expression of phospho-SMAD3 in the monocrotaline 
model, where miR-451 levels reached an up-regulation of 20 times (Figure 3-1). To 
further evaluate miR-451 regulation, we exposed rat PASMCs to TGF-beta and BMP4. 
First of all we assessed the mRNA expression level of plasminogen activator inhibitor-1 
(PAI1) and inhibitor of DNA binding-1 (ID1), main targets of the TGF-beta and the BMP 
signaling respectively (Miyazono and Miyazawa 2002; ten Dijke, Korchynskyi et al. 
2003; Otsuka, Agah et al. 2006; Otsuka, Stempien-Otero et al. 2007; Diebold, Kraicun 
et al. 2008; Samarakoon and Higgins 2008), in order to verify the efficiency of the 
stimulation (Figure 3-7A and B). Next, we quantified by TaqMan® Real-Time PCR miR-
136 
451 expression in the samples. Both agonists induced miR-451 levels significantly after 
5 h of stimulation (Figure 3-8A). Notably, values returned to the unstimulated level by 
24 h (Figure 3-8A). For a better understanding of the role of the TGF-beta super-family 
in the dysregulation of our miRNAs of interest, we also quantified the expression level 
of miR-21, miR-22, miR-30c, let-7f, let-7a and miR-322 after stimulation. Both TGF-beta 
and BMP4 stimulations induced the same profile of dysregulation we observed in 
hypoxic and monocrotaline-treated male rats. In fact, all the miRNAs down-regulated 
in vivo (miR-21, miR-22, miR-30c, let-7f and let-7a) were down-regulated after the TGF-
beta stimulation, however miRNAs were up-regulated after the treatment with BMP4, 
in agreement with the reduced BMP signaling observed in Long et al. in vivo analysis 
(Long, Crosby et al. 2009) (Figure 3-8B and C). On the contrary miR-322, up-regulated 
in hypoxic and monocrotaline treated rats, showed no up-regulation after the TGF-
beta stimulation, and a remarkably reduced expression after the BMP4 treatment, this 
again in correlation with our in vivo observations (Figure 3-8B and C). 
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Figure 3-6  Assessment of let-7d expression in vivo and in vitro. TaqMan
®
 Real-Time PCR 
analysis of total RNA extracted from the lung of hypoxic/monocrotaline-treated male rats (A, N = 
5/group) and rat 24 h hypoxic PAFs (B, N = 6/group) showing let-7d expression. Samples were 
tested in triplicate. Results were normalized to U87 values and expressed as relative fold 
change, with an arbitrary value of 1 assigned to the CTR and normoxic group respectively. Raw 
Ct values for the target miRNAs are indicated above each column. For statistical analysis: (A) 
Data are expressed as mean ± SEM and analyzed by two way ANOVA followed by Bonferroni’s 
post-hoc test. *P<0.05, ***P<0.001 compared to CTR rats; (B) Data were analyzed using an 
unpaired t-test. *P<0.05 compared to normoxic samples. 
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Figure 3-7  Analysis of PAI1 (A) and ID1 (B) expression in TGF-beta and BMP4 stimulated 
rat PASMCs. TaqMan
®
 Real-Time PCR of total RNA extracted from passage 4 PASMCs 
stimulated with the two agonists for 5 and 24 h. Samples were tested in triplicate. Results were 
normalized to GAPDH values and expressed as relative fold change, with an arbitrary value of 1 
assigned to the CTR group (unstimulated cells). Raw Ct values for the target genes are 
indicated above each column. Data are expressed as mean ± SEM and analyzed by one way 
ANOVA followed by Bonferroni’s post-hoc test. ***P<0.001 compared to CTR rats. N = 3/group. 
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Figure 3-8  TGF-beta/BMP4 stimulation can induce the significant dysregulation of miR-
451, miR-322, miR-21, miR-22, miR-30c, let-7a and let-7f in PASMCs. Passage 4 rat 
PASMCs were stimulated and total RNA extracted after 5 and 24 h of stimulation from both 
nontreated and stimulated cells. Each sample was analyzed in triplicate by TaqMan
®
 Real-Time 
PCR for testing miR-451 (A) and miR-21, miR-22, miR-30c, let-7f, let-7a and miR-322 (B and C) 
expression level. Results were normalized to U87 values and expressed as relative fold change, 
with an arbitrary value of 1 assigned to the CTR group. For miR-451 expression, Raw Ct values 
for the target miRNA are indicated above each column. For the other miRNAs in graphs B and 
C, raw Ct values are the following: graph B: miR-21= 19.9, 20.6 (5 and 24h respectively); miR-
22= 26.3, 26.9; miR-30c= 23.9, 23.5; let-7f= 26.4, 26.9; let-7a= 24.7, 24.2; miR-322= 29.8, 30.5. 
Graph C: miR-21= 19.9, 20.5 (5 and 24h respectively); miR-22= 25.6, 26.4; miR-30c= 24, 24.5; 
let-7f= 26.6, 26; let-7a= 24.7, 25; miR-322= 32.4, 30.2. Data are expressed as mean ± SEM and 
analyzed by one way ANOVA followed by Bonferroni’s post-hoc test. *P<0.05, **P<0.01, 
***P<0.001 compared to CTR rats. N = 3/group. 
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3.2.8 Prediction of Potential miRNA Targets 
In order to identify a list of targets for our miRNAs of interest, the 3' UTRs of mRNAs 
was screened for the 6-mer seeds of the miRNAs of interest as described in details in 
Chapter 2 (Section 2.12). Following specific criteria (e.g. high number of seed sites 
located at short distance to each other, good site accessibility) we generated a list of 
targets for the down-regulated miRNAs miR-21, miR-22 and miR-30c, the three 
miRNAs with the same profile of dysregulation (i.e. reduction) sharing the higher 
number of targets (Table 3-4). We also generated a preliminary list for miR-451 and 
miR-322 targets (Table 3-5). However, this list was characterized by a very high 
number of targets, but all with a low number of seeds (no more than 1 or 2), making it 
difficult to identify the best predicted targets to shortlist. For this reason, we decided 
to focus our attention on miR-21, miR-22 and miR-30c targets for the validation. 
Nevertheless it is important to notice that certain targets could be identified in both 
the lists (marked in lilac in Table 3-5), thus adding additional complexity. In particular, 
4 targets were included in the group of those targets selected for further analysis for 
the down-regulated miRNAs because matching all the criteria (KCNJ6, NFAT5, YWHAZ 
and TACC1, see below for more details), including multiple number of seeds for more 
than one miRNA of the group and short distance between the seed sequences. 
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adenosine deaminase, RNA-specific, B1 miR-22 ADARB1
transforming growth factor, beta receptor 1  miR-21 and miR-22TGFBR1
transforming growth factor, beta receptor associated protein 1 miR-21 and miR-22TGFBRAP1 
tyrosine 3-monooxygenase/tryptophan  5-monooxygenase activation protein, zeta polypeptidemiR-30cYWHAZ
trinucleotide repeat containing 6a miR-30cTNRC6A
recombining binding protein suppressor of hairless (Drosophila)miR-21RBPSUH
transforming, acidic coiled-coil containing protein 1 miR-21 and miR-30cTACC1
nuclear factor of activated T-cells 5 miR-22 and miR-30cNFAT5
protein phosphatase 2, regulatory subunit B(B56), epsilon isoformmiR-21 and miR-22PPP2R5E
potassium inwardly-rectifying channel, subfamily J, member 6 miR-22 and miR-30cKCNJ6
Target functionTarget ofTarget name
 
 
Table 3-4  Predicted targets for the three down-regulated miRNAs miR-21, miR-22 and miR-30c.
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Target name Also target of Target function
ANKFY1 ankyrin repeat and FYVE domain containing 1
ANKS1A ankyrin repeat and sterile alpha motif domain containing 1A
BCL9 B-cell CLL/lymphoma 9
CYBRD1 cytochrome b reductase 1
DHX37 DEAH (Asp-Glu-Ala-His) box polypeptide 37
DISP2 dispatched homolog 2 (Drosophila)
ELK4 ELK4, ETS-domain protein (SRF accessory protein 1)
FBXO21 F-box protein 21
GLS glutaminase
GRM2 glutamate receptor, metabotropic 2
KCNJ6 Mir-22 and miR-30c potassium inwardly-rectifying channel, subfamily J, member 6
KCNK5 potassium channel, subfamily K, member 5
KIAA0174 KIAA0174
MGAT4B mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme B
MOBKL1B MOB1, Mps One Binder kinase activator-like 1B (yeast)
NFAT5 Mir-22 and miR-30c nuclear factor of activated T-cells 5, tonicity-responsive
PATL1 protein associated with topoisomerase II homolog 1 (yeast)
PDZD8 PDZ domain containing 8
PLXNC1 plexin C1
PMEPA1 prostate transmembrane protein, androgen induced 1
PPM1L protein phosphatase 1 (formerly 2C)-like
RAB22A Mir-22 and miR-30c RAB22A, member RAS oncogene family
RCAN2 regulator of calcineurin 2
RGD1561661 similar to Ferritin light chain (Ferritin L subunit)
SAR1A SAR1 homolog A (S. cerevisiae)
SLC11A2 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2
SLC12A2 solute carrier family 12 (sodium/potassium/chloride transporters), member 2
SLC25A22 solute carrier family 25 (mitochondrial carrier: glutamate), member 22
SNX11 sorting nexin 11
SNX27 sorting nexin family member 27
TACC1 Mir-21 and miR-30c transforming, acidic coiled-coil containing protein 1
TGFA transforming growth factor, alpha
TPCN1 two pore segment channel 1
UBE2K Mir-21 and miR-22 ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast)
UBE4A ubiquitination factor E4A (UFD2 homolog, yeast)
UNC5C unc-5 homolog C (C. elegans)
ZBTB39 zinc finger and BTB domain containing 39
ZNF592 zinc finger protein 592  
 
Table 3-5  Predicted targets for the two up-regulated miRNAs miR-451 and miR-322. 
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3.2.9 Analysis of miR-21, miR-22, and miR-30c Targets in 
Hypoxic and Monocrotaline-Treated Lungs 
Based on the targets identified in (Table 3-4), we performed TaqMan® Real-Time PCR 
validations on the same sample set used for miRNA profiling (Figure 3-9). In general, a 
number of the predicted genes, but not all, were regulated as expected. For example, 
KCNJ6 (G protein-activated inward rectifier potassium channel 2, inward-rectifier type 
potassium channel) mRNA levels were significantly enhanced after both hypoxia- and 
monocrotaline induced injuries (Figure 3-9). MiR-21 was only down-regulated in 
monocrotaline-induced injury. Likewise, TACC1 (transforming acidic coiled-coil-
containing protein 1, its function is not precisely known but it is suspected to play a 
role in carcinogenesis and to regulate mRNA processing) (Conte, Charafe-Jauffret et al. 
2002), which has predicted targets for miR-21 and miR-30c, was only up-regulated in 
the monocrotaline-treated lungs (Figure 3-9). Serine/threonine-protein phosphatase 
2A regulatory subunit epsilon isoform (PPP2R5E) was up-regulated only after 
monocrotaline-induced injury, again perhaps indicative of miR-21 regulation. Similarly, 
transforming growth factor beta receptor 1 (TGFBR1, serine/threonine protein kinase), 
transforming growth factor, beta receptor associated protein 1 (TGFBRAP1, it 
associates with inactive heteromeric TGF-beta receptor complexes and is released 
upon activation of signalling) and nuclear factor of activated T-cells 5 (NFAT5, 
transcription factor that regulates the expression of genes involved in the osmotic 
stress) (Aramburu, Drews-Elger et al. 2006), targets of miR-22/miR-21 and miR-22/miR-
30c respectively, showed significant up-regulation selectively in the monocrotaline 
model (Figure 3-9). The up-regulation of YWHAZ (14-3-3 protein zeta/delta, able to 
interact with TPH1, the rate-limiting enzyme in the biosynthesis of serotonin) 
(Ichimura, Uchiyama et al. 1995; Winge, McKinney et al. 2008) and TNRC6A 
(trinucleotide repeat-containing gene 6A protein) characteristic only of the 
monocrotaline-treated rats could be indicative of a significant role of miR-30c in gene 
regulation after injury (Figure 3-9). Although the dysregulation of several targets 
correlates well with miRNA dysregulation, some of them seem to be regulated in a 
different way. RBPSUH (recombining binding protein suppressor of hairless, it is the 
DNA-binding component of the transcription complex regulated by Notch signaling) for 
example, target of miR-21, is down-regulated in the hypoxic model. As mentioned in 
145 
the previous section, 4 of the validated targets (KCNJ6, NFAT5, YWHAZ and TACC1) can 
also be identified in the list of miR-322 and miR-451 potentially regulated proteins, 
suggesting that the action of these miRNAs, up-regulated in both the models, could 
“balance” the action of miR-21, miR-22 and miR-30c and explain, at least partially, why 
the expression of these targets does not completely match with the dysregulation of 
the down-regulated miRNAs. Considering the relevant role of the TGF-beta super-
family in pulmonary vascular SMC signaling in PAH (Richter, Yeager et al. 2004; 
Dewachter, Adnot et al. 2009; Morrell, Adnot et al. 2009; Morrell 2010; Morrell 2010) 
(Chapter 1, Section 1.2.4.1), we decided to select TGFBR1 for further analysis. To 
validate the up-regulation of the target at the protein level, we quantified by western 
blot analysis the expression of TGFBR1 in monocrotaline day 7-treated and untreated 
male rats. The signal obtained from 4 samples for each group showed a significant up-
regulation of this protein in monocrotaline-treated rats (Figure 3-10A and B). 
Moreover, on day 7, we also localized TGFBR1 protein in paraffin sections from control 
and monocrotaline-treated rat lungs with immunohistochemistry assays. Again, this 
experiment showed TGFBR1 up-regulation in the monocrotaline model 7 days after 
initiation of treatment (Figure 3-10C).  
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Figure 3-9  Assessment of miRNA target mRNA levels in rat lung following hypoxic and 
monocrotaline injuries. Total RNA was extracted from lung samples of hypoxic (light grey 
bars) and monocrotaline-treated (black bars) male rats. cDNA was prepared and mRNA levels 
were tested in triplicate by TaqMan
®
 Real-Time PCR and plotted as fold change versus control 
samples. Results were normalized to GAPDH values. The miRNAs that possess predicted seed 
sequences for each target are indicated. Data are expressed as mean ± SEM and analyzed by 
two way ANOVA followed by Bonferroni’s post-hoc test. *P<0.05, **P<0.01, ***P<0.001 
compared to CTR rats. N = 5/group. 
 
 
 
 
 
 
3.2.10 Analysis of TGFBR1 Expression in Stimulated and 
Hypoxic- Treated Rat Cells 
Next, we assessed the expression level of this target in the rat PASMCs stimulated with 
TGF-beta and BMP4 previously analyzed for miRNA expression. TGFBR1 was 
significantly up-regulated after TGF-beta stimulation and significantly down-regulated 
after BMP4 stimulation, an expression profile consistent with profile of miR-22 and 
miR-21, its potential regulators (i.e. down-regulated by TGF-beta and up-regulated by 
BMP4 stimulation) (Figure 3-11A). However, TGFBR1 was not dysregulated in 24 h 
hypoxic PAFs (Figure 3-11B). 
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Figure 3-10  Assessment of TGFBR1 protein expression level in total rat lung protein 
extracts and its localization in rat lung paraffin sections. (A) TGFBR1 expression level was 
quantified by western blot analysis in proteins extracted from lung samples of monocrotaline-
treated male rats on day 7 (MD7) and control (CTR) rats. Four samples were tested for each 
group, and the intensity of the western blot bands was measured using specific software (Scion 
Image software). The resulting quantification bars are represented in the graph (B), with the 
monocrotaline day 7 group represented by the light gray bar. Data are expressed as mean ± 
SEM and analyzed by unpaired t-test. *P<0.05 compared to CTR rats.TGFBR1 was localized in 
lung paraffin sections using an immunohistochemistry assay. (C) TGFBR1 staining in CTR rat 
lungs. (D) TGFBR1 staining in lungs after monocrotaline exposure for 7 days (MD7). (E) Lung 
stained with a nonimmune isotype-IgG CTR antibody. Scale bar = 100 m. 
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Figure 3-11  Tgfbr1 expression in stimulated and hypoxic rat cells. The expression level of 
Tgfbr1 was assessed by TaqMan
®
 Real-Time PCR in rat PASMCs stimulated with TGF-beta 
and BMP4 for 5 and 24 h (A), and in rat PAFs exposed to hypoxia for 24 h. Samples were 
tested in triplicate. Results were normalized to GAPDH values. Raw Ct values for the target 
gene are indicated above each column. For statistical analysis: (A) Data are expressed as 
mean ± SEM and analyzed by one way ANOVA followed by Bonferroni’s post-hoc test. *P<0.05, 
***P<0.001 compared to CTR rats. N = 3/group. (B) An unpaired t-test was conducted, but no 
significant dysregulation was identified. N = 6/group. 
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3.2.11 miRNA Expression in Hypoxic Mice 
The identified dysregulation of specific miRNAs in two different rat models of PAH and 
the similar changes observed in targets potentially involved in the development of PAH 
suggest a potentially important role for miRNAs in the development of this pathology. 
To prove the conserved character of this dysregulation, we next analyzed the 
expression level of our miRNAs of interest in WT male mice exposed to hypoxia for 14 
days. Total RNA (including miRNA) was extracted from the whole lung of 10 weeks old 
normoxic and hypoxic mice and TaqMan® Real-Time PCR experiments were 
performed. The analysis of these data confirmed the dysregulation identified in the rat 
models. In fact, we observed a significant down-regulation of miR-22, miR-30c and let-
7a, while miR-21 and let-7f did not show any dysregulation (Figure 3-12). The only 
differentially regulated miRNA was miR-451. Although miR-451 was substantially up-
regulated in both the rats PAH models, we couldn’t observe any dysregulation in 14 
days hypoxic male mice (Figure 3-12). MiR-322, a rat specific miRNA, was not analyzed 
in these samples. 
 
3.2.12 miRNA Dysregulation in Human Hypoxic Cells 
To verify whether the dysregulation of specific miRNAs could be identified in human 
samples, human fetal PAFs and human PAECs were exposed to chronic hypoxia for 24 
h and then assessed by TaqMan® Real-Time PCR for the expression of the miRNA 
group identified in the rat study. The analysis of human PAFs showed a significant 
dysregulation of all the five miRNAs down-regulated in rats (even miR-21 in this case 
resulted significantly dysregulated after the hypoxic treatment), while in hypoxic 
PAECs only miR-30c resulted modestly down-regulated (Figure 3-13A and B). MiR-451, 
undetectable in PAFs, showed no significant changes in PAECs (Figure 3-13A and B). 
MiR-322, (rat specific) was not analyzed in human samples. 
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Figure 3-12  miRNa expression in hypoxic mice. TaqMan
®
 Real-Time PCR analysis of 
normoxic and 14 days hypoxic WT male mice. Total RNA was extracted from the lung of 
normoxic (dark grey bars) or hypoxic (light grey bars) 10 weeks old male mice. 6 mice/group 
were analyzed. Every sample was tested in triplicate. Results were normalized to U6 values and 
expressed as relative fold change, with an arbitrary value of 1 assigned to the control group. 
Raw Ct values for the target miRNAs are indicated above each column. For statistical analysis, 
an unpaired t-test was conducted. **P<0.01, ***P<0.001 compared to normoxic mice. 
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Figure 3-13  miRNA expression is regulated by hypoxia in vitro in human cells. (A and B) 
TaqMan
®
 Real-Time PCR analysis of hypoxic fetal human PAECs (A) and human PAFs (B) 
showing the expression level of miR-21, miR-22, miR-30c and let-7f after 24 h of stimulation. 
These experiments were performed with total RNA extracted from both the control and the 
hypoxic cells. Samples were tested in triplicate. Results were normalized to Rnu-48 values and 
expressed as relative fold change, with an arbitrary value of 1 assigned to the control group. 
Raw Ct values for the target miRNAs are indicated above each column. For statistical analysis, 
an unpaired t-test was conducted. *P<0.05, ***P<0.001 compared to CTR. N = 6/group. 
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3.2.13 Expression Level of miR-22 and miR-451 in Idiopathic 
Pulmonary Arterial Hypertension Patients  
Considering the high level of dysregulation observed in male rats both in vivo and in 
vitro for miR-451 and miR-22, the effect of both TGF-beta and BMP4 on their 
expression level, and the correlation between miR-22 dysregulation and TGFBR1 
expression previously shown in the rat study, we next analyzed total RNA extracted 
from paraffin-embedded lungs of patients with IPAH and HPAH and unaffected 
controls in order to assess the dysregulation of these two miRNAs in the human 
pathology. A significant down-regulation of miR-22 was observed, while miR-451 was 
not altered (Figure 3-14A and B).  
 
 
3.2.14 Expression Level of miR-22 and miR-451 in PASMCs 
Obtained From Patients with a Mutation in the BMPR2 
Gene 
We next analysed RNA extracted from PASMCs isolated from patients with HPAH and 
in particular with an identified mutation in the BMPR2 gene. The analysis of these 
samples in comparison with cells obtained from unaffected controls completely 
concurred with previous results, showing a significant down-regulation of miR-22 and 
no alteration of miR-451 expression level (Figure 3-15A and B). Taken together, the 
analyzed human samples suggest a conserved dysregulation of miR-22 across species, 
and a selective dysregulation of miR-451 in rat models of this pathology. 
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Figure 3-14  miR-22 and miR-451 expression level in PAH patients. TaqMan
®
 Real-Time 
PCR analysis of miR-22 (A) and miR-451 (B) expression level in paraffin-embedded human 
lungs of patients with idiopathic and heritable PAH and controls (CTRs). Samples were 
analyzed in triplicate, normalized to Rnu-48 values and expressed as relative fold change, with 
an arbitrary value of 1 assigned to the CTR group. Raw Ct values for the target miRNAs are 
indicated above each column. Data are expressed as mean ± SEM and analyzed by two way 
ANOVA followed by Bonferroni’s post-hoc test. ***P<0.001 compared to CTR.  
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Figure 3-15  Analysis of miR-451 and miR-22 in PASMCs isolated from PAH patients 
known to harbour a mutation in BMPR2. TaqMan
®
 Real-Time PCR analysis of miR-451 (A) 
and miR-22 (B) expression in human PASMCs. Total RNA was extracted from PASMCs of 
HPAH patients with a mutation in the BMPR2 gene. Passage 4 primary cells were used. 
Samples were tested in triplicate. Results were normalized to Rnu-48 and expressed as relative 
fold change, with an arbitrary value of 1 assigned to the control group. Raw Ct values for the 
target miRNAs are indicated above each column. For statistical analysis, an unpaired t-test was 
conducted. **P<0.01 compared to CTR. N = 5/group. 
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3.3 Discussion 
Target gene dysregulation mediated by miRNA in the progression of several diseases is 
becoming increasingly relevant (Erson and Petty 2008; Zhang 2008; Small and Olson 
2011). Here, we profiled miRNA signatures in the WT lung and compared them 
longitudinally with rats exposed to either chronic hypoxia or monocrotaline injuries at 
2, 7, and 21 days. We show that a small subset of miRNAs is significantly changed (i.e. 
miR-21, miR-22, miR-30c, let-7f, let-7a, miR-322, and miR-451). These miRNA profiles 
were validated by TaqMan® Real-Time PCR to confirm the microarray result, and their 
dysregulation was also mimicked in in vitro models involving exposure of rat PAFs, rat 
PASMCs, human PAFs, and human PAECs to hypoxia, or exposure of rat PASMCs to 
TGF-beta or BMPs. While some differences were observed across species or conditions 
of analysis (i.e. miR-451 dysregulation was observed in rat, but not in mouse and 
human samples), we observed some clear profile of miRNA in all the experiments 
performed. A clear example of this is represented by miR-22 expression, substantially 
decreased in rat and mouse PAH models but also in human pathological samples and in 
cells exposed to TGF-beta and BMP4. 
 
By using bioinformatics analysis, we also predicted the target sequences for the 
dysregulated miRNAs identified. A number of predicted targets were regulated in a 
manner consistent with the miRNA dysregulation pattern. Moreover, a preliminary 
analysis of targets of the down-regulated miRNAs (i.e., miR-21, miR-22, and miR-30c) 
and targets of the up-regulated miRNAs (i.e., miR-451 and miR-322) showed the 
presence of several proteins in common, an indication of the potential complex 
regulation of such targets in vivo. This could explain why the expression level of several 
targets did not always correlate perfectly with the modulation of a single miRNA. More 
experiments will be necessary to correlate directly miRNA dysregulation and targets 
expression level. In particular, a luciferase assay (performed by cloning the seed 
sequence for a miRNA of interest at the end of the gene coding for the luciferase gene) 
will allow us to show if the dysregulation of a specific miRNA is able to modify directly 
in vitro the expression of luciferase. 
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Hypoxia and monocrotaline-injection induced consistent changes in miR-451, miR-322 
and to some extent miR-30c and let-7f. let-7a, miR-21 and miR-22 were regulated 
differently between the two models. This suggests that hypoxia- and monocrotaline-
induced PAH share some common elements relating to miRNA regulation but also 
differential regulation. Such differential regulation is not entirely unexpected as the 
result of the diverse pathobiology induced by hypoxia and monocrotaline (Wilson, 
Segall et al. 1989; Hessel, Steendijk et al. 2006; Stenmark, Fagan et al. 2006; Stenmark, 
Meyrick et al. 2009; Firth, Mandel et al. 2010). Monocrotaline challenge mainly targets 
the pulmonary vascular endothelium and triggers an inflammatory process, especially 
monocyte recruitment, both of which play an important role in the course of human 
PAH (Ono and Voelkel 1991; Voelkel and Tuder 1995; Voelkel and Tuder 2000). The 
course of the development of PAH is also different in each model, as is well-known and 
confirmed in the present study. Hypoxia stimulates changes in medial, adventitial, and 
endothelial layers of the pulmonary artery; however, hypoxia leads to less 
inflammation than monocrotaline. The underlying pathobiology in both models leads 
to differences at protein level. For example, by using a proteomic approach, it has 
recently been shown that in the hypoxic model, proteins of the nitric oxide, carbon 
monoxide, and vascular endothelial growth factor pathways are significantly increased 
(Laudi, Steudel et al. 2007). In the monocrotaline model, proteins involved in serotonin 
synthesis, the enhanced unfolded protein response, and intracellular chloride channels 
are significantly elevated (Laudi, Steudel et al. 2007). Dysregulation of BMP and TGF-
beta signaling occurs in both the hypoxic and monocrotaline models of PAH, but not 
exactly in the same way. In fact, the monocrotaline rat model appears to be more 
clearly regulated by TGF-beta than the hypoxic rat model (Long, Crosby et al. 2009). 
Specifically, a reduced lung expression of BMPR2 is observed in both the models, while 
a reduced BMP signaling (via the downstream Smad1/5 pathway) and an increased 
TGF-beta signaling (with increased Smad3 phosphorylation and increased expression of 
TGF-beta target genes) have pronounced effects only in the monocrotaline model 
(Long, Crosby et al. 2009). 
 
 Interestingly, responsive elements for SMAD3 (GTCTGGCCT) and SMAD4 (GTCTAGTCT) 
have recently been identified in the promoter region of miR-451 (Gal, Pandi et al. 
2008). Thus, activation of TGF-beta signaling could be responsible for the increased 
expression of miR-451 observed in our study in rats pathological samples and in 
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particular in the monocrotaline model, where the TGF-beta signaling increase is more 
evident, as previously discussed (Long, Crosby et al. 2009). In fact, the stimulation of 
rat PASMCs with TGF-beta resulted in a significant and early up-regulation of this 
miRNA (after 5 h), while levels comparable with the untreated cells were observed 
after 24 h.  Despite the increase number of studies on miRNA role in different systems, 
the function of this miRNA is still quite poorly understood. In particular, miR-451 has 
been proven to play a central role in erythropoiesis regulation through at least two 
different direct targets, YWHAZ, an intracellular regulator of cytokine signaling, and 
GATA-1, a critical hematopoietic transcription factor (Dore, Amigo et al. 2008; Patrick, 
Zhang et al. 2010). Moreover, mice deficient for miR-451 display a reduction in 
hematrocrit, an erythroid differentiation defect, and ineffective erythropoiesis in 
response to oxidative stress (Patrick, Zhang et al. 2010). Concerning the action of this 
miRNA on YWHAZ, it is interesting to notice that here we include the same protein in 
the list of targets of miR-30c, down-regulated in the in vivo rat study and in our in vitro 
stimulations. MiR-451 has also been recently studied for its potential involvement in 
the pathobiology of glioblastoma through its capacity of regulating the LKB1/AMPK 
pathway in response to altered energy availability (Godlewski, Bronisz et al. 2010; 
Godlewski, Nowicki et al. 2010), but its role in other pathological models has never 
been evaluated. Here we show like a substantial increase (up to 20 times) of this 
miRNA can be observed in both the analyzed rat models and in particular in the 
monocrotaline model after 7 days from the treatment. However, no significant 
changes can be identified in 14 days hypoxic male mice or in human samples obtained 
from patients with idiopathic or familial PAH, suggesting a specific role for this miRNA 
in the rat pathology. It is also interesting to notice that this miRNA is so significantly 
up-regulated in both the rat models despite the down-regulation of the expression 
level of DICER, essential for the maturation of a pre-miRNA in its final form, observed 
in vivo in the hypoxic model. Recent studies showed that the maturation of this 
specific miRNA is DICER-independent but involves a biogenesis pathway that uses 
AGO2 catalytic activity. MiR-451 levels are therefore refractory to DICER loss of 
function or dysregulation (Cheloufi, Dos Santos et al. 2010; Cifuentes, Xue et al. 2010; 
Yang and Lai 2010; Yang, Maurin et al. 2010).  More experiments will be necessary in 
order to define the role of miR-451 in the hypoxic and monocrotaline-induced 
pathology in rats and confirm if this highly significant dysregulation can be considered 
specific of this species. In particular, in situ analysis will be important to localize in lung 
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sections miR-451 expression, while the analysis of KO animals will allow observing the 
effect of miR-451 depletion on PAH development. 
 
As previously mentioned, the stimulation of PASMCs resulted as expected in a 
significant up-regulation of miR-451, but also the other miRNAs identified in the in vivo 
rat study responded to the stimulation in a compatible way with our previous 
observations. In fact, the TGF-beta stimulation was able to induce the down-regulation 
of miR-21, miR-22, miR-30c, let-7f and let-7a in our experiments, mimicking our in vivo 
observations. On the contrary, rat cells stimulated with BMP4 showed the significant 
up-regulation of the same miRNAs in a time-dependent manner. These results suggest 
the involvement of the TGF-beta super-family in the regulation of this group of 
miRNAs.  
 
If some of the miRNAs analyzed in this study showed a significant dysregulation only in 
specific models or in particular conditions (e.g. miR-451 or miR-21), others were 
consistently altered in all the analyzed samples, suggesting a conserved role and 
regulation in rat, mouse and human PAH. MiR-22 for example displayed a 
characteristic down-regulation in the models evaluated. The involvement and 
importance of this miRNA in disease pathogenesis is becoming increasing well 
documented. For example, recent studies show evidences of a mutual regulation 
between miR-22 and the tumor suppressor PTEN, a lipid phosphatase involved in the 
regulation of the cell cycle. PTEN was identified as a direct target of this miRNA (Bar 
and Dikstein 2010). In particular, in cardiomyocytes miR-22 up-regulation, and 
consequent PTEN down-regulation, significantly increases cell size and markedly 
influences the expression of hypotrophic markers, suggesting a role for miR-22 in 
cardiomyocytes hypertrophy (Xu, Song et al. 2011). Moreover, through direct 
repression of both the c-Myc binding protein and the obligate c-Myc binding factor 
Max, miR-22 was recently shown to be able to regulate the activity of this oncogenic 
transcription factor, with effects on cell proliferation (Xiong, Du et al. 2010). 
Here, we show that miR-22 is significantly down-regulated after exposure to hypoxia 
or monocrotaline injection, even if at different time points as previously mentioned. 
Monocrotaline can rapidly (after 2 days) induce a reduction in miR-22 expression, but 
no changes are observed at 7 and 21 days, while miR-22 dysregulation in hypoxic rats 
become significant after 7 days of exposition and reach its maximum level after 21 
161 
days. Thus, if a direct effect of this miRNA on c-Myc family members could be proved 
also in our models, a relevant role for miR-22 in the vascular cell proliferation observed 
in PAH could be hypothesized, at least partially through its involvement in the 
regulation of this pathway. Future experiments will clarify this aspect of miR-22 
activity. In this study we decided to focus our attention on another miR-22 target, 
TGFBR1 (also known as ALK-5), a member of the TGF-beta super-family already known 
for its dysregulation in IPAH patients and for being involved in the progression of the 
pathology induced by monocrotaline (Morty, Nejman et al. 2007; Zaiman, Podowski et 
al. 2008; Long, Crosby et al. 2009; Thomas, Docx et al. 2009) (Chapter 1, Section 
1.2.4.1). Several studies have demonstrated that vascular cells and lung tissues 
isolated from patients with IPAH exhibit elevated TGFBR1 signaling, with induction of 
cell proliferation. This favors muscularization and subsequent remodeling of the small 
pulmonary arterioles (Richter, Yeager et al. 2004; Castanares, Redondo-Horcajo et al. 
2007; Thomas, Docx et al. 2009). Moreover, the use of TGFBR1 inhibitors (able to 
decrease the TGF-beta/Smad3 activity) can prevent the development of 
monocrotaline-induced PAH in rats, suggesting that strategies to inhibit TGFBR1 
signaling may have therapeutic benefit on the progression of this pathology (Zaiman, 
Podowski et al. 2008; Long, Crosby et al. 2009; Thomas, Docx et al. 2009). However, 
the mechanism implicated in TGFBR1 dysregulation has not been fully elucidated, 
suggesting the involvement of other elements. The negative regulation of miR-22 on 
this target could therefore have a precise role in the regulation of the TGFBR1-
mediated TGF-beta pathway. Here we show that TGF-beta stimulation of PASMCs is 
able to induce the down-regulation of miR-22, resulting in the up-regulation of 
TGFBR1, while BMP4 stimulation has an opposite effect on both the miRNA and the 
target. PAFs exposed to hypoxia for 24 h were significantly down-regulated for miR-22 
expression, but did not show any dysregulation of this target. A 3’ UTR luciferase 
reporter assay would need to be performed to verify the direct effect of miR-22 
dysregulation on TGFBR1 expression in vitro. Also, for this and other miRNAs, it will be 
critical to define the potential effect of miRNA modulation in disease prevention. In 
the future, it will be important to generate reliable methods to deliver miRNA 
therapeutics to the lung efficiently and selectively. This might require new strategies to 
modulate the tropism of a gene delivery system (e.g. viruses) and to generate selective 
agents and cells.  
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Here, we have focused on those miRNAs showing the largest changes after the onset 
of injury. However, recent studies have shown that even subtle changes in miRNA 
expression can lead to large changes in phenotype (Baek, Villén et al. 2008; Selbach, 
Schwanhäusser et al. 2008). Thus, the large changes we have observed in miRNAs in 
this study are likely to strongly affect the cell biology and pathobiology associated with 
the development of PAH.  
 
In summary we have reported the global miRNA profiles of rat lungs after exposure to 
hypoxia and monocrotaline injury, and proved that the dysregulation of specific 
miRNAs is conserved in mouse models and PAH-affected patients. This highlights the 
potential importance of miRNA in disease progression and possible targets (either the 
miRNAs themselves or their mRNA targets) for future therapeutic intervention. 
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4. MiR-143 and miRNA-145 Expression in Pulmonary 
Arterial Hypertension: Evidence from Mouse Models 
and Patient Samples 
4.1 Introduction 
Several recent studies have assessed the direct role of miRNAs in vascular 
inflammation and in the development of vascular pathologies (Ji, Cheng et al. 2007; 
Urbich, Kuehbacher et al. 2008; Zhang 2009; Kartha and Subramanian 2010). In this 
chapter we evaluated the role of miR-143 and miR-145, already known for being 
abundantly expressed in the vessel wall (Cheng, Liu et al. 2009), in the development of 
PAH.  
 
MiR-143 and miR-145 are transcribed in cluster as a long pri-miRNA coded on human 
chromosome 5 (≈ 1.7 Kb) and on mouse chromosome 18 (≈ 1.4 Kb) (Figure 4-1). The 
analysis of the promoter of this transcript revealed the presence of a cardiovascular 
specific enhancer, highly conserved from human to opossum, located between -3328 
and -3056 bp upstream of the gene. This region contains a serum response factor (SRF) 
binding site, known as CArG box (Xin, Small et al. 2009; Rangrez, Massy et al. 2011). 
Cordes et al. and Boettger et al. recently analyzed the expression profile of miR-143 
and miR-145 during mouse development. In agreement with the presence of a 
cardiovascular specific enhancer, both the groups observed, in the mouse embryo, a 
specific expression of the cluster in the heart, vascular and visceral SMCs. However, 
during late fetal and postnatal development, miR-143/145 expression was decreased 
in the heart but still high in vascular and visceral SMCs, suggesting a role for these 
miRNAs in the regulation of this cells type in the adult. In fact, in the postnatal 
organism, VSMCs are highly plastic and are able to modulate their phenotype in 
response to specific environmental stimuli, switching from a differentiated (known as 
contractile) to a dedifferentiated (called synthetic) state, required for cell proliferation 
and migration (Sobue, Hayashi et al. 1999). VSMCs acquire a synthetic state during 
angiogenesis, but is also in a variety of proliferative cardiovascular diseases such as 
atherosclerosis and hypertension, in which it leads to vascular occlusion (Owens, 
Kumar et al. 2004). The role of miR-143 and miR-145 was mainly assessed through the 
pharmacological or genetic ablation of a single miRNA or the whole cluster in vitro and 
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in vivo, although the results observed were sometimes controversial. In vitro, 
antagomiR-mediated inhibition of miR-145 expression blocked the ability of myocardin 
(myocd), a potent SRF co-activator, to convert fibroblasts into VSMCs, with only a little 
effect of miR-143 knock-down. Moreover, the up-regulation of miR-145 (but not miR-
143) in neural crest stem cells was sufficient to induce the conversion of ≈75% of cells 
into VSMCs (Cordes, Sheehy et al. 2009). In vivo, abnormalities in the vessel wall of the 
aorta and other arteries, noticeably thinner than those of WT animals, were observed 
in miR-145 and miR-143/145 double KO mice. These changes were ascribed to a 
reduction in the cell size of VSMCs isolated from mutated mice, due to a decreased 
number of actin-based stress fiber, characteristic of fully differentiated SMCs, 
identified in the cytoplasm of these cells. This result suggests a central role of miR-145 
in the modulation of cytoskeletal assembly (Xin, Small et al. 2009). However, while 
Boettger et al. reported a severe reduction in the number of differentiated VSMCs in 
KO mice, Xin et al. could not observe any difference in the expression level of markers 
of smooth muscle cell differentiation between WT and miR-145 deleted cells, 
concluding that miR-145, and to a lesser extent miR-143, are required for the 
production of normal actin stress fibers but not for SMC differentiation per se 
(Boettger, Beetz et al. 2009; Xin, Small et al. 2009). Also, Xin et al. reported, in miR-145 
KO mice subjected to carotid artery ligation, the nearly abolished formation of 
neointima,  abundantly observed in WT animals (Xin, Small et al. 2009). On the 
contrary, Cheng et al. study showed that adenoviral-mediated over-expression of miR-
145 inhibits neointima formation in the carotid of rats in response to balloon injury 
(Cheng, Liu et al. 2009). Although embryonic KO and post-natal knock-down/over-
expression of a sequence of interest can definitely have different consequences on cell 
differentiation/proliferation, these controversial results complicate the identification 
of a specific role for miR-143/miR-145 cluster in VSMCs plasticity. However, despite 
the communal regulation of these two miRNAs, it is important to notice that selective 
modulation of miR-145 (but not miR-143) is sufficient for the observation of 
abnormalities in the vasculature and pathological phenotypes, suggesting a 
predominant role for this miRNA in SMC regulation.  
 
Several targets for miR-143 and miR-145 have already been validated in vitro and in 
vivo, and they are mostly involved in VSMCs differentiation (Figure 4-2). In particular, it 
is interesting to notice that despite the lack of sequence homology between miR-143 
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and miR-145, these miRNAs are often predicted to target the same genes (Xin, Small et 
al. 2009). The validated targets include kruppel-like factor 4 and 5 (KLF4 and 5), which 
are positive regulators of smooth muscle proliferation (Figure 4-2) (Cordes, Sheehy et 
al. 2009), but are also able to up-regulate SM alpha-actin in specific cell types (Adam, 
Regan et al. 2000); angiotensin converting enzyme (ACE), which converts circulating 
angiotensin I into its active form angiotensin II, a major regulator of the contractile 
phenotype of VSMCs (Boettger, Beetz et al. 2009); E twenty-six (ETS)-like transcription 
factor 1 (Elk-1), a competitor of myocd (Figure 4-2) (Cordes, Sheehy et al. 2009). 
Myocd itself is regulated by miR-143 and miR-145, and its induction is observed in 
response to their up-regulation (Figure 4-2) (Cordes, Sheehy et al. 2009).   
 
Very recently, the mechanism behind miR-143/145 regulation has been partially 
clarified through the observation that agonists within the TGF-beta super-family are 
able to regulate miR-143/145 cluster via a Smad-dependent pathway. In fact, both 
TGF-beta and BMP4, already known for their capacity to promote the contractile 
phenotype in VSMCs, can activate transcription of miR-143/145 cluster through the 
CArG box present in its promoter, although this induction is mediated by distinct SRF 
coactivators, Myocd and Myocd-related transcription factor A (MRTF-A) respectively  
(Davis-Dusenbery, Chan et al. 2011; Long and Miano 2011) (Figure 4-3). 
 
In the previous chapter we did not observe any dyregulation of miR-145 expression in 
the lung of male hypoxic or monocrotaline-injected rats when assessed by TaqMan® 
Real-Time PCR (Caruso, MacLean et al. 2010) but we did not assess the expression of 
this miRNA in mouse or human models, nor did we further investigate miR-145 more 
in detail in either rat model. MiR-143 expression was never evaluated in that study 
(Caruso, MacLean et al. 2010). 
 
Here, in consideration of the reported importance of miR-145/143 in smooth muscle 
cell biology (Cheng, Liu et al. 2009; Cordes, Sheehy et al. 2009; Zhang 2009; Rangrez, 
Massy et al. 2011), coupled with the importance of this cellular compartment in the 
etiology of PAH, we examined the expression and function of miR-145 and miR-143 in 
the development of PAH. In this study, we employed mouse models and human 
samples derived from patients with either IPAH or HPAH as well as control human 
lung. We show that both these miRNAs are significantly up-regulated in female mice in 
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response to chronic hypoxia and that genetic ablation of miR-145 alone is protective 
against the development of PAH in this animal model. Further, both miR-143 and miR-
145 are up-regulated in mice heterozygous for a truncating BMPR2 mutation. In 
human tissues we show elevation of pre- and mature forms of miR-145 and miR-143 in 
lung and isolated PASMCs obtained from PAH patients with a mutation in the BMPR2 
gene compared to controls. In consideration of the protective role of miR-145 
observed in hypoxic mice, we propose a critical role for this miRNA in the development 
of PAH and identify miR-145 as a potential new target for therapeutic intervention. 
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Figure 4-1 Biogenesis of miR-143 and miR-145. miR-143 and miR-145 are co-transcribed as 
a single pri-miRNA. This long precursor is then processed to obtain 2 mature miRNAs as 
described in Chapter 1 (Sections 1.3.3.3-1.3.3.6). Reproduced from (Rangrez, Massy et al. 
2011). 
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Figure 4-2  miR-143 and miR-145 regulation of smooth muscle cell proliferation and 
differentiation. miR-143 and miR-145 can repress multiple factors that normally promote the 
less differentiated, more proliferative smooth muscle phenotype (lavender). These factors 
include Klf4 and Elk-1, which both interact with SRF and can also repress Myocd. miR-145 can 
also induce Myocd activity to promote the more differentiated smooth muscle phenotype 
(peach). Dashed lines indicate indirect effects. Reproduced from (Cordes, Sheehy et al. 2009). 
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Figure 4-3  Schematic representation of BMP and TGF-beta induction of pri-miR-143/145. 
TGF-beta and BMP4 can activate transcription of miR-143/145 cluster through the CArG box 
present in its promoter. In particular, TGF-beta induction if Smad4 dependent and it is mediated 
by Myocd, whereas BMP4 can stimulate miR-143/145 transcription through MRTF-A. Mature 
miR-145 can therefore repress KLF4 expression allowing enhanced binding of Myocd/ or 
MRTF-A/SRF complexes to the CArG boxes of contractile genes and increase contractile gene 
expression. Adapted from (Davis-Dusenbery, Chan et al. 2011). 
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4.2 Results 
4.2.1 Expression and Regulation of miR-143 and miR-145 in WT 
Hypoxic Mice 
In chapter 3 we reported that miR-145 is not altered in the RNA extracted from whole 
lung samples of male rats treated with hypoxia or monocrotaline and compared to 
controls in a longitudinal study (Caruso, MacLean et al. 2010). However, due to the 
importance of miR-145 and miR-143  in vascular smooth muscle cell biology (Cheng, 
Liu et al. 2009; Zhang 2009), and their reported dysregulation in acute vascular 
remodeling and neointima formation (Boettger, Beetz et al. 2009; Cheng, Liu et al. 
2009; Elia, Quintavalle et al. 2009), we decided to assess the expression of both these 
miRNAs in female and male WT mice exposed to chronic hypoxia, in order to establish 
their role in a different animal model of PAH and also identify a potential gender 
difference.  In fact both idiopathic and familial forms of PAH predominantly affect 
women through an unknown mechanism (the ratio of females to males in the human 
pathology is 1.9:1, Chapter 1, Section 1.2.1) and it has been recently observed that 
female gender predisposes SERT+ mice to the development of PAH with a critical role 
played by 17beta oestradiol in this process (White, Dempsie et al. 2011; White, 
Loughlin et al. 2011). Our analysis showed a significant up-regulation of miR-143 and 
miR-145 in response to 14 days of chronic hypoxia in female, but not male mice (Figure 
4-4A and B). For the purpose of subsequent experiments, we therefore focused on 
female mice. Next, the expression level of miR-143 and miR-145 was assessed in the 
RNA extracted from the spleen, the kidney and the brain of female WT mice exposed 
to chronic hypoxia for 14 days, in order to understand if the dysregulation of these 
miRNAs in this animal model of PAH is lung specific or characteristic of all the organs. 
These experiments showed no alteration of miR-145 in these tissues, while miR-143 
was slightly up-regulated only in the kidney of the treated mice but stable in spleen 
and brain (Figure 4-5). Thus, miR-145 and miR-143 are expressed in smooth muscle 
cells in the lung of mice and their up-regulation after 14 days of chronic hypoxia is 
mainly lung specific. 
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Figure 4-4 miR-143 (A) and miR-145 (B) expression in female and male WT mice exposed 
to chronic hypoxic for 14 days. Total RNA was extracted from the lung of normoxic (dark grey 
bars) and hypoxic (light grey bars) female and male mice at the age of 10 weeks. Samples were 
tested in triplicate. Results were normalized to U6 values and expressed as relative fold 
change, with an arbitrary value of 1 assigned to the normoxic female group. Raw Ct values for 
the target miRNAs are indicated above each column. Data are expressed as mean ± SEM and 
analysed by one way ANOVA followed by Bonferroni’s post-hoc test. *P<0.05, ***P<0.001 
compared to normoxic mice. N = 3/group. 
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Figure 4-5  miR-143 and miR-145 expression in the brain, kidney and spleen of hypoxic 
WT female mice. Total RNA was extracted from each organ and tested in triplicate by TaqMan
®
 
Real-Time PCR. Raw Ct values for the target miRNAs are indicated above each column. Data 
were analyzed using an unpaired t-test. *P<0.05 compared to normoxic mice. N = 4/group. 
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4.2.2 Characterization of miR-143 and miR-145 Expression in 
miR-145-/- Mice and Quantification of the Development of 
PAH in This Model in Comparison to Controls 
Based on the up-regulation of miR-145 in hypoxic mice, we next evaluated the effect of 
miR-145 ablation on the development of PAH and assessed the expression level of 
miR-143 in this animal model. 8 weeks old miR-145-/- mice and WT control age-
matched mice were exposed to chronic hypoxia or maintained in normoxic conditions 
for 14 days and analyzed for the development of PAH using a series of in vivo 
measurements. Homozygous miR-145 KO mice were viable at birth and did not display 
any obvious disorder in normal conditions, indicating that this miRNA is not crucial for 
development. The absence of miR-145 expression in the KO animals used in the study 
was confirmed by TaqMan® Real-Time PCR and in situ hybridization (Figure 4-6A and 
B). In agreement with our previous experiment, WT control mice exposed to hypoxia 
showed a significant increase in miR-145 expression in comparison with normoxic 
animals (Figure 4-6A). Since miR-145 is transcribed in its pri- form clustered with miR-
143, we also analyzed WT and KO animals for the expression of this miRNA under both 
normoxic and hypoxic conditions to ensure that miR-143 levels were not substantially 
altered in the lung following genetic ablation of miR-145 and in response to hypoxic 
insult. TaqMan® Real-Time PCR analysis of miR-143 expression showed the up-
regulation of this miRNA in WT hypoxic mice in comparison with normoxic animals 
(Figure 4-7). However, although a down-regulation of miR-143 was identified in 
normoxic mice depleted for miR-145, no differences in its expression level were 
observed between WT and miR-145 -/- animals in response to hypoxia (Figure 4-7), 
suggesting that the genetic ablation of miR-145 does not influence miR-143 regulation 
in pathological conditions. Thus, any change in the development of PAH in miR-145 -/- 
mice in response to hypoxia is specific to the selective loss of miR-145. In consideration 
of this, in situ hybridization was performed to localize miR-145 within the lung of 
control mice since this has not previously been evaluated. We observed positive 
staining for this miRNA within the smooth muscle layer of vessels and bronchi in the 
lungs of WT mice (Figure 4-8). 
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We next quantified the development of PAH in WT and miR-145 -/- mice. It has been 
recently reported how the genetic ablation of miR-145 (and to a lesser extent of miR-
143) is able in mice to determine an alteration in the structure of the aorta that show a 
thinner wall than the WT (Xin, Small et al. 2009). This abnormality is due to a reduction 
in cell size of VSMCs identified in KO animals in comparison with WT, reduction caused 
by the dramatic decrease of the number of actin-based stress fibers (characteristic of 
completely differentiated cells) observed in KO VSMCs. Here, we show like the KO of 
miR-145 alone is sufficient to determine a significant reduction of the mean systemic 
arterial pressure (SAP), confirming that the ablation of this miRNA can induce a 
widespread alteration in the wall formation of the vasculature due to its involvement 
in VSMCs proliferation and differentiation (Figure 4-9A, Table 4-1). However, both in 
WT and KO mice the exposition to chronic hypoxia doesn’t determine any alteration in 
SAP as showed in previous studies (Morecroft, Dempsie et al. 2007; Mair, MacLean et 
al. 2008; Morecroft, Doyle et al. 2011) (Figure 4-9A, Table 4-1). Moreover, in WT mice, 
we observed a significant and expected increase in systolic right ventricular pressure 
(sRVP) and right ventricular hypertrophy (RVH) (Figure 4-10A and B, Table 4-1 and 
Table 4-2) whereas miR-145-/- animals displayed no increase in these parameters 
(Figure 4-10A and B, Table 4-1 and Table 4-2). Interestingly, there was no difference in 
baseline systolic RVP or RVH between wild type and miR-145 -/- mice but a different 
response to the hypoxic insult (Figure 4-10A and B, Table 4-1 and Table 4-2). No 
changes in heart rate (HR) were reported (Figure 4-9B, Table 4-1). Histological analysis 
showed the presence of pulmonary vascular remodeling in small PAs of WT animals 
following exposure to hypoxia but this was reduced in lungs harvested from miR-145 
KO animals, a finding confirmed by quantitative scoring (Figure 4-11A and B). 
Therefore, genetic ablation of miR-145 was able alone to protect mice against the 
development of PAH in response to hypoxia without any compensatory effect on miR-
143 expression. 
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Figure 4-6  Analysis of miR-145 expression in miR-145 -/- female mice in comparison with 
WT mice. miR-145 genetic ablation in 10 weeks old, KO mice was confirmed in the lung by 
TaqMan
®
 Real-Time PCR (A) and in situ analysis (B). In (A) data are expressed as mean ± 
SEM and analysed by two way ANOVA followed by Bonferroni’s post-hoc test. ***P<0.001 
compared to normoxic mice. Raw Ct values for the target miRNAs are indicated above each 
column.  N = 6/group. In (B) images all x100 magnification, scale bars = 100 m. 
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Figure 4-7  miR-143 expression in WT and miR-145 -/- female mice in response to 
hypoxia. TaqMan
®
 Real-Time PCR analysis of normoxic and 14 days hypoxic WT and KO 
mice. Total RNA was extracted from the lung of normoxic (dark grey bars) or hypoxic (light grey 
bars) 10 week old mice. 6 mice/group were analyzed. Samples were tested in triplicate. Results 
were normalized to U6 values and expressed as relative fold change, with an arbitrary value of 
1 assigned to the control group. Raw Ct values for the target miRNAs are indicated above each 
column. Data were analyzed using a two-way ANOVA followed by Bonferroni’s post-hoc test. 
***p<0.001 compared to normoxic samples. 
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Figure 4-8  miR-145 localization in mouse lung sections. (A-F) In situ hybridization showing 
miR-145 localization in mouse lung. Paraffin sections were rehydrated and incubated with an 
anti-miR-145 (A, C) or scramble probe (B, D) as negative control. For co-localization, alpha-
actin was detected in the same samples using an immunohistochemistry assay (F), with non-
immune isotype-IgG antibody as negative control (E). Images x100 (A, B) or x400 (C-F) 
magnification, scale bars = 50 m. 
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Figure 4-9  Assessment of systemic arterial pressure (SAP, A, n = 6–9) and heart rate 
(HR, B, n=8-10) in WT and miR-145 -/- mice, normoxic and hypoxic.  10 weeks old female 
mice were assessed. Data were analyzed using a two-way ANOVA followed by Bonferroni’s 
post-hoc test. **p<0.005 compared to WT hypoxic mice. 
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Figure 4-10  Effect of miR-145 genetic ablation on PAH development in mice. Assessment 
of sRVP (A, n = 9–10) and RVH (B, n = 9–10) in 10 weeks old female WT and miR-145 -/- mice, 
normoxic or exposed to chronic hypoxia for 14 days. Data were analyzed using a two-way 
ANOVA followed by Bonferroni’s post-hoc test. *P<0.05, **P<0.01, ***P<0.001 compared to 
normoxic mice or WT hypoxic mice as indicated. NS = non-significant change. 
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342.08 ± 14.78325.88 ± 6.67329.18 ± 12.66329.42 ± 8.92Heart rate, bpm
70.92 ± 5.59**71.34± 8.14**94.01± 2.9183.22 ± 1.55SAP, mmHg
24.07± 1.38†21.21± 0.6129.71± 1.16***20.00 ± 0.80sRVP, mmHg
KO HypoxicKO NormoxicWT hypoxicWT NormoxicParameter
 
Table 4-1  Haemodynamics in WT and miR-145 -/- mice, normoxic and 
hypoxic. Systolic right ventricular pressure (sRVP), systemic systolic arterial pressure (SAP) 
and heart rate measurements in normoxic and chronically hypoxic female WT and miR-145 -/- 
mice. **P<0.005, ***P<0.001 compared to WT normoxic mice; †P<0.01 compared to WT 
hypoxic mice; Data expressed as mean + SEM. n=9-10. 
 
 
 
0.28 ± 0.014††68.63 ± 1.9219.21 ± 0.85miR-145 -/- Hypoxic
0.27 ± 0.01469.74 ± 3.0818.60 ± 1.25miR-145 -/- Normoxic
0.35 ± 0.012***73.69 ± 1.7725.71 ± 0.84WT Hypoxic
0.26 ± 0.01585.12 ± 1.2422.06 ± 1.13WT Normoxic
RV/LV+SLV+S (mg)RV (mg)Group
 
Table 4-2  Ventricle weight in WT and miR-145 -/- mice. Right ventricle (RV) 
weight, left ventricle plus septum (LV+S) weight and RV/LV+S ratio. ***P<0.001 compared to 
WT normoxic mice; ††P<0.005 compared to WT hypoxic mice. Data expressed as mean + 
SEM. N = 9-10. 
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Figure 4-11  Effect of miR-145 genetic ablation on vessel remodelling in mice. (A) 
Representative PAs stained with elastic-Van Gieson.  Images all x40 magnification, scale bars = 
20 m. (B) Pulmonary arterial remodelling from normoxic and hypoxic WT and miR-145 -/- 
female mice (n = 5/group). Mice were subjected to chronic hypoxia for 14 days and analyzed at 
10 weeks of age.  Lung sections (5 sections/group) were stained with Elastin-Van Gieson and 
microscopically assessed in a blanded fashion. Pulmonary arteries (≤ 80 microns external 
diameter) were considered muscolarized if they possessed a distinct double elastic lamina for at 
least half the diameter of the vessel cross section. Approximately 150 arteries from each sagittal 
lung section were assessed. Data were analyzed using a two-way ANOVA followed by 
Bonferroni’s post-hoc test. *p<0.05 compared to normoxic mice or WT hypoxic mice as 
indicated. NS = non-significant change. 
WT           miR-145 -/- 
Normoxic 
Hypoxic 
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4.2.3 miR-145 Expression in the Right Ventricle and the Left 
Ventricle Plus Septum of WT Hypoxic Mice 
Considering the reduction in RVH observed in miR-145 KO mice, we also evaluated 
miR-145 expression in the right ventricle and the left ventricle plus septum of WT and 
miR-145 -/- mice exposed to chronic hypoxia for 14 days. The analysis of the KO mice 
confirmed the absence of miR-145 expression in these tissues, while in WT mice we 
observed a significant up-regulation of this miRNA in comparison with normoxic 
animals (Figure 4-12A and B), suggesting that miR-145 could be not only indirectly 
(because of its involvement in vascular remodelling) (Cheng, Liu et al. 2009) but also 
directly involved in the RVH characteristic of this animal model. 
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Figure 4-12  miR-145 expression in the left ventricle plus septum (A) and the right 
ventricle (B) of WT and miR-145 -/- female mice. Total RNA was extracted from the left 
ventricle plus septum (A) or the right ventricle (B) of normoxic (dark grey bars) or 14 days 
hypoxic (light grey bars) 10 week old mice. 6 mice/group were analyzed. Every sample was 
tested in triplicate. Results were normalized to U6 values and expressed as relative fold 
change, with an arbitrary value of 1 assigned to the control group. Raw Ct values for the target 
miRNAs are indicated above each column. Data were analyzed using a two-way ANOVA 
followed by Bonferroni’s post-hoc test. **p<0.005, ***p<0.001 compared to wt normoxic mice.  
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4.2.4 Analysis of miR-145 Targets in the Total Lung of miR-145 
KO Mice in Comparison with Control Animals 
In order to verify the effect of miR-145 genetic ablation on gene and protein 
expression, several miR-145 gene targets, already validated in literature (Section 4.1) 
or identified using TargetScan and PicTar prediction algorithms and selected for their 
involvement in PAH were analyzed by TaqMan® Real-Time PCR and western blot in 
total lung of WT and miR-145 KO animals. As for Chapter 3, GAPDH was selected as 
housekeeping gene after evaluation of its stability in hypoxia. Representative results 
are showed for KLF4 and KLF5 analysis (Figure 4-13). The selected targets included 
KLF4 and KLF5, both involved in SMCs proliferation and differentiation, ACE, which 
converts circulating angiotensin I into its active form angiotensin II, major regulator of 
the contractile phenotype of VSMCs, Myocd, a potent SRF co-activator involved in 
VSMCs differentiation, and also SMAD4 and SMAD5, members of the TGF-beta super-
family (Chapter 1, Section 1.2.4.1), not validated to date in the literature.  Analysis of 
RNA revealed a significant up-regulation of both SMAD4 and SMAD5 in miR-145 -/- 
normoxic mice in comparison with WT normoxic mice but no changes were observed 
in WT mice in response to hypoxia (Figure 4-14A and B). ACE and Myocd were down-
regulated in WT mice in response to hypoxia (result compatible with miR-145 up-
regulation in these samples), but no increase in their expression was observed in KO 
mice in comparison with WT, in contrast with previous observations (Boettger, Beetz 
et al. 2009; Cordes, Sheehy et al. 2009) (Figure 4-14C and D). KLF4 was elevated both in 
normoxic and hypoxic miR-145 -/- mice in comparison with WT while KLF5 expression 
was significantly up-regulated in WT hypoxic versus miR-145 -/- hypoxic mice (Figure 
4-14E and F), suggesting that the genetic ablation of miR-145 has an effect on the 
expression of these two genes in particular in response to chronic hypoxia, responsible 
in WT mice of altered proliferation of PASMCs. The western blot analysis of KLF4 
protein expression in WT and KO animals in hypoxic conditions confirmed the 
significant up-regulation of this target, whereas no significant changes were observed 
in nomoxia (Figure 4-15). On the contrary, KLF5 was not significantly up-regulated in 
the same samples both in normoxic and hypoxic conditions (Figure 4-15). 
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Figure 4-13  GAPDH row Ct values in hypoxic mice, WT and miR-145 KO, in comparison 
with normoxic mice. GAPDH expression level was evaluated in hypoxic mice and compared 
with normoxic animals in order to assess weather hypoxia can induce its expression as 
previously reported. Raw data are indicated for each sample analyzed in triplicate by TaqMan
®
 
Real-Time PCR, with a lane representing the mean value for each group. 
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Figure 4-14  Analysis of miR-145 selected targets. The expression level of SMAD4 (A), 
SMAD5 (B), ACE (C), Myocd (D), KLF4 (E) and KLF5 (F) was assessed by TaqMan
®
 Real-Time 
PCR in the total lung of WT and miR-145 -/- female mice, normoxic and 14 days hypoxic. 
Samples were tested in triplicate. Results were normalized to GAPDH values and expressed as 
relative fold change, with an arbitrary value of 1 assigned to the control group. Raw Ct values 
for the target genes are indicated above each column. Data were analyzed using a two-way 
ANOVA followed by Bonferroni’s post-hoc test. *p<0.05, ***p<0.001 as indicated. N = 6/group. 
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Figure 4-15  Analysis of KLF4 and KLF5 protein expression level in WT and miR-145 -/- 
hypoxic female mice. (A, D) The expression level of KLF4 and KLF5 was assessed by western 
blot in the total lung of WT and miR-145 -/- mice exposed to chronic hypoxia for 14 days. 4 
mice/group were analyzed, and the intensity of the western blot bands was measured using a 
specific software (Scion Image software). The resulting quantification bars are represented in 
graphs in B, C, E and F. Results were normalized to GAPDH values and expressed as fold 
increase, with an arbitrary value of 1 assigned to the WT group. Data were analyzed using an 
unpaired t-test. **p<0.005 compared to wt mice. 
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4.2.5 MiR-145 and miR-143 in Human PAH 
We next assessed whether miR-145 and miR-143 are dysregulated in patients with PAH 
and examined their expression levels in the lung of patients with IPAH and HPAH in 
comparison with control lung tissue. Although miR-145 KO alone had a protective 
effect against the development of PAH in hypoxic mice without any compensatory 
effect on miR-143 expression, we decided to evaluate also miR-143 expression in PAH 
patients, in consideration of the up-regulation of this miRNA observed in hypoxic 
female mice. We first extracted miRNAs from paraffin-embedded lung sections. 
Compared to controls, both miR-143 and miR-145 were significantly elevated in both 
HPAH and IPAH samples (Figure 4-16A and B). We next used in situ hybridization to 
localize expression of miR-145 and miR-143 in human lungs selected from the above 
patients (Figure 4-17 and Figure 4-18). In concordance with analysis of the mouse lung, 
expression of miR-145 and miR-143 in control lung sections was confined to smooth 
muscle cells, including both vascular and bronchiolar lineages (Figure 4-17 and Figure 
4-18). PAH is characterized by the development of both constrictive and complex 
arterial lesions involving the pre- and intra-acinar pulmonary arteries. In patients with 
IPAH and HPAH, both these miRNAs were expressed by arterial smooth muscle cells 
and observed within the muscular component of constrictive lesions and complex 
vascular lesions wherever present (Figure 4-17 and Figure 4-18). Mir-145 and miR-143 
positive cells were also observed in pre- and intra-acinar arteries with increased 
thickness and muscularization (Figure 4-17 and Figure 4-18). In addition, newly 
muscularized arterioles at the level of alveolar ducts expressed abundant levels of both 
these miRNAs. Although in situ localization is not quantitative, we also observed 
vessels with extensive remodeling where neotintimal SMC has notably reduced levels 
of miR-145 compared to SMCs resident within the medial layer (Figure 4-17C), 
accordingly with previous observations (Cheng, Liu et al. 2009; Cordes, Sheehy et al. 
2009). Since the growth and characteristics of SMCs isolated from patients with 
BMPR2 mutations are fundamentally different to those isolated from patients without 
germline mutations, we used human primary cells in culture to assess the effect of 
BMPR2 mutations on miR-145 and miR-143 regulation. We therefore cultured primary 
human PASMCs obtained from PAH patients and quantified the expression of our 
miRNAs of interest at the pre-miRNA and mature miRNA level. The pri- form of both 
 191 
miR-145 and miR-143 was undetectable, possibly because pri-miRNA transcripts are 
rapidly processed into their mature forms. miR-145 and miR-143 resulted significantly 
elevated in cells derived from patients with known BMPR2 mutations compared to 
unaffected controls (Figure 4-19A and B and Figure 4-20A and B) in the pre- and the 
mature forms. We next performed northern blot analysis to confirm and quantify the 
differential levels of the mature miR-145 and miR-143 in the same samples. In 
concordance with the Real-Time PCR analysis, miR-145 and miR-143 were significantly 
elevated in the RNA extracted from patients with mutations in BMPR2 compared to 
non-mutated control PASMCs (Figure 4-19C and D and Figure 4-20C and D). Therefore, 
we can conclude that basal levels of miR-145 and miR-143 are elevated in patients 
with germline BMPR2 mutations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 192 
 
0
0.5
1
1.5
2
B
CTR IPAH HPAH
m
iR
-1
4
3
/r
n
u
-4
8
 l
e
v
e
l
p
a
ra
ff
in
-e
m
b
e
d
d
e
d
 h
u
m
a
n
 l
u
n
g
(F
o
ld
 C
h
a
n
g
e
)
***
**
miR-143
A
0
0.5
1
1.5
2
m
iR
-1
4
5
/r
n
u
-4
8
 l
e
v
e
l
p
a
ra
ff
in
-e
m
b
e
d
d
e
d
 h
u
m
a
n
 l
u
n
g
(F
o
ld
 C
h
a
n
g
e
)
CTR IPAH HPAH
**
*
miR-145
m
iR
-1
4
3
/r
n
u
-4
8
 l
e
v
e
l
p
a
ra
ff
in
-e
m
b
e
d
d
e
d
 h
u
m
a
n
 l
u
n
g
(F
o
ld
 C
h
a
n
g
e
)
m
iR
-1
4
5
/r
n
u
-4
8
 l
e
v
e
l
p
a
ra
ff
in
-e
m
b
e
d
d
e
d
 h
u
m
a
n
 l
u
n
g
(F
o
ld
 C
h
a
n
g
e
)
 
 
Figure 4-16  Assessment of miR-145 and miR-143 expression level in IPAH and HPAH 
human lung. TaqMan
®
 Real-Time PCR analysis of RNA extracted from paraffin-embedded 
human lungs of IPAH (n = 6), HPAH (n = 5) and control patients (n = 6) showing the expression 
level of miR-145 (A) and miR-143 (B). All samples were tested in triplicate and normalized to 
Rnu-48 values and expressed as relative fold change, with an arbitrary value of 1 assigned to 
the control group. Raw Ct values for the target miRNAs are indicated above each column. Data 
were analyzed using a one-way ANOVA followed by Bonferroni’s post-hoc test. *p<0.05, 
**p<0.005, ***p<0.001 compared to CTR group. 
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Figure 4-17  In situ analysis of miR-145 expression in paraffin sections obtained from the 
same samples used in figure 4.14. (A, B, C) Arteries of different sizes and different examples 
of lesions are shown. A scramble probe was used as negative control. For co-localization, 
alpha-actin was detected in the same samples using immunohistochemistry on serial sections, 
with non-immune isotype-IgG antibody as negative control. Images demonstrate increased 
expression of alpha-actin and miR-145 in a typical complex lesion and in newly muscularized 
arterioles and arteries. (A) scale bars = 50 m, (B) scale bars = 100 m. (C) miR-145 detection 
in the neointimal lesion of HPAH patients. Images show a decreased expression of alpha-actin 
and miR-145 in the neointima formation of big arteries in comparison with SMCs resident within 
the medial layer. Scale bars = 100 m. 
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Figure 4-18  In situ analysis of miR-143 expression in paraffin sections obtained from the 
same samples used in Figure 4.14. (A, B) Arteries of different sizes and different examples of 
lesions are shown. A scramble probe was used as negative control. For co-localization, alpha-
actin was detected in the same samples using immunohistochemistry on serial sections, with 
non-immune isotype-IgG antibody as negative control. Images demonstrate increased 
expression of alpha-actin and miR-145 in a typical complex lesion and in a newly muscularized 
arteriole. (A) scale bar = 50 m, (B) scale bars = 100 m.  
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Figure 4-19  Analysis of miR-145 in human BMPR2 mutated PASMCs. (A, B) TaqMan
®
 
Real-Time PCR analysis of miR-145 expression in human PASMCs. Total RNA was extracted 
from PASMCs of HPAH patients with a mutation in the BMPR2 gene. Passage 4 primary cells 
were used. cDNA was analyzed in triplicate for pre- (A) and mature-miR-145 expression (B) in 
comparison with unaffected controls. Results were normalized to GAPDH for the pre- and Rnu-
48 for the mature-miR-145 and expressed as relative fold change, with an arbitrary value of 1 
assigned to the control group. Raw Ct values for the target miRNAs are indicated above each 
column. Data were analyzed using an unpaired t-test. **p<0.005, ***p<0.001 compared to 
control samples. (C, D) The same total RNA extracted from WT and BMPR2 mutated cells was 
also used for northern blot analysis in order to confirm the TaqMan
®
 Real-Time PCR results. 
The blot quantification (D) was performed with Scion Image software (www.scioncorp.com): 
band intensities of the miRNA of interest were established and normalized to the relative U6 
signal. Data were analyzed using an unpaired t-test. ***p<0.001 compared to control samples. 
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Figure 4-20  Analysis of miR-143 in human BMPR2 mutated PASMCs. (A, B) TaqMan
®
 
Real-Time PCR analysis of miR-143 expression in human PASMCs. Total RNA was extracted 
from PASMCs of HPAH patients with a mutation in the BMPR2 gene. Passage 4 primary cells 
were used. cDNA was analyzed in triplicate for pre- (A) and mature-miR-143 expression (B) in 
comparison with unaffected controls. Results were normalized to GAPDH for the pre- and Rnu-
48 for the mature-miR-143 and expressed as relative fold change, with an arbitrary value of 1 
assigned to the control group. Raw Ct values for the target miRNAs are indicated above each 
column. Data were analyzed using an unpaired t-test. **p<0.005, ***p<0.001 compared to 
control samples. (C, D) The same total RNA extracted from WT and BMPR2 mutated cells was 
also used for northern blot analysis in order to confirm the TaqMan
®
 Real-Time PCR results. 
The blot quantification (D) was performed with Scion Image software (www.scioncorp.com): 
band intensities of the miRNA of interest were established and normalized to the relative U6 
signal. Data were analyzed using an unpaired t-test. *p<0.05 compared to control samples. 
30.2 
29.3 
24.8 
24.1 
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4.2.6 miR-145 and miR-143 Expression in BMPR2 R899X mice 
Considering the dysregulation observed in miR-145 and miR-143 expression level in 
human PASMCs isolated from HPAH patients harbouring a mutation in the BMPR2 
gene, we evaluated the effect of a truncating BMPR2 mutation on miR-145 and miR-
143 expression in heterozygous R899X +/- mice. West et al. recently reported these 
mice, which harbor a mutation in the BMPR2 gene tail domain, develop PAH and 
significant vascular remodeling (West, Harral et al. 2008). RNA was extracted from the 
whole lung of 6 month old mice and analyzed by TaqMan® Real-Time PCR and 
northern blot for miR-145 and miR-143 expression. This revealed a significant up-
regulation of both these miRNAs in mutated mice compared to controls (Figure 4-21). 
In situ localization if miR-145 in paraffin lung sections confirmed positive staining 
within the smooth muscle layer of pulmonary vessels and bronchi of both wt and 
BMPR2 mutated mice, with strong staining observed in mutated animals (Figure 4-22).  
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Figure 4-21  miR-145 and miR-143 expression in WT and BMPR2 R899X mice. RNA was 
extracted from the total lung of 3 WT mice and 4 animals heterozygous for a nonsense mutation 
in the BMPR2 gene, and tested in triplicate for miR-145 (A) and miR-143 (B) expression by 
TaqMan
®
 Real-Time PCR and northern blot (C-F). Real-Time PCR results were normalized to 
U6 expression and analyzed using an unpaired t-test. ***p<0.001 compared to BMPR2 +/+ 
mice. Blots quantification (D, F) was performed with Scion Image software 
(www.scioncorp.com). Results were normalized to U6 values and expressed as fold increase, 
with an arbitrary value of 1 assigned to the BMPR2 +/+ group. Raw Ct values for the target 
miRNAs are indicated above each column. Results were analyzed using an unpaired t-test. 
***p<0.001, *p<0.05 compared to BMPR2 +/+ mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 201 
 
 
 
 
 
 
Figure 4-22  miR-145 localization in WT and BMPR2 R899X mouse lung. In situ 
hybridization showing miR-145 localization in the lung of the animals used for the experiments 
showed in Figure 4.15. Paraffin sections were rehydrated and incubated with an anti-miR-145 or 
scramble probe as negative control. For co-localization, alpha-actin was detected in the same 
samples using an immunohistochemistry assay, with non-immune isotype-IgG antibody as 
negative control. Images x200 magnification, scale bars = 50 m. 
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4.2.7 Effect of BMPR2 Down-Regulation on miR-143 and miR-
145 Expression in Human PASMCs 
Davis-Dusembery et al. recently reported that BMP4 is able to induce the expression of 
the miR-143/145 cluster through the CArG box present in its promoter (Section 4.1) 
(Davis-Dusenbery, Chan et al. 2011). However, we reported the up-regulation of both 
these miRNAs in systems characterized by an impairment of the BMP signaling due to 
mutations in the type II receptor BMPR2. For this reason we decided to evaluate in 
vitro the effect of a siRNA-mediated knock-down of BMPR2 on miR-143 and miR-145 
expression level in human WT PASMCs. Cells were therefore transfected with a short 
interfering (si) sequence, able to target and down-regulate specifically BMPR2, or with 
a siScramble as negative control. RNA was extracted from these samples and from 
untreated cells after 72 h for comparison. The efficacy of the down-regulation of 
BMPR2 was assessed through TaqMan® Real-Time PCR analysis (Figure 4-23A). In 
agreement with our previous findings, the down-regulation of BMPR2 induced the 
significant up-regulation of both miR-143 and miR-145, whereas no changes were 
observed in untreated or siScramble-treated cells (Figure 4-23B and C). 
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Figure 4-23  miR-143 and miR-145 up-regulation in human PASMCs down-regulated for 
BMPR2 expression via a siRNA. Primary human PASMCs were transfected with a siRNA able 
to target and repress specifically BMPR2 expression or with a siScramble as a negative control. 
Total RNA was extracted after 72 h from these samples and untreated cells for comparison and 
tested in triplicate. The efficiency of BMPR2 down-regulation was evaluated by TaqMan
®
 Real-
Time PCR (A). miR-143 (B) and miR-145 (C) expression were also assessed in the same 
samples. All Samples were tested in triplicate. Results were normalized to GAPDH for BMPR2 
and Rnu-48 for miR-143 and miR-145 and expressed as relative fold change, with an arbitrary 
value of 1 assigned to the control group. Raw Ct values for the target miRNAs and gene are 
indicated above each column. Data were analyzed using a one-way ANOVA followed by 
Bonferroni’s post-hoc test. **p<0.005, ***p<0.001 compared to CTR or si-Scramble group as 
indicated. 
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4.3 Discussion 
In this chapter we describe the expression and regulation of miR-145 and miR-143 in 
the lung under normal physiology and in response to hypoxic injury. We show that 
these two miRNAs are mainly expressed in the SMC compartment both in lungs taken 
from mice subjected to normoxic or hypoxic conditions as well as in human lungs from 
control subjects and patients with either HPAH or IPAH. In the hypoxic mouse model 
we show elevation of miR-143 and miR-145 levels in total lung and in the heart of 
female animals compared to controls with no dysregulation in other organs such as 
brain, spleen and kidney. These observations suggest that miR-143/145 deregulation in 
response to hypoxia is specific of the cardiovascular system. 
 
We also hypothesize an essential role for miR-145 (but potentially not miR-143) in the 
development of PAH. Recently, several studies pointed out not only the specific 
smooth muscle localization of these miRNAs, but also their fundamental role in the 
differentiation of this cell type (Rangrez, Massy et al. 2011). In particular, miR-145 has 
been identified as the most abundant miRNA in normal arteries and in differentiated 
VSMCs (Cheng, Liu et al. 2009). Considering the central role of PASMCs remodeling in 
the small peripheral, normally non-muscular PAs during the development of PAH, we 
decided to evaluate the effect of the ablation of this miRNA in mice exposed to 
hypoxia. In particular, we used KO mice deleted for the sequence coding for miR-145 
but able to express miR-143, transcribed in the same precursor. This is relevant since a 
recent study showed how the introduction of miR-145, but not miR-143, into neural 
crest stem cells was sufficient to guide 75% of cells into the VSMC lineage within only 
24 hours (Cordes, Sheehy et al. 2009). Also, antagomiR-mediated inhibition of miR-145 
expression blocked the ability of myocd to convert fibroblasts into VSMCs, with only a 
little effect of miR-143 knock-down (Cordes, Sheehy et al. 2009). A different study 
demonstrated that reintroduction of miR-145, but not miR-143, into vascular SMC 
rescues the reduction in SMC marker expression in Dicer KO vascular SMCs (Albinsson, 
Suarez et al. 2010). These observations suggest a predominant role of miR-145 in SMCs 
differentiation, leading us to use a single miR-145 -/- in this study in order to evaluate 
its role in the development of PAH. A functional analysis of the vasculature of miR-145 
-/- mice revealed a reduced response to hypoxia: when these mice were exposed to 
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hypoxia for two weeks, systolic pressure did not show a significant rise as in WT mice. 
A similar result was obtained for right ventricular hypertrophy. In addition, the 
percentage of remodeled vessels was significantly reduced in the KO animals, 
suggesting a protective role for miR-145 ablation in PAH development. This occurred in 
the absence of any modulation of miR-143, thus confirming the importance of miR-145 
alone in the development of PAH. A different in vivo study very recently conducted by 
our group proved that the antagomiR-mediated substantial down-regulation of miR-
145 (but not miR-143) also has a protective effect against the development of PAH in 
hypoxic mice, confirming what we show in this Chapter (data not shown). 
 
mRNA analysis of the expression of some predicted targets confirmed in some cases 
their up-regulation in miR-145 ablated samples, both in normoxic and hypoxic 
conditions, whereas other targets did not present the expected regulation in KO mice. 
This is the case of ACE, down-regulated in miR-145 -/- samples, although it was 
possible to observe its significant down-regulation in WT hypoxic mice, characterized 
by the up-regulation of miR-145. It is important to remember that the capacity of miR-
145 to regulate the expression of this specific target has been previously reported 
(Boettger, Beetz et al. 2009). In particular, Boettger et al. recently showed the up-
regulation of ACE in VSMCs of miR-143/145 depleted mice and explained, at least in 
part, with this observation the shift from the contractile to the synthetic phenotype 
observed in these mutant mice. This finding could not be confirmed in our miR-145 KO 
mice, since no up-regulation in ACE expression was observed, both in normoxic and 
hypoxic conditions, in the total lung. A western blot analysis will clarify in the future if 
such a regulation occurs at protein level, whereas the analysis of the PAs will be 
important to evaluate in a more specific way the effect of miR-145 ablation on the 
vasculature. On the other hand, both KLF4 and KLF5 were significantly up-regulated in 
KO mice exposed to chronic hypoxia at mRNA and protein level, suggesting a direct 
role for these targets in the protective effect against the development of PAH 
observed in these mutant mice. Future experiments will be conducted to assess the 
effect of KLF4/KLF5 manipulation on PAH development. A different case is represented 
by myocd, since the up-regulation of this factor was previously reported as a 
consequence of miR-143 and miR-145 induction, suggesting its role as an indirect 
targets of these miRNAs (Cordes, Sheehy et al. 2009). Moreover, myocd plays an 
important role in the TGF-beta-mediated induction of the miR-143/145 cluster, as 
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recently reported (Davis-Dusenbery, Chan et al. 2011). However, we could not observe 
any up-regulation of myocd in WT hypoxic mice, nor a significant down-regulation in 
the KO animals. These findings suggest that in our system miR-143/145 induction is not 
myocd-mediated and that myocd itself is not influenced by the deregulation of this 
cluster. A western blot analysis of myocd protein expression level and the analysis of 
PAs will be necessary to confirm this hypothesis. Immunohistochemistry assays will 
also be important to localize myocd expression. As future work, a microarray based 
analysis of mRNA expression could be important to have a global view of the effects of 
miR-145 genetic ablation on gene regulation. In particular, such a study could be 
conducted using total lung but more conveniently PAs in order to assess directly the 
component of the pulmonary vasculature involved in PAH development. Moreover, 
luciferase assays performed in vitro on PASMCs will further confirm the direct effect of 
miR-145 manipulation on the expression of specific genes in our system. 
 
Moreover, we have demonstrated significant up-regulation of both miR-143 and miR-
145 in HPAH and IPAH patients and in particular in BMPR2 mutated PASMCs extracted 
from HPAH patients. A similar level of up-regulation of the cluster was also identified in 
mice carrying a mutation in this gene. This conserved dysregulation suggests the 
presence of a link between the regulation of miR-143 and miR-145 and the TGF-beta 
super-family, already involved in the maturation process of other miRNAs including 
miR-21, through the interaction of SMADs with DROSHA during the second step of 
miRNA biogenesis (Davis, Hilyard et al. 2008) (Chapter 1, Section 1.3.3.4). Very 
recently, this link has been proved with the observation that both TGF-beta and BMP4 
are able to activate transcription of miR-143/145 cluster through the CArG box present 
in its promoter, but with a different mechanism. In fact, MRTF-A results essential for 
BMP4-dependent induction of the cluster, while TGF-beta enhance miR-143/145 
expression inducing SRF and myocd expression, as already mentioned (Davis-
Dusenbery, Chan et al. 2011; Long and Miano 2011). However, since the BMP signaling 
is impaired in the presence of mutations in the BMPR2 gene, our findings do not 
correlate well with this theory. Our observations of an up-regulation of miR-143 and 
miR-145 in BMPR2-mutated human cells and mouse models was also confirmed in 
vitro, since a similar dysregulation of these two miRNAs was induced in human 
PASMCs by the down-regulation of BMPR2 expression, obtained via a siRNA able to 
inhibit specifically the expression of this gene. More experiments will be necessary to 
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elucidate further the role of the TGF-beta super-family in the regulation of the miR-
143/145 cluster (particularly in vivo) and to identify the effector of their up-regulation 
in mice exposed to chronic hypoxia and PAH patients, including for example 
stimulations in vitro with different members of the TGF-beta super-family to evaluate 
their effect on miR-143 and miR-145 expression or vice-versa specific-inhibition, in 
vitro and in vivo, of these elements. 
 
Localization studies revealed miR-143 and miR-145 expression both in medial and 
neointimal SMCs of complex lesions. Interestingly, consistently with the up-regulation 
of these two miRNAs observed in the total lung of the analyzed PAH patients, the in 
situ localization of miR-143 and miR-145 in the vessels of IPAH and HPAH patients 
showed their abundant expression in hypertrophied arteries, pulmonary vascular 
lesions and newly muscularized arterioles. However, lower expression of miR-145 was 
observed in neointima formation in comparison with medial hypertrophy and 
adventitial thickening and with newly muscularized arterioles. The lack of neointimal 
expression of this miRNA is consistent with the presence of a dedifferentiated 
mesenchymal cell in this area of the vessel. It has been reported that lack of miR-145 
profoundly impedes the development of a neointima in the mouse carotid injury 
model due to diminished migratory activity of SMCs (Xin, Small et al. 2009). However, 
it is important to notice that the mouse hypoxic model is a model of distal 
muscularization of the pulmonary circulation, rather than neointima formation, and for 
this reason it does not represent the ideal model to evaluate this aspect. For this 
reason, it will be necessary in the future to evaluate more extensively this aspect in 
human pathological samples in comparison with unaffected controls. Nevertheless, 
taken together our findings and results in the systemic circulation suggest that 
inhibition of miR-145 may perturb both the process of muscularization and neointima 
formation.  
 
It is also important to note that a miR-145 up-regulation in the PASMCs obtained from 
IPAH patients has been recently marked in another study (Courboulin, Paulin et al. 
2011), confirming our findings. However, in that study the focus was on the role of 
miR-204 in PAH, without further analysis of miR-145 expression and regulation.  
Dysregulation of several miRNAs in the pathological samples (animal or human) in PAH 
is now clear, each miRNA having potentially many hundreds of potential gene targets. 
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This defines a complex situation, with several pathways and cell types potentially 
involved, all important but not necessarily regulated at the same time or at the same 
level. The manipulation of individual miRNAs, however, such as miR-145 here, or miR-
204 (Courboulin, Paulin et al. 2011), appears to exert a substantial impact on the 
development of PAH. For this reason, our study also highlights the potential for miR-
145 down-regulation as a novel therapeutic approach for PAH. Strategies to achieve 
this may require selective delivery to the pulmonary system to avoid potentially 
deleterious effects of down-regulation of miR-145 in the peripheral vasculature, 
considering that a significant reduction of SAP was observed in mice genetically 
depleted for this miRNA. Our in situ studies in mouse and human show almost 
exclusive expression of miR-145 in the smooth muscle cells of the lung and within 
vascular lesions associated with PAH, hence strategies to delivery selectively within the 
lung are attractive.  
 
Taken together, this study demonstrates an essential role for miR-145 in the 
development of PAH through remodeling associated with the SMC compartment and 
association of elevated miR-145 levels in patients with mutations in the BMPR2 
receptor.  
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5. MiR-21 Expression in Pulmonary Arterial 
Hypertension: Evidence from Mouse Models and 
Patient Samples 
5.1 Introduction 
miR-21 is a miRNA highly expressed in the cardiovascular system (Cheng, Ji et al. 2007; 
Ji, Cheng et al. 2007), and its role in different human pathologies has been studied in 
detail in the last years. Here we will evaluate the role of this miRNA in the 
development of PAH. 
 
miR-21 was one of the first miRNAs identified in the human genome, and it shows a 
strong evolutionary conservation across a wide range of vertebrate species (Cai, 
Hagedorn et al. 2004). miR-21 is encoded by a single gene that in Homo sapiens is 
located on chromosome 17 (and on chromosome 10 and 21 in rat and mouse 
respectively) (Figure 5-1), where it overlaps with the protein-coding gene VMP1 
(vacuole membrane protein-1, also known as TMEM49, transmembrane protein-49) 
(Selcuklu, Donoghue et al. 2009). However, it has been demonstrated that the 3433 nt 
long pri-miR-21 is independently transcribed from a conserved promoter localized 
within an intron of the overlapping protein-coding gene (Fujita, Ito et al. 2008).   
 
Unlike miR-143 and miR-145, selectively expressed in SMCs, miR-21 is universally 
expressed in mammal organs such as lung, heart and spleen, and also in different cells 
types including fibroblasts, endothelial and smooth muscle cells (Lagos-Quintana, 
Rauhut et al. 2002). The function of miR-21 in cancer has been evaluated in several 
studies, and its over-expression has been observed in the majority of cancer types 
analyzed, including glioblastoma (Chan, Krichevsky et al. 2005), lung cancer (Yanaihara, 
Caplen et al. 2006; Hatley, Patrick et al. 2010), prostate cancer (Volinia, Calin et al. 
2006), pancreas (Lee, Gusev et al. 2007) and breast cancer (Iorio, Ferracin et al. 2005). 
In particular, the over-expression of miR-21 in primary breast cancer is correlated with 
advanced clinical stage and poor prognosis (Yan, Huang et al. 2008). These 
observations lead to the conclusion that this miRNA has oncogenic activity and can be 
classed as an “oncomir”. 
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More recently, the role of miR-21 in cardiovascular biology and disease has been 
evaluated. Ji et al. reported in rats a fivefold increase of the expression level of this 
miRNA in balloon-injured arteries compared with normal control vessels, and miR-21 
knock-down substantially inhibited neointimal lesion formation (Ji, Cheng et al. 2007). 
Moreover, they observed that inhibition of miR-21 significantly decreased proliferation 
of VSMCs in vitro (Ji, Cheng et al. 2007). Since neointimal formation is a common 
pathological characteristic of diverse proliferative cardiovascular disorders including 
atherosclerosis, coronary heart disease and PAH, this observation includes miR-21 in 
the list of miRNAs potentially involved directly in the development of such pathologies.  
 
More controversial are the results reported so far about miR-21 involvement in cardiac 
hypertrophy and heart failure. In several studies the significant up-regulation of this 
miRNA in hypertrophic animal hearts was observed (van Rooij, Sutherland et al. 2006; 
Cheng, Ji et al. 2007; Sayed, Hong et al. 2007). However, whereas Thum et al. reported 
that the antagomiR-mediated depletion of miR-21 prevents cardiac hypertrophy and 
fibrosis in response to pressure overload induced by transaortic constriction (TAC), 
Patrick et al. could not confirm this result in mice pharmacologically or genetically 
depleted for miR-21 expression (Thum, Gross et al. 2008; Patrick, Montgomery et al. 
2010), suggesting a role for this miRNA more difficult to clarify. In addition to this, 
observations concerning miR-21 role in angiogenesis are also quite controversial. In 
fact, in human prostate cancer cells over-expression of miR-21 induced tumor 
angiogenesis increasing the expression of HIF-1alpha (Hypoxia-Inducible Factor 1 
alpha) and VEGF (Liu, Li et al. 2011), whereas a recent study reported an impaired 
angiogenesis and a reduced endothelial cell proliferation and migration in response to 
miR-21 over-expression (Sabatel, Malvaux et al. 2011). These findings are probably due 
to different roles played by this miRNA in different cells types. 
 
Several targets of miR-21 negative regulation have been identified so far. Among them, 
the tumor suppressors phosphatase and tensin homolog (PTEN), and programmed cell 
death 4 (PDCD4). PTEN is expressed in cardiomyocytes but also in vascular cells where 
it modulates cell survival/apoptosis, hypertrophy and contractility (Oudit, Sun et al. 
2004; Ji, Cheng et al. 2007), whereas PDCD4, already known as a tumor suppressor 
gene (Lankat-Buttgereit and Goke 2009), has been recently involved in cardiovascular 
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biology by regulating apoptosis mechanisms in vascular smooth muscle cells and 
cardiac cells (Cheng, Liu et al. 2009; Lin, Liu et al. 2009). 
 
As we reported in Chapter 4 about miR-143 and miR-145, BMPs and TGF-beta (Chapter 
1, Section 1.2.4.1) can stimulate the expression of miR-21. In this case this stimulation 
occurs at a post-transcriptional level since ligand-specific SMAD proteins can interact 
with the DROSHA microprocessor subunit p68 to induce pre-miRNA accumulation. In 
PASMCs, this stimulation negatively regulates way the expression of PDCD4 as a result 
of miR-21 induction, causing the increase of different SMC markers including SMA, 
calponin and Sm22alpha. We can therefore conclude that TGF-beta and BMPs induce a 
contractile phenotype in SMCs via the increase of miR-21 (Davis, Hilyard et al. 2008).  
 
In Chapter 3 we showed that miR-21 is significantly down-regulated in male rats 
injected with the pneumotoxic alkaloid monocrotaline, but levels do not change in 
response to chronic hypoxia in rats (Chapter 3, Section 3.2.2). Also, rat PAFs and 
PASMCs exposed to hypoxia for 24 h did not present any dysregulation of miR-21, 
whereas this miRNA was significantly down-regulated in human hypoxic PAFs, 
suggesting that miR-21 could be differentially regulated in different species or cell 
types (Caruso, MacLean et al. 2010). For this reason, considering that we had not 
analyzed miR-21 expression in mouse models of PAH, we evaluated in detail miR-21 
expression in mouse models of PAH and in human samples derived from patients with 
either IPAH or HPAH as well as in control human lung. Here, we show that miR-21 is 
significantly up-regulated in female mice in response to chronic hypoxia and that 
genetic ablation of miR-21 can induce an exaggerated hypoxia-induced PAH.  Further, 
we show the down-regulation of miR-21 in the total lung of idiopathic and heritable 
PAH patients, whereas in PASMCs isolated from PAH patients with a mutation in the 
BMPR2 gene miR-21 is up-regulated in its pri-form, does not change in its pre-
precursor and it is down-regulated in its mature form. This suggests that the regulation 
of miR-21 expression occurs at a post-transcriptional step. Also, both TGF-beta and 
BMP4 can induce in vitro miR-21 expression, but the expression of this miRNA is 
decreased in cells down-regulated for BMPR2. However, the observation that miR-21 is 
not dysregulated in the total lung of mice harboring a truncating mutation in the 
BMPR2 gene suggests that miR-21 regulation could be complex and different in 
different species.   
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Figure 5-1  miR-21 location and structure. (A) miR-21 location on human chromosome 17. 
(B) pre-miR-21 sequence and stem-loop structure. Mature miR-21 sequence is shown in bold. 
(C) mature miR-21 sequence. Both the guide strand (predominant) and the passenger strand 
(minor) (Chapter 1, Section 1.3.3.2) are shown. adapted from (Selcuklu, Donoghue et al. 2009). 
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Figure 5-2  Schematic representation of BMP and TGF-beta induction of pre-miR-21. TGF-
beta and BMP signaling stimulates the production of pre-miR-21 by inducing the formation of a 
complex comprising R-Smads, Pri-miR-21 and members of the microprocessor complex such 
as Drosha and p68. Reproduced from (Davis and Hata 2009). 
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5.2 Results 
5.2.1 Expression and Regulation of miR-21 in WT Hypoxic Mice 
In Chapter 3 we reported that miR-21 is not dysregulated in WT male rats exposed to 
chronic hypoxia (Caruso, MacLean et al. 2010). However, considering the gender 
specific up-regulation of miR-145 observed in response to hypoxia (proper of female 
mice only) in the mouse study described in Chapter 4, we decided to analyze miR-21 
expression level in male and female WT mice exposed to chronic hypoxia for 14 days. 
The decision to investigate more in detail the expression pattern of this miRNA in the 
hypoxic mouse model of PAH was also due to the significant down-regulation of miR-
21 observed in rats injected with monocrotaline and also in human PAFs exposed to 
chronic hypoxia for 24 h, described in Chapter 3 (Sections 3.2.2 and 3.2.4) (Caruso, 
MacLean et al. 2010). As observed for miR-143 and miR-145 (Chapter 4, Section 4.2.1), 
our analysis showed a significant up-regulation of miR-21 in response to 14 days of 
chronic hypoxia in female, but not male mice (Figure 4-4). For the purpose of 
subsequent experiments, we therefore focused on female mice.  
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Figure 5-3 miR-21 expression in female and male WT mice exposed to chronic hypoxic 
for 14 days. Total RNA was extracted from the lung of normoxic (dark grey bars) and hypoxic 
(light grey bars) female and male mice at the age of 10 weeks. Samples were tested in 
triplicate. Results were normalized to U6 values and expressed as relative fold change, with an 
arbitrary value of 1 assigned to the female normoxic group. Raw Ct values for the target miRNA 
are indicated above each column. Data are expressed as mean ± SEM and analysed by one 
way ANOVA followed by Bonferroni’s post-hoc test. ***P<0.001 compared to female normoxic 
mice. N = 3/group. 
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5.2.2 Quantification of the Development of PAH miR-21 -/- Mice 
in Comparison with Controls 
Based on the up-regulation of miR-21 in hypoxic female mice, we next evaluated the 
effect of miR-21 genetic ablation on the development of PAH. 8 weeks old miR-21 -/- 
mice and control age-matched mice were exposed to chronic hypoxia or maintained in 
normoxic conditions for 14 days and analyzed for the development of PAH using a 
series of in vivo measurements. As already reported from Patrick et al. (Patrick, 
Montgomery et al. 2010), homozygous miR-21 KO mice were viable at birth and did 
not display any obvious disorder in normal conditions, indicating that this miRNA is not 
crucial for development. The absence of miR-21 expression in the KO animals used in 
the study was confirmed by TaqMan® Real-Time PCR in the total lung, PA, right 
ventricle (RV) and left ventricle plus septum (LV + S) (Figure 5-4A and B and Figure 5-5A 
and B). In agreement with our previous experiment, WT female mice exposed to 
chronic hypoxia showed a significant increase in miR-21 expression in the total lung in 
comparison with normoxic animals (Figure 5-4A). To understand more in detail miR-21 
regulation in WT mice in response to hypoxia we also analyzed miR-21 expression in 
PA, RV and LV + S. miR-21 resulted more up-regulated in the PA than in the total lung 
(Figure 5-4A and B), and also significantly dysregulated in the RV but not in the LV + S, 
suggesting that alterations in the expression level of this miRNA could be proper only 
of the ventricle affected by hypertrophy in PAH (Figure 5-5A and B).  
 
We next quantified the development of PAH in WT and miR-21 -/- mice. No changes in 
HR or mean SAP were reported between normoxic/hypoxic or WO/KO mice (Figure 
4-9A and B and Table 5-1). As expected, we observed a significant increase in sRVP and 
RVH in WT normoxic mice in comparison with hypoxic (Figure 4-10A and B, Table 5-1 
and Table 5-2). However, miR-21 KO mice exposed to hypoxia presented a worsen 
sRVP in comparison with WT mice (Figure 4-10A and Table 5-1). No differences in 
baseline sRVP between WT and miR-145 -/- in normoxia were identified but a 
significant increase was mrasured in hypoxia (Figure 4-10A and Table 5-1). RVH 
increased at the same level in WT and KO mice in response to hypoxia but a significant 
increase was identified in hypoxic WT versus hypoxic KO animals (Figure 4-10B and 
Table 5-2). Histological analysis showed the presence of pulmonary vascular 
remodelling in small PAs of WT animals following exposure to hypoxia and this was 
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worsen in lungs harvested from miR-21 KO animals, a finding confirmed by 
quantitative scoring (Figure 4-11A and B). Also, we observed a significant increase of 
pulmonary vascular remodelling in normoxic WT versus normoxic KO animals and in 
hypoxic WT versus hypoxic KO mice, suggesting that the genetic depletion of miR-21 
can induce vascular remodelling also in normoxic conditions (Figure 4-11). Therefore, 
genetic ablation of miR-21 induced in mice more severe haemodynamic 
measurements.  
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Figure 5-4  Analysis of miR-21 expression in total lung and PA isolated from miR-21 -/- 
female mice or WT female mice. miR-21 expression was assessed in the total lung (A) and 
the PA (B) of WT and KO 10 weeks old female mice, normoxic or exposed to chronic hypoxia 
for 14 days. Samples were tested in triplicate. Analysis of KO samples confirmed miR-21 
genetic ablation in the tissues. Results were normalized to U6 values and expressed as relative 
fold change, with an arbitrary value of 1 assigned to the WT normoxic group.  Raw Ct values for 
the target miRNA are indicated above each column. Data are expressed as mean ± SEM and 
analysed by two way ANOVA followed by Bonferroni’s post-hoc test. ***P<0.001 compared to 
normoxic mice. N = 6/group.  
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Figure 5-5  Analysis of miR-21 expression in the RV and the LV + S isolated from miR-21 -
/- female mice or WT female mice. miR-21 expression was assessed in the RV (A) and the LV 
+ S (B) of WT and KO 10 weeks old female mice, normoxic or exposed to chronic hypoxia for 
14 days. Samples were tested in triplicate. Analysis of KO samples confirmed miR-21 genetic 
ablation in the tissues. Results were normalized to U6 values and expressed as relative fold 
change, with an arbitrary value of 1 assigned to the WT normoxic group.  Raw Ct values for the 
target miRNA are indicated above each column. Data are expressed as mean ± SEM and 
analysed by two way ANOVA followed by Bonferroni’s post-hoc test. ***P<0.001 compared to 
normoxic mice. N = 6/group.  
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Figure 5-6  Assessment of systemic arterial pressure (SAP, A, n = 6–9) and heart rate (HR, 
B, n=8-10) in WT and miR-21 -/- mice, normoxic and hypoxic. 10 weeks old female mice, 
normoxic (dark grey bars) and hypoxic (light grey bars) were assessed. Data were analyzed 
using a two-way ANOVA followed by Bonferroni’s post-hoc test, but no significant differences 
were observed.  
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Figure 5-7  Effect of miR-21 genetic ablation on PAH development in mice. Assessment of 
sRVP (A, n = 9–12) and RVH (B, n = 9–10) in 10 weeks old female WT and miR-145 -/- mice, 
normoxic (dark grey bars) or exposed to chronic hypoxia for 14 days (light grey bars). Data 
were analyzed using a two-way ANOVA followed by Bonferroni’s post-hoc test. *P<0.05, 
**P<0.01, ***P<0.001 compared to normoxic mice or WT hypoxic mice as indicated. 
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375.85 ± 14.96370.3 ± 11.06352.45 ± 13.10371.78 ± 28.72Heart rate, bpm
93.84 ± 5.8094.24 ± 10.1891.70 ± 6.6891.80 ± 7.68SAP, mmHg
36.36 ± 0.10†††§§§21.75 ± 0.7828.41 ± 1.07***22.21± 1.18sRVP, mmHg
KO HypoxicKO NormoxicWT hypoxicWT NormoxicParameter
 
Table 5-1  Haemodynamics in WT and miR-21 -/- mice, normoxic and 
hypoxic. Systolic right ventricular pressure (sRVP), systemic systolic arterial pressure (SAP) 
and heart rate measurements in normoxic and chronically hypoxic female WT and miR-21 -/- 
mice. ***P<0.001 compared to WT normoxic mice; §§§P<0.001 compared to miR-21 -/- mice; 
†††P<0.001 compared to WT hypoxic mice; Data expressed as mean + SEM. n=6-10. 
 
 
0.34 ± 0.025††§§§115.96 ± 8.4635.92 ± 0.85miR-21 -/- Hypoxic
0.25 ± 0.01085.81 ± 2.4421.15 ± 0.88miR-21 -/- Normoxic
0.30 ± 0.010***113.31 ± 6.2333.62 ± 1.82WT Hypoxic
0.20 ± 0.01394.26 ± 4.0819.27± 1.41WT Normoxic
RV/LV+SLV+S (mg)RV (mg)Group
 
Table 5-2  Ventricle weight in WT and miR-21 -/- mice. Right ventricle (RV) 
weight, left ventricle plus septum (LV+S) weight and RV/LV+S ratio. ***P<0.001 compared to 
WT normoxic mice; §§§P<0.001 compared to miR-21 -/- mice; ††P<0.005 compared to WT 
hypoxic mice; Data expressed as mean + SEM. n=9-10. 
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Figure 5-8  Effect of miR-21 genetic ablation on vessel remodelling in mice. (A) 
Representative PAs stained with elastic-Van Gieson.  Images all x40 magnification, scale bars = 
20 m. (B) Pulmonary arterial remodeling from normoxic and hypoxic WT and miR-21 -/- female 
mice (n = 5/group). Mice were subjected to chronic hypoxia for 14 days and analyzed at 10 
weeks of age.  .  Lung sections (5 sections/group) were stained with Elastin-Van Gieson and 
microscopically assessed in a blanded fashion. Pulmonary arteries (≤ 80 microns external 
diameter) were considered muscolarized if they possessed a distinct double elastic lamina for at 
least half the diameter of the vessel cross section. Approximately 150 arteries from each sagittal 
lung section were assessed. Data were analyzed using a two-way ANOVA followed by 
Bonferroni’s post-hoc test. *p<0.05, **P<0.01 compared to normoxic mice or WT hypoxic mice 
as indicated. 
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5.2.3 MiR-21 in Human PAH 
In consideration of the down-regulation of miR-21 observed in human PAFs exposed to 
hypoxia for 24 h, we next evaluated whether miR-21 is dysregulated in patients with 
PAH and examined its expression level in the lung of patients with IPAH and HPAH in 
comparison with control lung tissue. We first extracted miRNA from paraffin-
embedded lungs. Compared to controls, miR-21 was significantly down-regulated in 
both HPAH and IPAH samples (Figure 5-9). After that, we cultured primary human 
PASMCs obtained from HPAH patients and quantified the expression of our miRNA of 
interest at the pri-, pre- and mature miRNA level (Figure 5-10A, B and C). It is 
interesting to notice that the pri- form of miR-21 was up-regulated in BMPR2 mutated 
cells in comparison with WT (Figure 5-10A), the pre-form was not deregulated (Figure 
5-10B) whereas the mature form resulted significantly down-regulated (Figure 5-10C), 
suggesting that two different mechanisms of miRNA dysregulation could act at the 
same time, at transcriptional and post-transcriptional level.  
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Figure 5-9  Assessment of miR-21 expression level in IPAH and HPAH human lung. 
TaqMan
®
 Real-Time PCR analysis of RNA extracted from paraffin-embedded human lungs of 
IPAH (n = 6), HPAH (n = 5) and control patients (n = 6) showing the expression level of miR-21. 
All samples were normalized to Rnu-48 values and expressed as relative fold change, with an 
arbitrary value of 1 assigned to the control group. Raw Ct values for the target miRNA are 
indicated above each column. Data were analyzed using a one-way ANOVA followed by 
Bonferroni’s post-hoc test. *p<0.05, **p<0.005 compared to CTR group. 
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Figure 5-10  Analysis of miR-21 expression level in human BMPR2 mutated PASMCs. (A, 
B) TaqMan
®
 Real-Time PCR analysis of miR-21 expression in human PASMCs. Total RNA was 
extracted from PASMCs of HPAH patients with a mutation in the BMPR2 gene. Passage 4 
primary cells were used. cDNA was analyzed for pri- pre- and mature-miR-21 expression in 
comparison with unaffected controls. Results were normalized to GAPDH for the pre- and Rnu-
48 for the mature-miR-145 and expressed as relative fold change, with an arbitrary value of 1 
assigned to the control group. Raw Ct values for the target miRNA are indicated above each 
column. Data were analyzed using an unpaired t-test. **p<0.005 compared to control samples.  
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5.2.4 miR-21 Expression in BMPR2 R899X mice 
Considering the dysregulation observed in miR-21 expression level in human PASMCs 
isolated from HPAH patients harbouring a mutation in the BMPR2 gene, we evaluated 
the effect of a truncating BMPR2 mutation on miR-21 expression in heterozygous 
R899X +/- mice. RNA was extracted from the whole lung of 6 month old mice and 
analyzed by TaqMan® Reat-Time PCR. However miR-21 did not change, suggesting that 
a deregulation of miR-21 in response to an impaired BMPs signaling could be proper of 
human samples or PASMCs specific, and therefore difficult to detect in the whole lung 
(Figure 5-11).  
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Figure 5-11  miR-21 expression in WT and BMPR2 R899X mice. RNA was extracted from 
the total lung of WT mice and animals heterozygous for a mutation in the BMPR2 gene, and 
assessed for miR-21 expression by TaqMan
®
 Real-Time PCR. Values were normalized to U6 
expression and data were analyzed using an unpaired t-test. Raw Ct values for the target 
miRNA are indicated above each column. No statistically significant differences were observed 
between the groups. 
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5.2.5 Effect of BMPR2 Down-Regulation on miR-21 Expression in 
Human PASMCs 
Davis et al. recently demonstrated that BMP4 can induce the expression of miR-21. 
This stimulation occurs at a post-transcriptional level since ligand-specific SMAD 
proteins can interact with the DROSHA microprocessor subunit p68 to induce pre-
miRNA accumulation (Section 5.1) (Davis, Hilyard et al. 2008). Here we reported the 
down-regulation of miR-21 miRNAs in human PASMCs harboring a mutation in the 
BMPR2 gene, a systems characterized by an impairment of the BMP signaling (Section 
5.2.3). However, no changes where observed in mice with a truncating mutation in the 
same gene (Section 5.2.4). To have a confirmation of our results in human samples, we 
next evaluated the effect of a siRNA-mediated knock-down of BMPR2 on miR-21 
expression level in human WT PASMCs in vitro. As previously reported in Chapter 4 
(Section 4.2.7), cells were transfected with a si-RNA able to target and down-regulate 
specifically BMPR2, or with a siScramble as negative control. RNA was extracted from 
these samples and from untreated cells after 72 h for comparison. The efficacy of the 
down-regulation of BMPR2 was assessed through TaqMan® Real-Time PCR analysis 
(Figure 5-12A). In agreement with our previous findings, the down-regulation of 
BMPR2 induced the significant down-regulation of miR-21, whereas no changes were 
observed in untreated or siScramble-treated cells (Figure 5-12B). 
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Figure 5-12  miR-21 down-regulation in human PASMCs down-regulated for BMPR2 
expression via a siRNA. Primary human PASMCs were transfected with a siRNA able to 
target and repress specifically BMPR2 expression or with a siScramble as a negative control. 
Total RNA was extracted after 72 h from these samples and untreated cells for comparison. The 
efficiency of BMPR2 down-regulation was evaluated by TaqMan
®
 Real-Time PCR (A). miR-21 
(B) expression was also assessed in the same samples. Results were normalized to GAPDH for 
BMPR2 and Rnu-48 for miR-21 and expressed as relative fold change, with an arbitrary value of 
1 assigned to the control group. Raw Ct values for the target miRNA and gene are indicated 
above each column. Data were analyzed using a one-way ANOVA followed by Bonferroni’s 
post-hoc test. **p<0.005, ***p<0.001 compared to CTR or si-Scramble group as indicated. 
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5.3 Discussion 
In this chapter we assess the expression and regulation of miR-21 in the cardiovascular 
system in response to hypoxic injury and also in pathological samples. In the hypoxic 
mouse model we show elevation of miR-21 expression level in total lung of female (but 
not male) animals compared to controls. This miRNA was also significantly over-
expressed in PAs and in the right ventricle, with no changes observed in the left 
ventricle. The expression of miR-21 in other organs still needs to be evaluated in order 
to understand if this deregulation is specific of the cardiovascular system.  
 
We also evaluated the role of miR-21 in the development of PAH. Recently, different 
studies reported the involvement of this miRNA in cardiac hypertrophy and heart 
failure, showing the up-regulation of miR-21 in hypertrophic animal hearts (van Rooij, 
Sutherland et al. 2006; Cheng, Ji et al. 2007; Sayed, Hong et al. 2007). Also, Ji et al. 
reported in rats a substantial increase of the expression level of this miRNA in balloon-
injured arteries compared with normal control vessels, then showing an inhibition in 
neointima lesion formation in response to a miR-21 knock-down (Ji, Cheng et al. 2007). 
These observations led us to hypothesize an involvement of miR-21 also In the 
development of PAH, characterized by cell proliferation, neointima formation and RVH 
(Chapter 1, Section 1.2.2). We therefore decided to evaluate the effect of the genetic 
ablation of this miRNA in mice exposed to chronic hypoxia. Previous studies conducted 
on miR-21-depleted mice have given controversial results. In fact, whereas Thum et al. 
reported that the antagomiR-mediated depletion of miR-21 prevents cardiac 
hypertrophy and fibrosis in response to pressure overload induced by TAC, Patrick et 
al. could not confirm this result in mice pharmacologically or genetically depleted for 
miR-21 expression (Thum, Gross et al. 2008; Patrick, Montgomery et al. 2010). Two 
very recent studies have been conducted so far to analyze the effect of such a 
depletion on the lung and the pulmonary vasculature. In agreement with our data, 
Pullamsetti et al. and Yang et al. reported a significant increase of miR-21 expression in 
mice exposed to chronic hypoxia and then analyzed the effect of an antagomiR-
mediated down-regulation of miR-21 on hypoxia-induced PAH (Pullamsetti, Doebele et 
al. 2011; Yang, Banerjee et al. 2012). In particular, Pullamsetti et al. observed that this 
treatment was able to significantly lower the hypoxia-induced increase in sRVP in 
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comparison with placebo-treated mice, whereas no changes were reported on RVH 
and percentage of remodelled vessels (Pullamsetti, Doebele et al. 2011). Yang et al. on 
the contrary reported the significant reduction of RVH and percentage of remodelled 
vessels in antimiR-treated mice (Yang, Banerjee et al. 2012). These observations 
completely disagree with our findings. In fact, here we show that a functional analysis 
of the vasculature of miR-21 -/- mice revealed a worsened response to hypoxia: when 
these mice were exposed to hypoxia for two weeks, both sRVP and RVH resulted 
drastically increased in comparison with WT animals exposed to the same conditions. 
Also, the percentage of remodeled vessels was significantly increased in the KO 
animals, strongly suggesting a negative effect of miR-21 genetic ablation on PAH 
development. A more exhaustive analysis of miR-21 expression in the cardiovascular 
system revealed a significant up-regulation of this miRNA also in the PAs of female WT 
hypoxic mice. Interestingly, in these mice miR-21 was significantly up-regulated in the 
right ventricle but not in the left ventricle plus septum, suggesting a hypothetical direct 
involvement of this miRNA in the RVH reported. However, the mechanism responsible 
for the worsen phenotype observed in KO mice in response to hypoxia still need to be 
identified and also the differences observed between Pullamsetti et al. and Yang et al. 
studies (Pullamsetti, Doebele et al. 2011; Yang, Banerjee et al. 2012) and our findings 
still need to be clarified. These will require more extensive studies, although some 
hypotheses can be formulated about this second point. First of all, it is important to 
note that embryonic KO and post-natal knock-down can have very different 
consequences considering that in the second case the development of the treated 
animal is not influenced by the manipulation of the expression of the genomic 
sequence of interest. Moreover, pharmacological ablation results in the down-
regulation of the target sequence, with a basal expression still detectable. Finally, no 
mention of the gender of the mice used for the experiments can be found in both the 
Pullamsetti et al. and the Yang et al. studies (Pullamsetti, Doebele et al. 2011; Yang, 
Banerjee et al. 2012). Considering the differential regulation of miR-21 in response to 
hypoxia observed in female and male mice (Section 5.2.1), this information could be 
important to understand their results.  
 
It is important to mention that our in vivo study still needs to be completed, since no 
targets have been analyzed so far. The analysis of predicted/validated targets 
expression in lung, PA, RV and LV will give important information on the pathways 
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involved in the process. Regarding this, it is interesting to note that very recently new 
targets of miR-21 in the vasculature have been identified in several members of the 
DOCK (dedicator of cytokinesis) family (Kang, Davis-Dusenbery et al. 2011), previously 
involved in the regulation of cell motility and cytoskeletal assembly in particular in the 
nervous system (Miyamoto and Yamauchi 2010). This study demonstrate that miR-21 
mediated down-regulation of DOCKs is critical for the promotion of the contractile 
phenotype induced by BMP4 stimulation (Kang, Davis-Dusenbery et al. 2011). It will be 
therefore interesting to evaluate DOCKs expression in response to hypoxia and in miR-
21 -/- mice. Also, since unlike miR-143 and miR-145, miR-21 is universally expressed in 
mammal organs and cell types, in situ localization of this miRNA in the vasculature of 
normoxic and hypoxic mice will give important information about the specific cell 
types involved in miR-21 deregulation.  
 
In this chapter we also analyze miR-21 expression in human pathological samples. In 
particular, we demonstrate significant down-regulation of miR-21 in HPAH and IPAH 
patients and also in BMPR2 mutated PASMCs extracted from HPAH patients. As 
previously mentioned, and in agreement with our observations, the TGF-beta super-
family has been already involved in the maturation process of specific miRNAs 
(including miR-21), through the interaction of SMADs with Drosha complex during the 
second step of miRNA biogenesis (Davis, Hilyard et al. 2008) (Chapter 1, Section 
1.3.3.4). Our observations of a down-regulation of miR-21 in BMPR2-mutated human 
cells was also confirmed in vitro, since a similar dysregulation of this miRNA was 
induced in human PASMCs by the down-regulation of BMPR2 expression, obtained via 
a siRNA able to inhibit specifically the expression of this non-coding gene. However no 
changes in miR-21 expression were observed in mice carrying a mutation in this gene. 
It is important to mention that a recent study also reported a significant reduction in 
miR-21 expression in human PAECs down-regulated for BMPR2 expression, although 
no significant changes were observed in human PASMCs (Drake, Zygmunt et al. 2011). 
Further studies will be necessary to understand if the differences in miR-21 regulation 
observed in the two species can be correlated with the differences in PAH observed 
between the mouse model and the human pathology. For example, the exposure of 
mouse vascular cells to hypoxia could be important to confirm the up-regulation 
observed in vivo in these conditions. It is important to remember that in chapter 3 we 
reported the down-regulation of miR-21 in human PAFs exposed to chronic hypoxia for 
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24 h, confirming the dysregulation of this miRNA observed in human pathological 
samples in this chapter, whereas no changes were observed in PAECs. The analysis of 
PASMCs will complete that study. Moreover, the stimulation of both mouse and 
human cells with different members of the TGF-beta super-family will consent the 
identification of differential responses. Also, it is important to note that the analysis of 
BMPR2 mutated human PASMCs revealed the significant down-regulation of the 
mature miR-21, whereas the pri- form was up-regulated. Since the pri- is the first 
precursor of a miRNA, directly transcribed from the DNA, this finding could suggest the 
presence, in human samples, of two different types of regulation: one transcriptional, 
resulting in the accumulation of the first precursor, and one post-transciptional, 
leading to the down-regulation of the mature miRNA. If the post-transcriptional 
regulation could be identified in the already reported effect of BMPs on miR-21 
expression (with a reduced amount of mature miRNA in case of an impairment of the 
BMP signaling due to BMPR2 mutations), the transcriptional regulator of miR-21 in this 
system still need to be identified. Mouse models of PAH could present different types 
of regulations, or it could be hypothesized that the transcriptional regulation could be 
predominant in mouse model. An exhaustive analysis of pri- and pre-miR-21 in the 
hypoxic mouse model will be fundamental to clarify this aspect. Also, as already 
mentioned, in Section 5.2.1 we show that miR-21 up-regulation in response to hypoxia 
can be observed only in female mice with no effects of this treatment on males. 
Moreover, hypoxic male rats exposed to chronic hypoxia did not present any 
dysregulation in miR-21 expression, as reported in Chapter 3 (Section 3.2.2). The 
identification of the differences in miRNA and target expression between female and 
male mice, WT and miR-21 -/-, in response to hypoxia will give us many answers about 
the role played by gender in miR-21 deregulation in PAH. Also, it will be interesting to 
evaluate the effect of the genetic depletion of miR-21 on older mice, normally 
characterized by a more severe phenotype. In fact, as already reported for other 
animal models of PAH (MacLean, Deuchar et al. 2004), 5-6 months old mice could 
develop spontaneously the pathology or show a dramatic increase of sRVP and RVH in 
response to chronic hypoxia. Concerning the results obtained from the analysis of 
human samples, a detailed analysis of miR-21 expression also in PAECs and PAFs 
isolated from PAH patients, with or without mutations in the BMPR2 gene, will let us 
understand if the dysregulation observed in the total lung is specific of PASMCs or 
proper of all the cell types implicated in PAH. All these studies will be necessary to 
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further evaluate the role of miR-21 in the development of this pathology and 
understand the differences observed between the mouse model and human samples. 
 
Nevertheless, our preliminary observations about miR-21 dysregulation in PAH confirm 
a role for this miRNA in the development of this pathology, suggesting the possibility of 
a novel therapeutic approach in the future. Also, the identification of a specific miRNA 
expression profile could be used as a new efficient way to obtain an early diagnosis 
with substantial benefits for patients. 
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6. General Discussion 
Pulmonary arterial hypertension (PAH) is a complex, multifactorial pathology, rare but 
severe. It is characterized by high pulmonary artery pressure, vascular remodelling and 
right ventricular hypertrophy, and if untreated it culminates in right heart failure 
within 3 years (Eddahibi, Morrell et al. 2002; Jeffery and Morrell 2002). The etiology of 
PAH is not entirely understood, but a genetic component is known to contribute. 
Members of the TGF-beta super-family are major candidates since mutations in the 
gene encoding for a BMPs receptor (BMPR2) have been identified in 80% of families 
characterized by affected members (Machado, Aldred et al. 2006), and also 15-40% of 
patients with IPAH are carriers of similar genetic abnormalities (Thomson, Machado et 
al. 2000). In particular, the expression of BMPR2 is reduced in the pulmonary 
vasculature of HPAH patients carrying a mutation but also in IPAH patients in whom no 
mutation have been identified, suggesting a central role of BMPR2 in the pathogenesis 
of this pathology also in non-carriers. 
 
Also the serotonin system has been implicated in the pathobiology of PAH. In fact, 
several studies identified the serotonin transporter SERT as another genetic risk factor 
for the development of this pathology. In particular, an increased expression of the 
this gene has been observed in IPAH patients (Eddahibi, Humbert et al. 2001) and mice 
over-expressing SERT (SERT+) were reported to exhibit an enhanced RVP and vascular 
remodelling, and to develop an exaggerated PAH in response to hypoxia (MacLean, 
Deuchar et al. 2004).  
 
A more exhaustive knowledge of the regulation of these genes will be important to 
increase our current understanding of PAH and possibly improve the prognosis of 
patients, since all the treatments available at the moment can only provide a 
symptomatic relief (Chapter 1). For this reason, in this project we decided to evaluate 
the role played by miRNAs in the development of PAH. MiRNAs are small non-coding 
RNAs able to negatively regulate gene expression by binding to the 3’UTR of their 
specific target mRNAs, thereby promoting their degradation or inhibiting their 
translation. Biogenesis, activity and contribution of miRNAs to the development of 
several pathologies were outlined in Chapter 1.  
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The first part of this study (Chapter 3), published in 2010, was the first to report the 
significant dysregulation of specific miRNAs in rat models with correlation in human 
pathological samples. Considering the complete lack of information about this topic at 
that time, we decided to evaluate globally miRNA expression in hypoxic and 
monocrotaline-injected rats as starting point. For this reason we performed a 
microarray based analysis of miRNA expression, assessing in total 350 different 
miRNAs at three different time points (2, 7 and 21 days) after the 
hypoxic/monocrotaline treatment. For the identification of the most dysregulated 
miRNAs, a basal microarray signal intensity of 500 arbitrary units (AU) was chosen, as 
recommended by LC Sciences, commissioned to perform the experiment. This choice 
has been taken considering the scanner’s lower limit of detection and the efficiency of 
hybridization of the probes used, and it allowed us to consider only the most reliable 
data obtained. Of course it is important to take into account that specific miRNAs, 
expressed at low level but still relevant for the development of the pathology, could be 
excluded in this way from further analysis. This was the case of miR-204, poorly 
expressed in our samples and therefore excluded from our study but recently 
implicated in the development of PAH (Courboulin, Paulin et al. 2011). It is also 
possible that some miRNAs are expressed at a low level since specific of the 
vasculature, and therefore their concentration is diluted when assessed in the total 
lung. Aware of this, we decided to use these stringent criteria for a first screening in 
order to avoid experimental noise and select a manageable number of dysregulated 
miRNAs to be carried forward for further investigations. A lower cut-off value could be 
chosen in the future to re-analyze the data including a wider group of miRNAs. Using 
the threshold of 500 AU, we selected a group of seven miRNAs significantly altered in 
the hypoxic and/or the monocrotaline rat model (i.e. miR-21, miR-22, miR-30c, miR-
451, miR-322, let-7a and let-7f) and their expression was validated by TaqMan® Real-
Time PCR. The alteration of these miRNAs was also confirmed in vitro in rat PASMCs 
and PAFs exposed to chronic hypoxia, and a similar regulation was also observed in 
human cells. It is interesting to note that in agreement with the significant down-
regulation of Dicer observed in the hypoxic models and at the latest time point of the 
monocrotaline model, the majority of miRNAs significantly dysregulated in the 
microarray was down-regulated, suggesting that the process of miRNA maturation is 
impaired in these models. It will be therefore important in the future to evaluate the 
effects on miRNA dysregulation of Dicer manipulation in vivo. 
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Considering that the hypoxic and the monocrotaline rat models are well established 
animal models for the study of PAH but they do not completely represent the human 
pathology as explained in Chapter 1, we considered fundamental to investigate also 
human pathological samples and cells. In particular we focused our attention on miR-
451, up-regulated in a substantial way in both the models and especially in 
monocrotaline-treated rats, and miR-22, consistently down-regulated in all the rat 
pathological samples tested, in vivo and in vitro. The results obtained gave us the 
confirmation that miRNA regulation can be complex and not always conserved 
between different species. In fact, we could observe a dysregulation of miR-22 
compatible with what observed in rats, whereas miR-451 did not show any alteration 
in human pathological samples. Despite this and in consideration of the remarkable 
up-regulation observed in rats, an in vivo study is currently in progress to evaluate the 
effects of the genetic and pharmacological ablation of this miRNA on the development 
of PAH. The analysis of the other miRNAs identified in the study in the same human 
samples will be important as next step of this study to have a clearer view of the 
similarities between the hypoxic and the monocrotaline rat model and the human 
disease. A careful evaluation of the differences could contribute to explain those 
differences identified in the pathogenesis of PAH between species and also between 
different models within the same species. The analysis of different animal models, 
more recently introduced for the study of PAH (e.g. the sugen 5416 rat model, Chapter 
1, Section 1.2.3) could also confirm the dysregulation of defined miRNAs.  
 
In Chapter 3 we also used bioinformatics prediction algorithms to identify predicted 
target mRNAs of our miRNAs of interest. Several databases are currently available for 
this purpose, based on the most updated knowledge of miRNA biology. However, it is 
important to remember that the very rapid development of this field dictates a 
continuous improvement in these algorithms. An evident consequence of this is 
represented by the exclusion of BMPR2 from the list of targets validated in the rat 
model. In fact this enzyme, whose expression in altered in patients also in the absence 
of specific mutations, has been identified as a target of miR-21 (Qin, Zhao et al. 2009), 
but it was not reported in any databases when this study was conducted. TaqMan® 
Real-Time PCR analysis of BMPR2 mRNA levels in vivo and in vitro will be important to 
evaluate if its expression correlates with miR-21 alteration, although Long et al. 
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already reported the significant down-regulation of BMPR2 in monocrotaline-treated 
rats, characterized by a decreased expression of miR-21 (Long, Crosby et al. 2009). 
Therefore BMPR2 regulation does not seem to correlate well with miR-21 expression 
level, at least in monocrotaline-injected rats. In Chapter 5 we reported how the down-
regulation of BMPR2 results in a decreased expression of this miRNA, suggesting that 
this receptor can influence miR-21 regulation through the interaction of SMADs with 
DROSHA complex during the second step of miRNA biogenesis, as previously reported 
(Davis, Hilyard et al. 2008). If miR-21 should be proved to be able to regulate BMPR2 
expression in turn, the presence of a regulatory loop could be suggested, but further 
experiments will be necessary to evaluate this hypothesis. First of all, it will be 
important to analyze in the siBMPR2 samples not only the mature form, but also the 
miR-21 precursors in order to identify the step of miRNA maturation affected by the 
BMP signaling. This is particularly important in consideration of what observed in 
BMPR2 mutated PASMCs isolated from PAH patients. In those samples, as showed in 
Chapter 5, we observed an up-regulation of pri-miR-21 and a down-regulation of the 
mature form, suggesting that both a transcriptional and a post-transcriptional 
regulation of this miRNA take place in patients. After that, the si-mediated down-
regulation of specific members of the TGF-beta super-family, including receptors like 
Alk1 and Alk5, but also different Smads (Smad2-3 and Smad1-5-8) will let us identify 
the factors involved in the process. 
 
However, it is important to note that only male rats have been analyzed in Chapter 3, 
and an in vivo study involving female animals will be fundamental in the future, taking 
account of the differences observed between female and male hypoxic mice in 
Chapter 4 and Chapter 5. Gender in relation with miRNA expression could be an 
interesting topic to evaluate in detail in animal models and PAH affected patients, 
considering that it has been well reported from different epidemiological studies how 
this pathology is more frequent in women, with an incidence of both IPAH and HPAH 
up to three-fold higher in female patients (Humbert, Sitbon et al. 2006; Peacock, 
Murphy et al. 2007; Thenappan, Shah et al. 2007). Moreover, well established 
experimental models of PAH could not provide insight into this phenomenon, and 
paradoxically several of them exhibit male susceptibility, making the situation 
controversial and difficult to interpret (Rabinovitch, Gamble et al. 1981; Miller, Hislop 
et al. 2005; Hansmann, Wagner et al. 2007; Said, Hamidi et al. 2007). Both in Chapter 4 
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and Chapter 5 we show how miRNA regulation, in the same conditions, can be 
different between female and male mice exposed to chronic hypoxia, and this could be 
useful to clarify this aspect of PAH biology. An extensive evaluation of female 
hypoxic/monocrotaline-treated rats and male hypoxic (WT or KO for specific miRNAs) 
mice will give us important information about this topic.  
 
Relating to target analysis, no luciferase assays have been conducted so far to confirm 
the existence of a direct link between the dysregulation of a specific miRNA and the 
alteration of the expression of a gene, although both in Chapter 3 and Chapter 4 
several targets evaluated by TaqMan® Real-Time PCR and western blot were 
dysregulated in a way compatible with miRNA expression.  The alteration in vitro of a 
specific miRNA followed by the transfection of cells with a construct coding for a 
luciferase gene modified to carry at its 3’UTR seed sequences compatible with that 
miRNA will definitely prove that the dysregulation observed in vivo is due to the action 
of the miRNA itself. It is also important to consider that the computational approaches 
for miRNA target prediction via bioinformatics algorithms used in Chapter 3, based on 
the tendency of miRNAs to form complete base pairings to a target mRNA at miRNA 
nucleotides 2–8 (the seed region), do not consent to identify all those targets that do 
not conform to the seed theory, and have therefore evident limitations. For this 
reason, new methods have been developed in the last few years to improve targets 
identification. One of them was described in the Orom et al. study (Orom and Lund 
2007) and used by Kang et al. to identify miR-21 targets within the DOCK family (Kang, 
Davis-Dusenbery et al. 2011). Briefly, this method is based on the use of synthetic 
miRNA duplexes carrying a biotin group attached to the 3’-end of the sense strand. 
These duplexes are then transfected into a cell type of interest, where the tagged 
miRNA sense strands incorporate into miRISC complexes and associate with 
endogenous target mRNAs. The miRNA–mRNA complexes are captured on streptavidin 
beads and analyzed (Orom and Lund 2007). This method could be used in the future to 
identify novel targets of our miRNAs of interest. 
 
The study conducted in Chapter 3 proved us that miRNAs are significantly dysregulated 
in PAH and gave us important information about what happens in the lung in terms of 
coding and non-coding gene expression at different stages after the hypoxic and 
monocrotaline insult. However, it also let us understands the limitations of such a 
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study. In fact, although miRNAs normally work in families or groups to influence in a 
cooperative way the expression of a target, the simultaneous analysis of the effect of 
several miRNAs on gene expression can become extremely complex, expensive and 
time consuming, since each miRNA is normally reported to have several thousands of 
predicted target sequences. A microarray based mRNA study similar to that conducted 
in Chapter 3 for miRNA expression could be a solution, but it is important to consider 
the cost of such and assay and also the importance to validate the data obtained with 
a TaqMan® Real-Time PCR analysis of the selected genes, considering the high rate of 
false positive and false negative assigned to this kind of experiment. Moreover, the 
data obtained from such a global alteration of miRNA expression could be very difficult 
to interpret, especially if the field has been poorly studied. For this reason, in Chapter 
4 and Chapter 5 we decided to focus our attention on miR-143/145 cluster and miR-21 
respectively. A TaqMan® Real-Time PCR analysis of the expression of these miRNAs in 
the total lung of WT mice exposed to chronic hypoxia showed a selective up-regulation 
in females.  
 
To evaluate the effect of the genetic ablation of miR-145 or miR-21 on PAH 
development, we exposed to chronic hypoxia mice deleted for these genes. In both 
cases the result was relevant. In fact, miR-145 genetic ablation resulted significantly 
protective against the development of this pathology, reducing sRVP, RVH and 
percentage of remodelled vessels. As reported before (Boettger, Beetz et al. 2009; Xin, 
Small et al. 2009), SAP was reduced in KO mice, normoxic or hypoxic, making the 
possibility to obtain lung specific ablation of miR-145 to reduce the systemic effects 
attractive. The effect of miR-145 ablation on the vasculature, and in particular on the 
muscular component, described in detail in Chapter 4, had already been evaluated in 
previous studies (Boettger, Beetz et al. 2009; Xin, Small et al. 2009), but our study is 
the first to examine specifically the implications of this genetic modification on PAH. 
Our group also evaluated the effect of pharmacological ablation of this miRNA using an 
antimiR (data not shown), obtaining a similar result. This is particularly relevant since 
pharmacological ablation could be used on patients as therapeutic approach. For this 
reason we decided to evaluate the expression of miR-143 and miR-143 also in 
pathological human samples, in order to understand if a similar regulation can be 
identified in mice models and patients. In Chapter 4 we report the significant up-
regulation of miR-143 and miR-145 in the total lung of heritable and idiopathic PAH 
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affected patients, and also in PASMCs extracted from patients harboring a mutation in 
the BMPR2 gene, therefore confirming in human samples a dysregulation similar to 
that observed in hypoxic WT mice. For this reason it is possible to hypothesize that a 
pharmacological inhibition of miR-145 could have a positive effect on the prognosis of 
patients, although an extensive sperimentation will be necessary to prove it. First of 
all, an in vivo study will be conducted to evaluate if the pharmacological ablation of 
miR-145 is also able to reverse PAH in mice already exposed to hypoxia. This type of 
study, called “rescue study” will clarify if such a treatment can only prevent the onset 
of PAH or also reverse it in animals (ans eventually patients) already affected. 
 
A correlation between BMPR2 and miR-143/145 expression have been also observed 
in further experiments. In fact, mice heterozygous for a truncating mutation in this 
gene showed a significant up-regulation of the cluster in normoxic conditions, and an 
in vitro down-regulation of BMPR2, performed on human PASMCs, had the same 
consequence. These results appear interesting but in contrast with the recent 
observation that members of the TGF-beta super-family can induce miR-143 and miR-
145 expression (Davis-Dusenbery, Chan et al. 2011; Long and Miano 2011). If this 
mechanism would be fundamentally involved in the regulation of these miRNAs in our 
system, an impairment of the BMP signaling, induced by a BMPR2 down-regulation, 
should result in their down-regulation instead. An explanation for this still need to be 
identified and will required more experiments focused on the role played by different 
members of the TGF-beta super-family in this system. For example could be 
hypothesized that in case of an impairment of the BMP signaling via BMPR2, a 
different type of regulation is activated in the cell to complement this function. Also, 
since not only BMP4 but also TGF-beta has been reported to up-regulate miR-143 and 
miR-145 (Davis-Dusenbery, Chan et al. 2011; Long and Miano 2011), it could be 
hypothesized that not the BMP impairment but the subsequent increase of the TGF-
beta signaling observed in PAH could be responsible for this miRNA dysreguation. An in 
vitro manipulation of receptors (i.e. Alk5) or effectors (i.e. Smad2 and Smad3) of the 
TGF-beta signaling will be necessary to validate this theory. 
 
Also, considering the attractive possibility to use in the future the pharmacological 
ablation of miR-145 as a therapy for PAH patients, the gender difference in miR-145 
expression reported at the beginning of Chapter 4 will need to be further esamined. In 
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fact, we observed that 2 months old hypoxic female mice are characterized by miR-145 
up-regulation, with no dysregulation observed in males. Since older mice develop a 
more severe PAH in response to hypoxia, it will be important to analyze miR-145 
expression level also in 5-6 months old mice, both female and male, in order to 
understand if this differential expression can still be observed. Moreover, we have 
proved that the genetic (Chapter 4) and pharmacological (not shown) ablation of miR-
145 is protective in female mice against the development of PAH, but a similar study 
will have to be conducted in males, ideally at 2 and 5-6 months of age, to prove is a 
similar effect occours. Finally, since a mixture of female and male patients have been 
currently analyzed for miR-145 expression, it will be important as further step to 
improve the number of patients assessed in order to have a separate analysis of 
female and male samples. This part in particular will be challenging, considering the 
low number of affected patients and available human samples. 
 
Similarly to what we reported in Chapter 4, miR-21 genetic ablation showed a 
significant effect on PAH development, as reported in Chapter 5. In this case however, 
the lack of expression of this miRNA resulted in an exaggerated PAH in response to 
hypoxia, characterized by an increased sRVP, RVH and higher number of remodelled 
vessels. This study still need to be completed with the analysis of predicted targets, but 
the results obtained so far are in contrast with the observations reported very recently 
from two studies (Pullamsetti, Doebele et al. 2011; Yang, Banerjee et al. 2012). They 
both describe like the pharmacological ablation of miR-21 can induce a significant 
decrease in sRVP or RVH and percentage of remodeled vessels (in Pullamsetti et al. 
study and Yang et al. study respectively), with a protective effect against the 
development of PAH (Pullamsetti, Doebele et al. 2011; Yang, Banerjee et al. 2012). As 
mentioned in Chapter 5, these differences could be attributed to the use of an 
antagomiR sequence, different from a genetic ablation, but definitely need to be 
clarified in the future.  
 
Since as mentioned before only 2 months old mice have been assessed in this study, 
but older mice normally develop a more severe form of PAH, it will be interesting to 
see the effects of miR-21 genetic ablation on 5-6 months older mice. As it has been 
observed for SERT mice, these animals could in fact develop PAH spontaneously, 
without any hypoxic insult. Moreover, also in this case the gender issue will have to be 
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further evaluated to see if also male mice KO for miR-21 develop a more severe form 
of PAH in response to hypoxia. 
 
To make the situation more complex, the analysis of WT hypoxic mice, characterized 
by an over-expression of miR-21, at least in females, is in contrast with the results 
obtained from the assessment of human pathological samples, where a down-
regulation of miR-21 was observed. These findings seem to suggest a differential 
regulation of miR-21 in different species, as already reported for miR-451 in Chapter 3. 
A more extensive analysis of mouse and human samples will be necessary to confirm 
this hypothesis, but if this should be confirmed miR-21 manipulation as therapeutic 
approach could become complex. However, it is important to remember that the 
hypoxic mouse model, well established and often used for the study of PAH, is an 
acute but not chronic model of the pathology, unlike human PAH, whereas we 
observed a miR-21 decreased expression in the chronic monocrotaline rat model.  A 
genetic or pharmacologic ablation of this miRNA in this animal model could be 
important to determine the effect on PAH in a chronic system characterized by a 
regulation of miR-21 similar to that observed in human samples. Also, as mentioned 
before in this chapter, a comprehensive analysis of miR-145 precursors in mouse 
models and human samples will be fundamental in the future to evaluate if a 
transcriptional or post-transcriptional regulation of miR-21 can be observed and if this 
regulation is conserved across species or is different between mouse models and 
patients. 
 
The data reported in this thesis support the hypothesis that the modulation of specific 
miRNAs could have important clinical applications. Such a possibility has been already 
tested in few recent studies. For example, after reporting the capacity of a chemically-
synthesized inhibitor of miR-208 to suppress pathological cardiac remodelling in a 
model of heart failure induced by chronic high blood pressure (Montgomery, Hullinger 
et al. 2011), the preclinical-stage biopharmaceutical company MiragenTM Therapeutics 
has announced the intention to start in 2012, in collaboration with Servier, a research, 
development and commercialization programme for this drug candidate, with 
potential potent beneficial effects for patients suffering from heart failure. Moreover, 
the clinical-stage biopharmaceutical company Santaris Pharma A/S presented in 
November 2011 new data from a Phase 2a trial showing that a four-week 
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monotherapy treatment with miravirsen, a miRNA-targeted drug able to inhibit miR-
122, provided robust dose-dependent and prolonged Hepatitis C virus (HCV) reduction 
in infected patients, that was maintained for more than four weeks beyond the end of 
therapy. These are only two representative examples of the potential of miRNA use in 
clinical applications.  
 
In summary, the main observations of this thesis include the identification of a specific 
group of miRNAs dysregulated in different animal models of PAH but also in human 
pathological samples; the confirmation in vitro of those alterations observed in vivo; a 
comparison of miRNA regulation in different species, sometimes highly conserved but 
also different in specific cases; the evaluation in vivo of the effects of a genetic ablation 
of specific miRNAs on the development of PAH, never tested before. 
 
In conclusion, I have demonstrated for the first time the direct involvement of a 
specific group of miRNAs in the development of PAH, presenting the possibility, in a 
more distant future, to introduce the use of a miRNA-based therapy for the treatment 
of this fatal pathology. 
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